ASCP ANNUAL MEETING

LOEWS MIAMI BEACH HOTEL MAY 29-JUNE 2, 2017

SERVING THE NEEDS



OF THE DIVERSE POPULATION




WWW.ASCPMEETING.ORG



Dear Colleagues,

Welcome to Miami Beach!

On behalf of the American Society of Clinical Psychopharmacology (ASCP), I am pleased to welcome you to our very exciting annual meeting. I want to thank both the Program Committee and the Steering



Committee for their wonderful work putting together an extraordinary meeting. Our meeting includes not only a very stimulating Latin American Satellite Symposium but also the 25th iteration of our very successful New Investigators' Program. Our meeting has something for everyone. There are sessions that discuss innovation across not only syndrome-states and the life cycle but also in terms of public-private partnerships, teaching, as well as public health and dissemination research. And just when you think there could be nothing more to entice you out of the Florida sun, there are talks on the challenges posed by medical marijuana, to the role of technology in research and clinical practice to a special workshop on Hot Button Topics in Negotiation for Mid-Career Professionals in Psychopharmacology and Allied Fields. This year, we have added the Early Career Luncheon with panelists from diverse career trajectories, an FDA 101 Session, and a NIH Diversity Supplement Session. We have also renamed the Federal Agency Directors Plenary (formerly NIH Directors Plenary) and included additional federal agencies such as the Department of Defense and Patient-Centered Outcomes Research Institute. There is, of course, the very important and unique Regulatory Session that traditionally serves as the closing session of our meeting.

The ASCP is committed to finding and testing new therapies for our patients. We want to advance not only the field of psychopharmacology but treatment research in general. Many advances first presented at our annual meeting over the years have become mainstays not only in our treatment of serious mental disorders but in the way we design and conduct our clinical trials. I am sure that we will see presentations and posters at this meeting that will become important methods for caring for our patients in the future.

Our society has taken on a new responsibility in the past year and is actively becoming one of the places that legislators, federal agencies, and other groups interested in public policy turn to for advice on therapy and research questions about brain diseases. I want to thank Alan Gelenberg who was the initial co-chair of this working group. We have now formed a standing liaison committee to address these issues as they arise. As the experts in the field we have a responsibility to our patients and society to weigh in on these important issues. Please contact our colleagues at Parthenon Management Group if you have an interest in this or any other ASCP activities or committees.

I hope you have a wonderful time learning, presenting, and seeing old and new friends at our annual meeting.

Mark H. Rapaport, M.D.

M HRepapat us

President

American Society of Clinical Psychopharmacology

Welcome to the ASCP Annual Meeting

On behalf of the ASCP Annual Meeting Steering and Program Committees, we are delighted to welcome you to the ASCP Annual Meeting. The ASCP is committed to continue building on the past success of NCDEU with program innovation while preserving the rich history of this meeting. Below are some of the highlights of the 2017 meeting.

The annual meeting brings together academic investigators, industry scientists, U.S. and international regulators, National Institutes of Health (NIH) and other professionals who work in drug development and clinical trials.

· 2017 Program Highlights

- Monday, May 29th
 - Latin American Symposium
- Tuesday, May 30th
 - Conference Opening
 - Early Career Luncheon (RSVP Only)
 - NIH Diversity Supplement Session
 - Pharma Pipeline: 12 presentations of Phase 1 and Phase 2 developments
 - Individual Research Reports
- Wednesday, May 31st
 - 18th Annual Fun Run/Walk
 - Regulatory Plenary
 - ASCP Lifetime Awardee Talk
 - Poster Session I
 - FDA 101 Session
 - ASCP Reception
- o Thursday, June 1st
 - Keynote Plenary Session: Serving the Needs of the Diverse Population
 - Federal Agency Directors Plenary
 - Poster Session II
 - Clinical Updates in Psychopharmacology
- o Friday, June 2nd
 - Regulatory Wrap-Up Plenary with FDA and EMA regulators
- Throughout the meeting
- NIMH, NIDA, and FDA panels
- The New Investigator Program
 - A closed workshop for 20 New Investigators and informal breakfast sessions.
- Workshops: 2 hour intensive interactive sessions focused on problems and solutions
- Wednesday and Thursday Afternoons
- *Clinical Track* sessions focused on topics of immediate clinical relevance

Organization

- The meeting is sponsored by the American Society for Clinical Psychopharmacology (ASCP).
 - The Steering Committee organizes the meeting.
- The Program Committee evaluates submitted proposals and develops program innovations.
- o Federal agency collaborations:
 - CSR Center for Scientific Review
 - DoD Department of Defense
 - NIAAA National Institute on Alcohol Abuse and Alcoholism
 - NIDA National Institute of Drug Abuse
 - NIMH National Institute of Mental Health
 - NINDS National Institute of Neurological Disorders and Stroke
 - PCORI Patient-Center Outcomes Research Institute
- o Regulatory agency collaborations:
 - Food and Drug Administration (FDA)
 - Center for Drug Evaluation and Research (CDER)
 - European Medicines Agency (EMA)
 - Italian Medicines Agency (AIFA)
- o Parthenon Management Group organizes the ASCP Annual Meeting.

· And remember

- o The Fun Run/Walk is Wednesday, May 31st at 6:30 a.m. All are welcome to join!
- The ASCP Reception is Wednesday, May 31st from 6:45 p.m. 7:45 p.m.

The ASCP Annual Meeting is an opportunity for education and networking. We welcome your suggestions to make the event even better. Seek us out during the meeting or provide your views by completing the evaluation form.

Best Regards,

Marlene Freeman, M.D. Steering Committee Co-chair


Alan Gelenberg, M.D. Program Committee Co-chair John Newcomer, M.D. Steering Committee Co-chair

Holly A. Swartz, M.D. Program Committee Co-chair

Hotel Maps

Loews Miami Beach Hotel

Second Level



Third Level




Table of Contents

ASCP

Award Winners and Featured Speakers	5
Acknowledgements	.17
Meeting Announcements	.23
Monday, May 29, 2017	.27
Tuesday, May 30, 2017	.33
Wednesday, May 31, 2017	.49
Thursday, June 1, 2017	.61
Friday, June 2, 2017	.69
Poster Session I	.75
Poster Session II	.86
Author Index	.97

DISCLOSURES FOR ALL ASCP PRESENTERS CAN BE VIEWED AT WWW.ASCPMEETING.ORG

ASCP |

Notes

Award Winners

ASCP

Recipient of the Donald Klein Lifetime Achievement Award



David J. Kupfer, M.D. University of Pittsburgh School of Medicine

David J. Kupfer, M.D., is currently Distinguished Emeritus Professor of Psychiatry at the University of Pittsburgh School of Medicine. Between 1983 and 2009, Dr. Kupfer served as Chair of the Department of Psychiatry there and as Director of Research at Western Psychiatric Institute and Clinic. During that time, he facilitated the coordination and expansion of research among the department's more than

200 faculty members. Under his direction, WPIC became one of the nation's preeminent university-based psychiatric research centers, as evidenced by the quality and number of peer-review publications, as well as the amount of federal funding for mental health research. A prolific writer, Dr. Kupfer has authored or co-authored a combination of more than 1,120 articles, books, and book chapters. Dr. Kupfer's own research has focused primarily on long-term treatment strategies for recurrent mood disorders, the pathogenesis of depression, and the relationship between biomarkers and depression. In 1990, he was elected to the National Academy of Medicine (formerly the Institute of Medicine).

Dr. Kupfer has served as President of the Society of Biological Psychiatry and the American College of Neuropsychopharmacology and was the Founding President of the International Society of Bipolar Disorders. Dr. Kupfer chaired the American Psychiatric Association Task Force for DSM-5. His proudest accomplishment, however, is the number of individuals he has mentored who have, in turn, become leaders in the fields of neuroscience and psychopharmacology.

ASCP

Award Winners

Recipient of the Paul Wender Best Paper in the Journal of Clinical Psychiatry Award

Emil F. Coccaro, M.D.
Pritzker School of Medicine, University of Chicago

Nominated for: *Toxoplasma gondii Infection: Relationship With Aggression in Psychiatric Subjects*

Emil F. Coccaro, M.D.; Royce Lee, M.D.; Maureen W. Groer, Ph.D.; Adem Can, Ph.D.; Mary Coussons-Read, Ph.D.; and Teodor T. Postolache, M.D.

Dr. Emil F. Coccaro is currently the Ellen C. Manning Professor in the Department of Psychiatry & Behavioral Neuroscience at the Pritzker School of Medicine, University of Chicago. He received his undergraduate B.S. degree in Biology from Fordham University, where he graduated Magna Cum Laude in Cursu Honoram in 1975. Dr. Coccaro continued his studies at the New York University School of Medicine, completing his M.D. degree in 1979. After a medical internship at the University of Cincinnati Medical Center and a psychiatric residency at the Mount Sinai Medical Center in New York City, Dr. Coccaro joined the faculty of the Department of Psychiatry at the Mount Sinai School of Medicine in 1983. In 1989, Dr. Coccaro moved to Philadelphia to found and direct the Clinical Neuroscience Research Unit at the MCP Hahnemann School of Medicine. Dr. Coccaro moved to the Pritzker School of Medicine at the University of Chicago as the Director of the Clinical Neuroscience & Psychopharmacology Research Unit in September 1999. In 2004, he became Chairman of the Department and continued in that position through 2016. Dr. Coccaro is a Distinguished Fellow of the American Psychiatric Association (APA) and a Fellow of the American College of Neuropsychopharmacology (ACNP).

Dr. Coccaro's work involves neurobiologic and treatment studies of impulsive aggressive behavior in humans. This work led to his authorship of the DSM-5 Criteria for Intermittent Explosive Disorder (IED). He is the recipient of various awards, including the A.E. Bennett Award for Outstanding Research and the National Alliance for the Mentally III's Exemplary Psychiatrist Award. He serves on the editorial boards of several journals, among them the Journal of Psychiatric Research, Journal of Personality Disorders, and Aggression and Violent Behavior. In addition, he is the Editor of Behavioral Neuroscience Reports, and has been the Impulse Control and Personality Disorders Section Editor for Current Psychiatry Reports. Dr. Coccaro has been the recipient of a number of research grants from the National Institute of Mental Health, the American Foundation for Suicide Prevention, the Borderline Personality Disorder Research Foundation, and the Harry Frank Guggenheim Foundation. Dr. Coccaro is the author of more than 200 peer-reviewed journal articles, as well as more than 40 book chapters. He has edited three books, including Aggression: Psychiatric Assessment and Treatment, published by Marcel Dekker. He lectures widely on topics such as mood and personality disorders and the neuroscience, neuropsychopharmacology, genetics, and treatment of impulsive aggressive behavior.

Award Winners





New Investigator Awardees

Sofia Bouhlal, Ph.D.

National Institute on Alcohol Abuse and Alcoholism and Intramural Research Program, National Institute on Drug Abuse

Mehmet Burcu, Ph.D., M.S. University of Maryland Baltimore

Shanna L. Burke, Ph.D., MSW, LCSW

Florida International University

Marco Antonio Knob Caldieraro, M.D., Ph.D.

Massachusetts General Hospital & Harvard Medical School

Simmie Foster, M.D., Ph.D.

Massachusetts General Hospital & Harvard Medical School

Srinath Gopinath, M.D.

SUNY Health Science Center at Brooklyn

Laura M. Hack, M.D., Ph.D.

Emory University School of Medicine

Ayana Jordan, M.D., Ph.D.

Yale University School of Medicine

Bashkim Kadriu, M.D.

National Institute of Mental Health

Bhanu Prakash Kolla, M.D.

Mayo Clinic

Emily Olfson, M.D., Ph.D.

Child Study Center, Yale School of Medicine

Laura Politte, M.D.

University of North Carolina at Chapel Hill

Rajiv Radhakrishnan, M.D.

Yale School of Medicine

Jose M. Rubio, M.D.

The Zucker Hillside Hospital

Dongju Seo, Ph.D.

Yale University School of Medicine

Anup Sharma, M.D., Ph.D.

University of Pennsylvania

Deena Walker, Ph.D.

Icahn School of Medicine at Mount Sinai

Kristen Ward. Pharm.D.

University of Michigan

Samuel Wilkinson, M.D.

Yale School of Medicine

Jessica Wojtalik, MSW

University of Pittsburgh School of Social Work

2016 ASCP Research Grant Awardee

Virginie-Anne Chouinard, M.D.

Harvard Medical School, McLean Hospital

Nominated for: Glucose Metabolism and Brain Bioenergetics Measured by 31P Magnetic Resonance Spectroscopy in Unaffected Siblings of Patients With Psychotic Disorders

See Dr. Chouinard's poster on Thursday, June 1, 2017 at Poster #50.

ASCP

Featured Speakers

Regulatory Plenary Wednesday, May 31st from 8:30 a.m. – 10:00 a.m.



Tiffany Farchione, M.D. US Food and Drug Administration

Dr. Farchione received her medical degree from Wayne State University in Detroit, Michigan, and completed adult residency and child & adolescent fellowship training at the University of Pittsburgh's Western Psychiatric Institute and Clinic. Dr. Farchione is board certified in both general and child & adolescent psychiatry. Prior to joining FDA in 2010,

Dr. Farchione was affiliated with the University of Pittsburgh Medical Center, and was on the faculty of the University of Pittsburgh.

As the Deputy Director in the Division of Psychiatry Products at FDA, Dr. Farchione is involved in the oversight of new drug review for all psychiatric drug development activities conducted under INDs, and the review of all NDAs and supplements for new psychiatric drug claims.



Islam Younis, Ph.D. US Food and Drug Administration

Dr. Younis holds a B.Sc. in Pharmacy from An-Najah National University, Palestine and M.Sc. and Ph.D. degrees in Pharmaceutical Sciences from West Virginia University. Islam has completed additional training leading to graduate certificates in Public Health, Drug Development and Regulatory Sciences, and Pharmacoepidemiology from

Georgetown University, University of California at San Francisco, and University of Pennsylvania, respectively. He joined FDA in 2008 and worked as a clinical pharmacology reviewer on the CardioRenal and Psychiatry teams. In 2012, Islam was selected as the team leader for the Antiviral Team. In 2016, Islam was selected to also lead the Clinical Pharmacology team responsible for review of application submitted under the animal rule and as an associate member in the Office of Clinical Pharmacology OCP Guidance and Policy Team. Islam has been active in regulatory science and mentorship of Pharm D students and fellows. Islam has published 17 peer reviewed papers, 19 conference abstracts, and two book chapters and presented in national meetings. He is also leading multiple regulatory research projects focusing on leveraging prior knowledge toward optimizing clinical trials and improving drug development efficiency in schizophrenia and specific populations (mainly hepatic and renal impairment). Islam served as a member on several FDA guidance working groups including exposure-response, HIV, HCV, and HBV guidance working groups.

Featured Speakers





Luca Pani, M.D. European Medicines Agency

Luca Pani, M.D., specialized in Psychiatry, is an Expert in Pharmacology and Molecular Biology, and a Fellow of the National Research Council of Italy who has served as Director General of the Italian Medicines Agency (AIFA) from 2011 to 2016, with CEO roles of both Regulator and Negotiator / Payer.

He is currently Italian Alternate Member of the Committee for Human Medicine Products (CHMP); Full Member of the Scientific Advice Working Party (SAWP); participant of the Working Party on Central Nervous System (WPCNS) and has been the Chair of both the European Union Management Board Telematic Committee (EUMBTC) and the EU Network Pharmacovigilance Oversight Group for the European Medicines Agency (EMA) in London (UK) from 2013 to 2016.

Luca Pani is the author of over one hundred and fifty scientific publications, editor and author of several volumes and also a writer of successful leisure literature. He has attended over 1,000 conferences, seminars, workshops and national and international roundtables as an invited speaker. He is currently associated with the Faculty of the Department of Psychiatry and Behavioural Sciences at the University of Miami School of Medicine, in USA.



Valentina Mantua, M.D., Ph.D. Italian Medicines Agency (AIFA)

Valentina Mantua is a medical doctor and a psychiatrist with an extensive clinical experience in the field of psychosis and affective disorders both at the Maudsley NHS Trust in London and University Hospital in Pisa, Italy, where she also obtained a Ph.D. in Neurobiology of Affective Disorders.

She joined the regulatory world in 2012 as expert CNS assessor at the Italian Medicines Agency (AIFA) and she is currently Italian Alternate Member of the Scientific Advice Working Party (SAWP) and Full Member of the Central Nervous System Working Party on (CNSWP) at the European Medicines Agency (EMA). She is also the Italian representative at the EU-Innovation Network, supporting innovation in drug development both at a national and European level.

ASCP

Featured Speakers

Keynote Plenary: Serving the Needs of the Diverse Population Thursday, June 1st from 8:15 a.m. - 9:45 a.m.



Roberto Lewis-Fernández, M.D. Columbia University & New York State Psychiatric Institute

Roberto Lewis-Fernández, M.D. is Professor of Clinical Psychiatry at Columbia University and Director of the New York State Center of Excellence for Cultural Competence and the Hispanic Treatment Program, and Co-Director of the Anxiety Disorders Clinic, at New York State Psychiatric Institute. His research focuses on developing culturally

valid interventions and instruments to enhance patient engagement, reduce misdiagnosis, and help overcome disparities in the care of underserved cultural groups, especially Latinos. He is Chair of the Cultural Committee of the Group for the Advancement of Psychiatry, President of the Society for the Study of Psychiatry and Culture, President-elect of the World Association of Cultural Psychiatry, and Past President of the American Society of Hispanic Psychiatry. He was a member of the NIMH National Advisory Mental Health Council and Chair of the Cross-Cultural Issues Subgroup of DSM-5. Currently, he is Co-chair of the ICD-11 Working Group on Culture-Related Issues and a member of the Working Group on Somatic Distress and Dissociative Disorders.



Michael T. Compton, M.D., M.P.H.
Columbia University, College of Physicians and Surgeons

Michael T. Compton, M.D., M.P.H., is Professor of Psychiatry at the Columbia University College of Physicians & Surgeons. He is also Medical Director for Adult Services for the New York State Office of Mental Health, the State's public mental health system. OMH regulates, certifies, and

oversees more than 4,500 mental health programs, and also directly provides State-operated mental health services at 17 adult State hospitals and more than 60 adult outpatient clinics.

After completing medical school at the University of Virginia in 1997, Dr. Compton trained in general psychiatry, preventive medicine, public health, and community psychiatry, all at Emory University in Atlanta, Georgia. He served on faculty as an Assistant Professor, and then tenured Associate Professor, at Emory from 2003 to 2010. He then served as Professor and Director of Research Initiatives in the Department of Psychiatry and Behavioral Sciences at The George Washington University School of Medicine and Health Sciences in downtown D.C., from 2011 to 2013. Upon relocating to New York, he was Chairman of Psychiatry at Lenox Hill Hospital in the Upper East Side and Professor of Psychiatry at Hofstra Northwell School of Medicine for three years.

Featured Speakers

Dr. Compton has had continuous NIMH research funding for more than 15 years, conducting research on first-episode psychosis, the Crisis Intervention Team (CIT) model of collaboration between law enforcement and mental health, linguistic abnormalities in persons with schizophrenia, and the effectiveness of a new form of recovery-oriented community navigation for persons with serious mental illnesses and repeated hospitalizations. His research has led to more than 200 publications. He is also very interested in incorporating public health and prevention into psychiatry, one means of which is by addressing the social determinants of health. Dr. Compton teaches in a wide array of settings and serves on a number of institutional, regional, and national committees. He is a Fellow of the American College of Preventive Medicine and a Distinguished Fellow of the American Psychiatric Association. Recent honors include being a Visiting Professor at the University of Perugia, Italy last year; Honorary Professor at the Mexican Psychiatric Institute last year; and the 2016 Luke and Grace Kim Visiting Professor in Cultural Psychiatry at University of California - Davis earlier this year. His edited books include, among others, the Clinical Manual of Prevention in Mental Health (2009); The Social Determinants of Mental Health (2015), and Marijuana and Mental Health (2016).



Andrew Nierenberg, M.D. Massachusetts General Hospital & Harvard Medical School

Dr. Andrew Nierenberg is a graduate of the Albert Einstein College of Medicine of Yeshiva University, Bronx, NY. He completed his residency in psychiatry at New York University/Bellevue Hospital. He next studied clinical epidemiology at Yale University as a Robert Wood Johnson

Clinical Scholar and then joined the faculty at Harvard Medical School at McLean Hospital in Belmont, Massachusetts. He then joined the Department of Psychiatry at Massachusetts General Hospital in Boston, where he holds his current positions.

Dr. Nierenberg has published over 440 papers and has been listed in *The Best Doctors in America* for the treatment of mood and anxiety disorders in every edition since 1994. He was awarded the Gerald L. Klerman Young and Senior Investigator Awards by the Depression and Bipolar Support Alliance, the Brain and Behavior Research Foundation Colvin Prize, and was listed in 2014 and 2015 as among the world's most influential scientific minds by Thomson Reuters for having the top 1% of citations in psychiatry.

He is the incumbent holder of the Thomas P. Hackett, M.D. Endowed Chair in Psychiatry at MGH, and Director of the Dauten Family Center for Bipolar Treatment Innovation as well as professor of psychiatry at Harvard Medical School.

ASCP

Featured Speakers

Federal Agency Directors Plenary Thursday, June 1st from 10:00 a.m. – 12:30 p.m.



Raye Litten, Ph.D.

National Institute on Alcohol Abuse and Alcoholism

Dr. Litten is the Acting Director, Division of Medications Development at National Institute on Alcohol Abuse and Alcoholism (NIAAA), NIH. He manages the NIAAA medications development program to treat Alcohol Use Disorder (AUD). Dr. Litten oversees the development of

efficacious medications by translating neuroscience discoveries into lead compounds and advancing them through drug development pipeline. He oversees two recent NIAAA initiatives, the NCIG clinical trials network and the human laboratory program for testing candidate compounds. He is a member of the Steering Committee of the American Society of Clinical Psychopharmacology and the Alcohol Clinical Trials Initiative (ACTIVE) group. He is also a member of the Steering Committee of Department of Defense Alcohol and Substance Disorders Research Program.

Dr. Litten received his Ph.D. from the Department of Physiology, Virginia Commonwealth University and completed his post-doc in the Department of Physiology and Biophysics, University of Vermont. He arrived at NIAAA in 1989 and has served as Chief of the Treatment Research Branch and later as Associate Director in the Division of Treatment and Recovery Research.

Featured Speakers

ASCP



Amir Tamiz, Ph.D.

National Institute of Neurological Disorders and Stroke

Dr. Tamiz is the Director of the Division of Translational Research at the National Institute of Neurological Disorders and Stroke (NINDS). Prior to that he was a Program Director overseeing the NIH Blueprint Neurotherapeutics Network (BPN) and Innovation Grants to Nurture Initial Translational Efforts (IGNITE). Blueprint Neurotherapeutics Network is a collaborative effort among 15 of the agency's institutes

and centers, leveraging their resources to offer neuroscience researchers grant funding for drug discovery and development activities to confront major, cross-cutting challenges in neuroscience. The program was established as a pipeline between academic and industry drug development research and offers neuroscience researchers a "virtual pharma" to develop promising hit compounds from chemical optimization through Phase I clinical testing. Principal Investigators receive grant funding and in kind discovery and development resources such as medicinal chemistry, API synthesis and manufacture, formulation and drug product manufacture, IND enabling studies, and clinical trial capabilities. Launched in December 2014, IGNITE program is intended to create a more contiguous source of support from discovery to preclinical development. The first two programs include: 1) Assay Development and Therapeutic Agent Identification and Characterization to Support Therapeutic Discovery (PAR-15-070) and 2) Pharmacodynamics and in vivo Efficacy Studies for Small Molecules and Biologics/Biotechnology Products (PAR-15-071). Prior to joining NIH in 2012, Dr. Tamiz had held scientific and management positions in research and development of therapeutic programs at Corvas International (acquired by Dendreon), CovX (now part of Pfizer), and Alba Therapeutics. Dr. Tamiz received his Ph.D. at University of Oregon and conducted postdoctoral research at the Department of Neuroscience at Georgetown University Medical Center.

ASCP

Featured Speakers



Josh Gordon, M.D., Ph.D.
National Institute of Mental Health

Dr. Gordon received his M.D./Ph.D. at the University of California, San Francisco and completed his Psychiatry residency at Columbia University. He joined the Columbia faculty in 2004. He became the Director of the National Institute of Mental Health in September 2016.

Dr. Gordon's research focuses on the analysis of neural activity in mice carrying mutations of relevance to psychiatric disease. He employs a range of systems neuroscience techniques, including in vivo anesthetized and awake behaving recordings and optogenetics, the use of light to control neural activity. His work has direct relevance to schizophrenia, anxiety disorders, and depression.

Dr. Gordon has received several prestigious awards, including the The Brain and Behavior Research Foundation – NARSAD Young Investigator Award, the Rising Star Award from the International Mental Health Research Organization, the A.E. Bennett Award from the Society of Biological Psychiatry, and the Daniel H. Efron Award from the American College of Neuropsychopharmacology.



Kevin Walton, Ph.D. National Institute on Drug Abuse

Dr. Kevin Walton is the Chief of the Clinical Research Grants Branch in the Division of Therapeutics and Medical Consequences at the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH). His branch is responsible for leading the grant-funded clinical

research exploring new medication, behavioral, and device development for the treatment of substance use disorders. After a position as an Assistant Professor at the University of Michigan, Dr. Walton spent 15 years in neuroscience drug discovery in the biotech and pharmaceutical industries where he worked on developing novel medications for both neurological and psychiatric disorders. He has been at NIH since 2010 and joined NIDA in 2013. Dr. Walton received his Ph.D. in Pharmacology at the Johns Hopkins University School of Medicine.

Featured Speakers

ASCP



Richard K. Nakamura, Ph.D. Center for Scientific Review

Dr. Richard K. Nakamura is the Director of the Center for Scientific Review at National Institutes of Health. In that capacity, he leads the review of grant applications of the National Institutes of Health. Dr. Nakamura received his Bachelor of Arts in Psychology from Earlham College and his Ph.D. in Psychology from State University of New York (Stony Brook, NY). He was with the National

Institute of Mental Health from 1976 to 2011. In 2001, he received the NIH-Asian/Pacific American Organization (APAO) Outstanding Achievement Award for Administrative Work. In 2002, Dr. Nakamura was elected by the American Association for the Advancement of Science (AAAS) to the status of AAAS Fellow. Also in 2002, Dr. Nakamura was awarded the Presidential Rank Award for outstanding leadership. In 2004 and 2005 respectively, he received leadership awards from the Federation of Behavioral Psychological and Cognitive Sciences, and from the International Society for Behavioral Neuroscience. In 2009, he was awarded the NIH Director's Award for Outstanding Administration.



Grayson Norquist, M.D., MSPH Patient-Centered Outcomes Research Institute

Grayson Norquist, M.D., MSPH, is Vice-Chair, Emory University Department of Psychiatry and Behavioral Sciences, and Chief of Psychiatry Service at Grady Health System in Atlanta. Before joining Emory, he was Professor and Chair of the Department of Psychiatry and Human Behavior, at the University of Mississippi School of Medicine. He served in a number of leadership positions at the National Institute of Mental Health (NIMH), including

director of the Division of Services and Intervention Research, a division responsible for clinical, prevention, and services research at NIMH. Norquist has been a member of several journal editorial boards, including *Psychiatric Services, Archives of General Psychiatry* and *Journal of Mental Health Policy and Economics*, and received various national government and public awards, including the NIH Director's Award, the NIH Special Service Award, and the National Alliance for the Mentally III Exemplary Psychiatrist Award. He received a BA from the University of Mississippi, a MPH from the UCLA School of Public Health, and a M.D. from the University of Mississippi Medical Center. His research has focused on improving mental health services for underserved populations and development of quality measures.

ASCP

Featured Speakers



Colonel Dennis McGurk, Ph.D. Military Operational Medicine Research Program

COL Dennis McGurk entered the military in 1990 as an Infantryman in the Army Reserve. He was commissioned as a Medical Service Corps Officer in 1994. COL McGurk earned his Ph.D. in Experimental Psychology from Texas Tech University in 2002. He has served as a Platoon Leader, Operations Officer, Company Commander, Research Branch Chief, and Detachment Commander. During his

22+ years of military service, COL McGurk has deployed to Haiti, Kosovo, Iraq and Afghanistan. He has published in peer-reviewed journals, was the lead author on two book chapters, has presented to numerous scientific and military conferences and has briefed many senior military leaders to include the Under Secretary of Defense for Personnel and Readiness, the Secretary of the Army and the Secretary of the Navy.

Regulatory Wrap-Up Friday, June 2nd from 10:15 a.m. – 11:45 a.m.

Tiffany Farchione, M.D.
US Food and Drug Administration
See previous bio

Islam Younis, Ph.D.
US Food and Drug Administration
See previous bio

Luca Pani, M.D. European Medicines Agency See previous bio

Valentina Mantua, M.D., Ph.D. Italian Medicines Agency (AIFA) See previous bio

Acknowledgements

ASCP

Steering Committee Chairs



Marlene Freeman, M.D.



John Newcomer, M.D.

Program Committee Chairs



Alan Gelenberg, M.D.



Holly Swartz, M.D.

New Investigator Award Program Chairs



Mark H. Rapaport, M.D.



Christopher Sarampote, Ph.D.

ASCP | Acknowledgements

Steering Committee Members

Ross Baker, M.D. Otsuka Pharmaceuticals

★ Lori Davis, M.D.

Tuscaloosa VA Medical Center

Elliot Ehrich, M.D.

Alkermes Pharmaceuticals

★ Tiffany Farchione, M.D.

US Food and Drug Administration

Alan Gelenberg, M.D.

Journal of Clinical Psychiatry

David J. Kupfer, M.D.

University of Pittsburgh School of Medicine

Raye Litten, Ph.D.

National Institute of Alcohol Abuse and Alcoholism

Antony Loebel, M.D.

Sunovion Pharmaceuticals

Stephen Marder, M.D.

Semel Institute, University of California, Los Angeles

Stephanie O'Malley, Ph.D.

Yale University School of Medicine

Joseph Palumbo, M.D.

Mitsubishi Tanabe Pharma Development America

Luca Pani, M.D.

European Medicines Agency

Mark H. Rapaport, M.D.

Emory University School of Medicine

★ Holly Swartz, M.D.

University of Pittsburgh School of Medicine

★ Madhukar Trivedi, M.D.

University of Texas Southwestern Medical Center

Benedetto Vitiello, M.D.

University of Turin

Acknowledgements

ASCP

Program Committee Members

Scott Aaronson, M.D. Sheppard Pratt Health Systems

Mohammed Ahmed, M.D. University of California, San Diego

- ★ Isabelle Bauer, Ph.D. University of Texas at Houston
- ★ Ram Bishnoi, M.D. University of Texas Health Center, San Antonio

Leslie Citrome, M.D., M.P.H. New York Medical College

- ★ Crystal Clark, M.D. Northwestern University
- ★ Anita Clayton, M.D. University of Virginia

Lawrence Cohen, Pharm.D. University of North Texas Health Science Center

★ Christoph U. Correll, M.D. The Zucker Hillside Hospital

> Lynn Crismon, Pharm.D. The University of Texas at Austin

★ Tiffany Farchione, M.D. US Food and Drug Administration

Maurizio Fava, M.D. Massachusetts General Hospital

★ Bradley Gaynes, M.D.* University of North Carolina

> Ahmad Hameed, M.D. Pennsylvania State College of Medicine

Usman Hameed, M.D. Penn State Hershey Medical Center

★ Ebrahim Haroon, M.D. Emory University School of Medicine

ASCP | Acknowledgements

Program Committee Members (continued)

Michael Henry, M.D.

Massachusetts General Hospital

Richard Keefe, Ph.D.

Duke University Medical Center

Susan Kornstein, M.D.

Virginia Commonwealth University

Maria Lisotto, M.D.

Massachusetts General Hospital/McLean Hospital

Stephen Marder, M.D.

Semel Institute, University of California, Los Angeles

★ Tim Mariano, M.D., Ph.D.

Harvard Medical School

Barbara Milrod, M.D.

Weill Cornell University

★ Francisco Moreno, M.D.

University of Arizona

★ Craig Nelson, M.D.*

University of California, San Francisco

★ Katharine Phillips, M.D.

Rhode Island Hospital/Brown University

Bruce Saltz, M.D., P.A.

Mental Health Advocates, Inc.

★ Erika Saunders, M.D.

Pennsylvania State College of Medicine

Richard Shelton, M.D.

University of Alabama at Birmingham

★ Jair Soares, M.D.

University of Texas School of Medicine at Houston

Mark Stein, M.D.

University of Washington

Antonio Teixeira, M.D.

University of Texas Health Science Center at Houston

Acknowledgements

ASCP

Program Committee Members (continued)

Benedetto Vitiello, M.D. National Institute of Mental Health

- ★ Carlos A. Zarate, M.D. National Institute of Mental Health
- ★ Jianping Zhang, M.D., Ph.D. The Zucker Hillside Hospital

New Investigator Award Program Committee

- ★ Christoph U. Correll, M.D. The Zucker Hillside Hospital
- ★ Lori Davis, M.D. Tuscaloosa VA Medical Center
- ★ Tiffany Farchione, M.D.
 US Food and Drug Administration

Bruce Kinon, M.D. Lundbeck

Ivan Montoya, M.D., M.P.H. National Institute on Drug Abuse

Lynn Morin, M.A.

National Institute on Alcohol Abuse and Alcoholism

★ Katharine Phillips, M.D. Rhode Island Hospital / Brown University

A. John Rush, M.D. National University of Singapore

Nina R. Schooler, Ph.D. State University of New York, Downstate Medical Center

★ Holly A. Swartz, M.D. University of Pittsburgh School of Medicine

ASCP | Acknowledgements

ASCP Officers and Board

Mark H. Rapaport, M.D. – ASCP President Emory University School of Medicine

Maurizio Fava, M.D. - ASCP Past-President

Massachusetts General Hospital

Michael Thase, M.D. – ASCP Treasurer & ASCP President-elect University of Pennsylvania

John Newcomer, M.D. - ASCP Treasurer-elect

Charles E. Schmidt College of Medicine, Florida Atlantic University

Joseph Calabrese, M.D.

University Hospitals Cleveland Medical Center

Leslie Citrome, M.D., M.P.H.

New York Medical College

★ Christoph U. Correll, M.D. The Zucker Hillside Hospital

★ Kristina Deligiannidis, M.D.

The Zucker Hillside Hospital; Feinstein Institute for Medical Research; Hofstra Northwell School of Medicine

Marlene Freeman, M.D.*

Massachusetts General Hospital

Alan Gelenberg, M.D.

Journal of Clinical Psychiatry

Joseph Goldberg, M.D.*

Icahn School of Medicine at Mount Sinai

John Kane, M.D.*

The Zucker Hillside Hospital

Arifulla Khan, M.D.

Northwest Clinical Research Center

★ Katharine Phillips, M.D.

Rhode Island Hospital / Brown University

★ Madhukar Trivedi, M.D.

UT Southwestern Medical Center

Sidney Zisook, M.D.

University of California, San Diego

Stephen Marder, M.D.

Semel Institute, University of California, Los Angeles, Board Member-elect

Trisha Suppes, M.D.*

Stanford University, Board Member-elect

Meeting Announcements ASCP

Meeting Services

Registration Desk Hours:

Monday 10:00 a.m. – 5:00 p.m. Tuesday 7:30 a.m. – 6:00 p.m. Wednesday 7:30 a.m. – 7:00 p.m. Thursday 7:30 a.m. – 6:00 p.m. Friday 7:30 a.m. – 12:00 p.m.

*The registration/meeting information desk is located in the Rotunda East on the Second Level.

The ASCP Speaker Ready Room is open on the below dates and times for presenters to upload slides. <u>The meeting organizers ask that all speakers</u> upload their slides 24 hours prior to their scheduled presentation time.

The Speaker Ready Room is located in the Sundial meeting room, on the Third Level.

Monday 11:00 a.m. – 5:00 p.m. Tuesday - Thursday 7:30 a.m. – 6:30 p.m. Friday 7:30 a.m. – 10:30 a.m.

ASCP Wi-Fi

Network: ascp2017 Access PIN: ascp2017

Americans with Disabilities Act - It is the policy of ASCP not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please call the Executive Office at 615-649-3085 or send an email to info@ascpp.org.

<u>Discounts</u> – All ASCP Annual Meeting attendees who booked their room at the Loews Miami Beach through the ASCP meeting website will have the following resort amenities complimentary:

- Internet in the guest rooms
- Fitness Center admittance
- Access to Newspapers with Loews Mobile App

ASCP Membership - If you would like to join ASCP, you can log onto our website at https://www.ascpp.org/ and register online. Membership applications are available at the ASCP membership booth, located next to the meeting registration desk in the Rotunda East on the Second Level. You may also contact the ASCP office at 615-649-3085 to request one.

ASCP Fellow Membership

If you have been a member of ASCP for 10+ consecutive years and attended 5 or more meetings, you may be eligible for Fellowship Membership. Contact ASCP's Executive Office, info@ascpp.org, for more information or to confirm your status.

ASCP Meeting Announcements

Continuing Education Credits

Disclosures are available for all ASCP Annual Meeting presenters online at www.ASCPMeeting.org.

Continuing Education Credits are available for physicians, pharmacists, and psychologists. Self-Assessment maintenance of certification credits are available for physicians. Applications for credit must be completed online with the meeting evaluation survey. The survey may be completed during or after the conference at www.ASCPMeeting.org. Surveys for continuing education credit must be submitted no later than June 30, 2017. There is a \$40.00 administrative fee for CME/CE applications. It is the policy of the ASCP to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

THE AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY HAS REVIEWED THE ANNUAL MEETING AND HAS APPROVED THIS PROGRAM AS PART OF A COMPREHENSIVE SELF-ASSESSMENT PROGRAM, WHICH IS MANDATED BY THE ABMS AS A NECESSARY COMPONENT OF MAINTENANCE OF CERTIFICATION.



Satisfactory completion

Participants must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. NOTE: If you are seeking continuing education credit for a specialty not listed, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Meeting Announcements A

ASCP

Physicians/Nurse Practioners



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Amedco and the American Society of Clinical Psychopharmacology (ASCP). Amedco is

accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement – Amedoo designates this live activity for a maximum of 26.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists



Amedoo is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Successful completion of this program qualifies for up to 26.0 contact hours. Note: The Unique Activity Numbers are pending and

will be posted online at a later date.

In order to receive full credit, registrants must arrive no later than 10 minutes after the start of the meeting and must attend the entire meeting.

<u>Psychologists</u>



This course is co-sponsored by Amedco and American Society of Clinical Psychopharmacology (ASCP). Amedco is approved by the American Psychological Association to sponsor continuing education for psychologists. Amedco maintains responsibility for this program and its content. 26.0 hours. **Partial credit will not be awarded.**

All participants who request continuing education credits by June 30, 2017, should expect to receive their statement of credits via email in July.

The Meeting Evaluation Survey will be available at www.ASCPMeeting.org. We encourage all registrants to complete the evaluation. Attendees requesting CME, MOC, or CE credits must complete the survey in order to obtain credits. There is a \$40.00 administrative fee for CME/CE applications. Your candid input on the 2017 meeting is appreciated as we strive to improve the meeting each year.

ASCP | Meeting Announcements

ASCP would like to acknowledge the generosity of the following companies whose unrestricted educational grants have contributed to the overall quality of this meeting:

ACADIA Pharmaceuticals, Inc.
Alkermes, Inc.
Avanir Pharmaceuticals
Neurocrine
Sunovion Pharmaceuticals, Inc.

2018 ASCP Annual Meeting - Save the Date



The 2018 ASCP Annual Meeting will take place May 28 – June 1, 2018 at the Loews Miami Beach Hotel in Miami, Florida. Details regarding abstract submissions for the 2018 Meeting will be released in September 2017.

Monday

Monday, May 29, 2017 | ASCP

AT-A-GLANCE

8:00 a.m. - 4:15 p.m. **NIA Workshop (Invitation Only)**

Cowrie 2

10:00 a.m. - 5:00 p.m. **Registration**

Rotunda East

11:00 a.m. - 5:00 p.m. Speaker Ready Room

Sundial

12:00 p.m. - 1:50 p.m. Latin America Symposium*

Poinciana 1-2

1:50 p.m. - 2:00 p.m. **Break**

Poinciana 1-2

2:00 p.m. - 4:00 p.m. Latin America Symposium*

Poinciana 1-2

ASCP

Notes

Monday, May 29, 2017 | ASCP

FULL SCHEDULE

Monday, May 29, 2017

8:00 a.m. - 4:15 p.m. NIA Workshop (Invitation Only)

Cowrie 2

Co-chairs: Mark Rapaport, M.D., Emory University School of Medicine

Chris Sarampote, Ph.D., National Institute of Mental Health

The ASCP Annual Meeting offers a special program for New Investigators in an effort to promote the education and training of junior investigators in Established investigators were asked to nominate psychopharmacology. individuals who may be interested in a research career in psychopharmacology for this special program. These nominees submitted an abstract describing their current research or area of research interest, a letter of recommendation from their chair or mentor, a career statement and a curriculum vitae. The selection of awardees was based upon the scientific merit of the abstract, the level of training of the nominee and a committee of internal and external reviewers' assessment of the relative value of the specialized program to each applicant at this time in his/her career. The awardees will participate in this special educational workshop and present their posters during the scheduled poster sessions and orals during the Individual Research Reports on Tuesday, May 30, 2017. In addition, they will receive a travel expense award and a certificate acknowledging their participation in the program at an awards ceremony on Tuesday evening, May 30, 2017. This year marks the 25th year of the New Investigator program with 20 New Investigator awardees that are indicated with a ribbon in the poster section of this program; they will also be notated with a ribbon icon in the program book.

Faculty

Nina Schooler, Ph.D. SUNY Downstate Medical Center

A. John Rush, M.D. National University of Singapore

Holly Swartz, M.D. University of Pittsburgh

Michael Davis, M.D., Ph.D. US Food and Drug Administration Bruce Kinon, M.D. Lundbeck

Tiffany Farchione, M.D.

US Food and Drug Administration

Lynn Morin, M.A. National Institute on Alcohol Abuse and Alcoholism

Kevin Walton, Ph.D. National Institute on Drug Abuse

ASCP | **Monday, May 29, 2017**

10:00 a.m. - 5:00 p.m. Registration Open

Rotunda East

11:00 a.m. - 5:00 p.m. Speaker Ready Room

Sundial

12:00 p.m. - 1:50 p.m. Latin America Symposium*

Poinciana 1-2

Chair: Francisco Moreno, University of Arizona

12:00 p.m. - 12:20 p.m. Welcome and Introduction to the Latin American

Symposium Speaker Introduction

12:20 p.m. - 12:50 p.m. Overcoming Latino Mental Health Disparities via

Health Promotion

Daniel Jimenez, University of Miami

12:50 p.m. - 1:20 p.m. Identifying Patients With Bipolar Disorders in

Emergency Departments in Latin-American Countries: Comorbidity and Leading Symptoms Ruby Castilla Puentes, Johnson and Johnson

1:20 p.m. - 1:50 p.m. Effect of a Novel NMDA Receptor Modulator,

Rapastinel (Formerly GLYX-13) in OCD: Proof-of-

Concept

Carolyn Rodriquez, Stanford University

1:50 p.m. - 2:00 p.m. Break

Poinciana 1-2

Monday, May 29, 2017 | ASCP

2:00 p.m. - 4:00 p.m. Latin America Symposium*

Poinciana 1-2

Chair: Francisco Moreno, University of Arizona

2:00 p.m. - 2:10 p.m. Welcome and Introduction

2:10 p.m. - 2:40 p.m. Atypical Antipsychotics in the Treatment of PTSD

Gerardo Villarreal, University of New Mexico

2:40 p.m. - 3:10 p.m. **PTSD and Gender Violence: Ecuador Experience**

Victoria Valdez, International Federation of Societies

of Biological Psychiatry

3:10 p.m. - 3:40 p.m. Pharmacological Updates in Mood Disorders

Rodrigo Machado-Vieira, UTHSC at Houston,

School of Medicine

3:40 p.m. - 4:00 p.m. Closing: Wrap up and Final Remarks

ASCP |

Notes

Tuesday, May 30, 2017 | ASCP

AT-A-GLANCE

Tuesday, May 30, 2017

7:30 a.m. - 6:00 p.m. **Registration**

Rotunda East

7:30 a.m. - 6:30 p.m. Speaker Ready Room

Sundial

7:30 a.m. - 8:30 a.m. NIA Breakfast Roundtable (Invitation Only)

Neptune

7:30 a.m. - 9:00 a.m. **Morning Break**

Americana Foyer

8:30 a.m. - 9:00 a.m. Conference Opening

Salon 3

9:00 a.m. - 10:30 a.m. Panel Sessions

The Role of Modulators of the Opioid System in the Treatment of Neuropsychiatric Illnesses*	Implementing Measurement- Based Care in Clinical Practice*	Inflammation and Obesity in Depression: Neurobiological Mechanisms and Therapeutic Implications*	Pharmacotherapy and Psychosocial Treatment in First Episode Psychosis Studies: Models and Outcomes*
Poinciana 1-2	Poinciana 3-4	Salon 1	Salon 2

10:30 a.m. - 10:45 a.m. Break

Americana Foyer

ASCP | Tuesday, May 30, 2017

10:45 a.m. - 12:15 p.m. **Panel Sessions**

The Development and Selected Performance of Patient Reported Outcomes (PRO) in Psychopharmacotherapy	Targeting Treatment Needs in Women's Mental	Model-Based Approaches to Assist Clinical Development	Development of Antidepressants With Novel Mechanisms of Action*
Trials – Is the Juice Worth the Squeeze? A Review of	Health*	of Psychiatric Products	
Initiatives by the FDA, NIH, and the Alcohol Clinical Trials		Froducts	
Initiative (ACTIVE)			
Poinciana 1-2	Poinciana 3-4	Salon 1	Salon 2

12:15 p.m. - 1:15 p.m. Early Career Lunch (RSVP Only)

Cowrie 1

1:15 p.m. - 1:45 p.m. NIH Diversity Supplement Program*

Salon 1

2:00 p.m. - 4:00 p.m. Pharmaceutical Pipelines

Salon 3

4:00 p.m. - 4:15 p.m. **Break**

Americana Foyer

4:15 p.m. - 5:30 p.m. Individual Research Reports

Understanding and Optimizing Treatments for Special Populations: Hypersomnolence, Binge Eating Disorder, Pregnant Women With Depression, and Bipolar Depressive Episodes With Psychosis*	Treatment Adherence to Atypical Antipsychotic Medications, Ketamine, and Screening for Psychiatric Disorders*	Advances in Schizophrenia Treatment and Assessment*	Focus on Neurocognition, Neurodegeneration, and Alcohol Misuse*
Poinciana 1-2	Poinciana 3-4	Salon 1	Salon 2

6:15 p.m. - 7:45 p.m. **New Investigator Awards Ceremony (Invitation**

Only)

Cowrie 1-2

*of special interest to clinicians

Tuesday, May 30, 2017 ASCP

FULL SCHEDULE

Tuesday, May 30, 2017

7:30 a.m. - 6:00 p.m. Registration

Rotunda East

7:30 a.m. - 6:30 p.m. Speaker Ready Room

Sundial

7:30 a.m. - 8:30 a.m. NIA Breakfast Roundtable (Invitation Only)

Neptune

7:30 a.m. - 9:00 a.m. Morning Break

Americana Fover

8:30 a.m. - 9:00 a.m. Conference Opening

Salon 3

Panel Sessions

9:00 a.m. - 10:30 a.m. The Role of Modulators of the Opioid System in

the Treatment of Neuropsychiatric Illnesses*

Poinciana 1-2

Chair: Maurizio Fava, Massachusetts General Hospital

Discussant: Jonathan Alpert, Massachusetts General Hospital

9:00 a.m. - 9:10 a.m. Introduction

9:10 a.m. - 9:25 a.m. Preclinical Evidence for Potential Therapeutic

Effects of Opioid Modulators in Neuropsychiatric

Conditions

Simmie Foster, Massachusetts General Hospital &

Harvard Medical School

9:25 a.m. - 9:40 a.m. The Role of Buprenorphine/Samidorphan in the

Treatment of Resistant Depression

Elliot Ehrich, Alkermes, PLC

9:40 a.m. - 9:55 a.m. A Clinical Development Program in

Psychiatry for a Selective Kappa Antagonist

Ronald Marcus, Cerecor

*of special interest to clinicians

ASCP Tuesday, May 30, 2017

9:00 a.m 10:30 a.m. (continued)	The Role of Modulators of the Opioid System in the Treatment of Neuropsychiatric Illnesses* Poinciana 1-2
9:55 a.m 10:10 a.m.	Tramadol and Other Opioid Agents in Refractory OCD Paul Keck, Lindner Center of HOPE/University of Cincinnati
10:10 a.m 10:30 a.m.	Discussion
9:00 a.m 10:30 a.m.	Implementing Measurement-Based Care in Clinical Practice* Poinciana 3-4

Chair: Erika Saunders, Penn State College of Medicine **Discussant:** Alan Gelenberg, *Journal of Clinical Psychiatry*

9:00 a.m 9:10 a.m.	Introduction
9:10 a.m 9:25 a.m.	Measurement-Based Care: A Platform for Personalized Clinical Decision-Making A. John Rush, National University of Singapore
9:25 a.m 9:40 a.m.	Design and Implementation of the PCARES Program: Penn State Clinical Assessment and Rating Evaluation System Erika Saunders, Penn State College of Medicine
9:40 a.m 9:55 a.m.	Penn State Clinical Assessment and Rating Evaluation System for Youth Daniel Waschbusch, Penn State Milton S. Hershey Medical Center
9:55 a.m 10:10 a.m.	Mood Outcomes Program: National Network of Depression Centers David Katzelnick, Mayo Clinic
10:10 a.m 10:30 a.m.	Discussion

Tuesday, May 30, 2017 | ASCP

9:00 a.m. - 10:30 a.m. Inflammation and Obesity in Depression:

Neurobiological Mechanisms and Therapeutic

Implications*

Salon 1

Chair: Jennifer Felger, Emory University School of Medicine

Co-Chair, Discussant: Mark Rapaport, Emory University School of Medicine

9:00 a.m. - 9:10 a.m. Introduction

9:10 a.m. - 9:30 a.m. Obesity as a Moderator of Response to

Antidepressants

Richard Shelton, University of Alabama at

Birmingham

9:30 a.m. - 9:50 a.m. Inflammation Effects on Reward Circuitry

and Motivation: Treatment Considerations for

Depression

Jennifer Felger, Emory University School of

Medicine

9:50 a.m. - 10:10 a.m. Inflammatory Biomarkers as Viable Moderators

for Treatment Selection - Results From the

COMED Trial

Madhukar Trivedi, UT Southwestern Medical Center

10:10 a.m. - 10:30 a.m. **Discussion**

9:00 a.m. - 10:30 a.m. Pharmacotherapy and Psychosocial Treatment

in First Episode Psychosis Studies: Models and

Outcomes*

Salon 2

Chair: Nina Schooler, SUNY Downstate Medical Center **Co-Chair:** John Kane, The Zucker Hillside Hospital

Discussant: Dawn Velligan, University of Texas Health Science Center

9:00 a.m. - 9:10 a.m. **Introduction**

9:10 a.m. - 9:30 a.m. Impact of Antipsychotic Medication Dose and

Adherence on Improvement During Cognitive Remediation in Early Course Schizophrenia

Shaun Eack, University of Pittsburgh

^{*}of special interest to clinicians

ASCP | Tuesday, May 30, 2017

9:00 a.m. - 10:30 a.m. (continued)

Pharmacotherapy and Psychosocial Treatment in First Episode Psychosis Studies: Models and Outcomes*

Salon 2

9:30 a.m. - 9:50 a.m. Antipsychotic Medication Effects in the Context

of Psychosocial Treatments after an Initial

Episode of Schizophrenia

Keith Nuechterlein, Semel Institute for Neuroscience

& Human Behavior at UCLA

9:50 a.m. - 10:10 a.m. Psychopharmacological Treatment in the RAISE-

ETP Study: A Manual and Computer Decision Support System Based Intervention Within a Comprehensive First Episode Specialty Care

Program

Delbert Robinson, Hofstra NS-LIJ School of Medicine

10:10 a.m. - 10:30 a.m. **Discussion**

10:30 a.m. - 10:45 a.m. Break

Americana Foyer

Panel Sessions

10:45 a.m. - 12:15 p.m. The Development and Selected Performance

of Patient Reported Outcomes (PRO) in Psychopharmacotherapy Trials – Is the Juice Worth the Squeeze? A Review of Initiatives by the FDA, NIH, and the Alcohol Clinical Trials

Initiative (ACTIVE)

Poinciana 1-2

Chair: Stephanie O'Malley, Yale University School of Medicine

Co-Chair: Daniel Falk, NIAAA/NIH

Discussant: Bernard Silverman, Alkermes, Inc.

10:45 a.m. - 10:55 a.m. Introduction

10:55 a.m. - 11:15 a.m. Patient-Reported Outcomes to Capture the

Patient Voice in Drug Development: A Regulatory

Perspective

Elektra Papadopoulos, US Food and Drug

Administration

*of special interest to clinicians

Tuesday, May 30, 2017 | ASCP

10:45 a.m. - 12:15 p.m. The Development and Selected Performance (continued) of Patient Reported Outcomes (PRO) in Psychopharmacotherapy Trials – Is the Juice

Psychopharmacotherapy Trials – Is the Juice Worth the Squeeze? A Review of Initiatives by the FDA, NIH, and the Alcohol Clinical Trials

Initiative (ACTIVE)

Poinciana 1-2

11:15 a.m. - 11:35 a.m. Alcohol Clinical Trials Initiative (ACTIVE)

Validation of a Potential Patient-Reported Outcome Measure of Alcohol-Related

Consequences (the IMBIBE) and Its Use as an Endpoint in Alcohol Pharmacotherapy Trials

Daniel Falk, NIAAA/NIH

11:35 a.m. - 11:55 a.m. **The Patient-Reported Outcomes Measurement**

Information System (PROMIS) Program: An NIH-Funded Effort to Develop a Psychometrically-Sound Pro Item Bank: Tobacco and Alcohol

Banks

Maria Edelen, RAND Corporation

11:55 a.m. - 12:15 p.m. **Discussion**

10:45 a.m. - 12:15 p.m. Targeting Treatment Needs in Women's Mental

Health*

Poinciana 3-4

Chair: Marlene Freeman, Massachusetts General Hospital Discussant: Lee Cohen, Massachusetts General Hospital

10:45 a.m. - 10:55 a.m. Introduction

10:55 a.m. - 11:15 a.m. Brief Psychotherapy for Maternal Depression:

Impact on School Age Children

Holly Swartz, University of Pittsburgh School of

Medicine

11:15 a.m. - 11:35 a.m. Results From a Phase 2 Trial of SAGE-547 in

Severe Postpartum Depression

Samantha Meltzer-Brody, University of North

Carolina at Chapel Hill

^{*}of special interest to clinicians

ASCP | Tuesday, May 30, 2017

10:45 a.m 12:15 p.m. (continued)	Targeting Treatment Needs in Women's Mental Health* Poinciana 3-4
11:35 a.m 11:55 a.m.	Risk of Depressive Relapse in Women Undergoing Treatment for Infertility Marlene Freeman, Massachusetts General Hospital
11:55 a.m 12:15 p.m.	Discussion
10:45 a.m 12:15 p.m.	Model-Based Approaches to Assist Clinical Development of Psychiatric Products Salon 1

Chair: Hao Zhu, US Food and Drug Administration

Discussant: Mitchell Mathis, US Food and Drug Administration

10:45 a.m. - 10:55 a.m.
 10:55 a.m. - 11:15 a.m.
 Exposure-Response Analysis of Blood Pressure and Heart Rate Changes for Methylphenidate in Healthy Adults

 Yaning Wang, Center for Drug Evaluation and Research, US Food and Drug Administration

11:15 a.m. - 11:35 a.m. Population Pharmacokinetic Modeling and Simulation to Determine Dosing Strategies for

Long Acting Injectable Antipsychotics Hao Zhu, US Food and Drug Administration

11:35 a.m. - 11:55 a.m. Shortening the Duration of Acute Schizophrenia

Registration Trials is a PossibilityIslam Younis, US Food and Drug Administration

11:55 a.m. - 12:15 p.m. Discussion

Tuesday, May 30, 2017 | ASCP

10:45 a.m. - 12:15 p.m. Development of Antidepressants With Novel

Mechanisms of Action

Salon 2

Chair: George Papakostas, Massachusetts General Hospital Co-Chair: Maurizio Fava, Massachusetts General Hospital Discussant: Carlos Zarate, National Institute of Mental Health

10:45 a.m. - 10:55 a.m. Introduction

10:55 a.m. - 11:15 a.m. The Neurogenic Antidepressant Compound, NSI-

189, Shows Potential as a Broad Neurotrophic

Agent

Karl Johe, Neuralstem, Inc.

11:15 a.m. - 11:35 a.m. The Potential Therapeutic Role of Anti-

Inflammatory Agents for Mood DisordersGiacomo Salvadore, Janssen Pharmaceuticals

11:35 a.m. - 11:55 a.m. Synaptic and Extrasynaptic GABA-A Receptors

as Drug Targets in Postpartum Depression and Major Depressive Disorder: Development of Two

Positive Allosteric ModulatorsStephen Kanes, Sage Therapeutics

11:55 a.m. - 12:15 p.m. **Discussion**

12:15 p.m. - 1:15 p.m. Early Career Lunch (RSVP Only)

Cowrie 1

1:15 p.m. - 1:45 p.m. NIH Diversity Supplement Program*

Salon 1

Chair: Lynn Morin, NIH/NIAAA

The National Institutes of Health (NIH) Research Supplements to Promote Diversity in Health-Related Research Program, also known as the Diversity Supplement Program provides additional funds to parent awards to improve the diversity of the research workforce by recruiting and supporting students, post-doctorate and eligible investigators from groups that have been shown to be underrepresented in health-related research. This session will offer Investigators the opportunity to learn more about the program in general and specifics to NIAAA. Current and future student candidates are also encouraged to attend to ask questions regarding their current program, requirements and next steps and learn how this program can help advance their careers.

ASCP | Tuesday, May 30, 2017

2:00 p.m. - 4:00 p.m. **Pharmaceutical Pipeline Presentations** Salon 3 **Chair:** Carlos Zarate, National Institute on Mental Health 2:00 p.m. - 2:10 p.m. Introduction 2:10 p.m. - 2:20 p.m. Low-Dose Bedtime Sublingual Cyclobenzaprine (TNX-102 SL*) for the Treatment of Military-Related PTSD: Retrospective Analyses of the Mediators and Moderators of Treatment Response Gregory Sullivan, Tonix Pharmaceuticals, Inc. 2:20 p.m. - 2:30 p.m. Rationale for the Clinical Development of ITI-214, a PDE1 Inhibitor Kimberly Vanover, Intra-Cellular Therapies, Inc. 2:30 p.m. - 2:40 p.m. Single and Multiple Ascending Dose Study to **Evaluate the Safety, Tolerability, and Cardiac** Safety of Extended-Release Viloxazine (SPN-812) ER) in Healthy Adult Subjects Erika Roers, Supernus Pharmaceuticals, Inc. SAGE-547 and SAGE-217: Novel Positive 2:40 p.m. - 2:50 p.m. Allosteric Modulators of Synaptic and **Extrasynaptic GABA-A Receptors Being Investigated in the Treatment of Mood Disorders** Stephen Kanes, Sage Therapeutics 2:50 p.m. - 3:00 p.m. Bremelanotide (BMT) for Hypoactive Sexual Desire Disorder (HSDD): Efficacy Analyses From the Reconnect Study Anita Clayton, University of Virginia 3:00 p.m. - 3:10 p.m. Results of a Double-Blind, Placebo-Controlled, Tolerability Study of KarXT: A Novel Combination Targeting Muscarinic Acetylcholine Receptors Using Xanomeline With Trospium Chloride to Mitigate Cholinergic Side Effects

Stephen Brannan, Karuna

Tuesday, May 30, 2017 | ASCP

2:00 p.m 4:00 p.m. (continued)	Pharmaceutical Pipeline Presentations Salon 3
3:10 p.m 3:20 p.m.	A Phase Ib Dose Ranging Study of Direct Nose to Brain Delivery of Neuropeptide Y in Patients With Posttraumatic Stress Disorder James Murrough, Icahn School of Medicine at Mount Sinai
3:20 p.m 3:30 p.m.	Long-Term Efficacy and Safety of Extended-Release Molindone (SPN-810) to Manage Impulsive Aggression in Children With Attention-Deficit/Hyperactivity Disorder Toyin Adewole, Supernus Pharmaceuticals, Inc.
3:30 p.m 3:40 p.m.	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia Thomas A. Macek, Takeda Development Center Americas, Inc.
3:40 p.m 3:50 p.m.	Double-Blind, Placebo-Controlled Study of the Novel Therapeutic AEVI-001 in Adolescents With ADHD and Glutamatergic Network Gene Mutations Garry Neil, Aevi Genomic Medicine
3:50 p.m 4:00 p.m.	Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD) Maurizio Fava, Massachusetts General Hospital
4:00 p.m 4:15 p.m.	Break Americana Foyer

ASCP | Tuesday, May 30, 2017

Individual Research Reports

4:15 p.m. - 5:30 p.m.

Understanding and Optimizing Treatments for Special Populations: Hypersomnolence, Binge Eating Disorder, Pregnant Women With Depression, and Bipolar Depressive Episodes With Psychosis

Poinciana 1-2

Chair: Crystal Clark, Northwestern University

4:15 p.m. - 4:20 p.m. **Introduction**

4:20 p.m. - 4:35 p.m. **Dasotraline for the Treatment of Moderate to**

Severe Binge Eating Disorder in Adults: Results From a Randomized, Double-Blind, Placebo-

Controlled Study

Bradford Navia, Sunovion Pharmaceuticals, Inc.

4:35 p.m. - 4:50 p.m. The Prevalence and Correlates of

Hypersomnolence and Associated Role

Impairment in the National Co-Morbidity Survey

Replication (NCS-R)

Bhanu Prakash Kolla, Mayo Clinic

4:50 p.m. - 5:05 p.m. **Optimizing Medication Management for**

Pregnant Women With Depression

Katherine Wisner, Northwestern University Feinberg

School of Medicine

5:05 p.m. - 5:20 p.m. Treatment Outcomes of Acute Bipolar

Depressive Episode With Psychosis

Marco Antonio Caldieraro, Massachusetts General

Hospital

5:20 p.m. - 5:30 p.m. **Discussion**



Tuesday, May 30, 2017 | ASCF

4:15 p.m. - 5:30 p.m. Advances in Schizophrenia Treatment and Assessment

Salon 1

Chair: Richard Keefe, Duke University Medical Center

4:15 p.m. - 4:20 p.m. **Introduction**

4:20 p.m. - 4:35 p.m. Risk Factors for Suicidality in Patients With

Schizophrenia: A Systematic Review, Meta-

Analysis, and Meta-Regression

Fang Yang, The University of Texas Health Science

Center at Houston

4:35 p.m. - 4:50 p.m. Assessing Functional Capacity Using the UCSD

Performance-Based Skills Assessment (UPSA-2-VIM) and the Virtual Reality Functional Capacity

Assessment Tool (VRFCAT)
Alexandra Atkins, NeuroCog Trials

4:50 p.m. - 5:05 p.m. Schizophrenia Polygenic Risk Score Predicts

Antipsychotic Treatment Response in Patients

With First Episode Psychosis

Jianping Zhang, The Zucker Hillside Hospital

5:05 p.m. - 5:20 p.m. Lumateperone (ITI-007): Late Stage Clinical

Program in Schizophrenia

Cedric O'Gorman, Intra-Cellular Therapies, Inc.

5:20 p.m. - 5:30 p.m. **Discussion**

4:15 p.m. - 5:30 p.m. Focus on Neurocognition, Neurodegeneration,

and Alcohol Misuse

Salon 2

Chair: Usman Hameed, Penn State Hershey Medical Center

4:15 p.m. - 4:20 p.m. **Introduction**

4:20 p.m. - 4:35 p.m. **Trauma Exposure Moderates the Genetic**

Overlap Between Alcohol Misuse and Bipolar

Disorders in US Army Soldiers Renato Polimanti, Yale University

ASCP Tuesday, May 30, 2017

	4:15 p.m 5:30 p.m. (continued)	Focus on Neurocognition, Neurodegeneration, and Alcohol Misuse Salon 2
	4:35 p.m 4:50 p.m.	The Relationship Between Cognitive and Functional Performance and Measures of Neurodegeneration Among Hispanic and White Non-Hispanic Individuals With Normal Cognition, Mild Cognitive Impairment, and Dementia Shanna L. Burke, Florida International University
Ŕ	4:50 p.m 5:05 p.m.	Hazardous Alcohol Intake Alters Brain, Autonomic and Hypothalamic-Pituitary-Adrenal Axis Responses to Stress Dongju Seo, Yale University School of Medicine
	5:05 p.m 5:20 p.m.	The Impact of Cerebral Small Vessel Disease in Alzheimer's Disease and Other Late Life Neurocognitive Disorders Walter Swardfager, Sunnybrook Research Institute
	5:20 p.m 5:30 p.m.	Discussion
	4:15 p.m 5:30 p.m.	Treatment Adherence to Atypical Antipsychotic Medications, Ketamine, and Screening for Psychiatric Disorders Poinciana 3-4
	Chair: Bradley Gaynes, University of North Carolina	

Introduction
Differential Adherence to Antipsychotic Medication Impacts Clinical and Functional Outcomes in Antipsychotic-Naïve First-Episode Psychosis Patients: A Longitudinal Study Jessica Wojtalik, University of Pittsburgh School of Social Work
A Web-Based Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders Samuel Wilkinson, Yale School of Medicine

New Investigator Awardee

Tuesday, May 30, 2017 ASCP

4:15 p.m 5:30 p.m. (continued)	Treatment Adherence to Atypical Antipsychotic Medications, Ketamine, and Screening for Psychiatric Disorders Poinciana 3-4
4:50 p.m 5:05 p.m.	Screening for Psychiatric Disorders With Self- Administered Questionnaires Mark Zimmerman, Brown University
5:05 p.m 5:20 p.m.	Measuring the Relationship Between Patient Adherence to Atypical Antipsychotics and Their Other Medications Alison Silverstein, Precision Health Economics
5:20 p.m 5:30 p.m.	Discussion
6:15 p.m 7:45 p.m.	New Investigator Awards Ceremony (Invitation Only) Cowrie 1-2

ASCP |

Notes

Wednesday, May 31, 2017 | ASCP

AT-A-GLANCE

Wednesday, May 31, 2017

6:30 a.m 8:00 a.m.	18th Annual ASCP Fun Run/Walk Open to ALL Attendees! No prior registration necessary. St. Moritz Pool
7:00 a.m 8:15 a.m.	ASCP Steering Committee Meeting (Invitation Only) Crown Conch
7:30 a.m 7:00 p.m.	Registration Rotunda East
7:30 a.m 6:30 p.m.	Speaker Ready Room Sundial
7:30 a.m 8:30 a.m.	NIA Breakfast Roundtable (Invitation Only) Neptune
7:30 a.m 8:15 a.m.	ASCP Curriculum Committee Meeting (Invitation Only) Venus
7:30 a.m 9:00 a.m.	Morning Break Americana Foyer
8:30 a.m 10:00 a.m.	Regulatory Plenary with FDA & EMA Salon 3
10:00 a.m 10:15 a.m.	Break Americana Foyer
10:15 a.m 11:15 a.m.	ASCP Awards Ceremony and ASCP Lifetime Awardee Talk - David Kupfer: After Fifty Years, All Roads Converge Salon 3
11:15 a.m 1:00 p.m.	Poster Session I with Lunch Salon 4

ASCP Wednesday, May 31, 2017

1:00 p.m. - 2:30 p.m. **Panel Sessions**

Optimizing Neuromodulatory and Pharmacologic Approaches to Treatment Refractory Depression*	Impact of Abnormal Involuntary Movements Across Diverse Clinical Populations*	Regulatory and Methodological Considerations in the Evaluation of Drug Dependence in the Clinical Setting	Medication or Psychotherapy as First-Line Treatment for Posttraumatic Stress Disorder? An Update on the Clinical Practice Guidelines for the Prevention and Treatment of PTSD*
Poinciana 1-2	Poinciana 3-4	Salon 1	Salon 2

2:30 p.m. - 3:30 p.m. FDA 101 Session

Salon 3

3:30 p.m. - 3:45 p.m. **Break**

Americana Foyer

3:45 p.m. - 5:45 p.m. **Workshops**

Novel Applications of Ketamine*	Hot Button Topics in Negotiation for Mid-Career Professionals in Psychopharmacology and Allied Fields*	Reducing Health Disparities by Promoting Functional and Life-Satisfaction Assessments in Research and Clinical Practice: Consensus Guidelines to Enhance Measurement-Based Care of Depression*	Tardive Dyskinesia: The Forgotten Adverse Event*
Poinciana 1-2	Poinciana 3-4	Salon 1	Salon 2

5:45 p.m. - 6:45 p.m. ASCP Business Meeting & Reception (ASCP

Members Only)
Poinciana 3-4

6:45 p.m. - 7:45 p.m. **ASCP Reception**

Americana Lawn

*of special interest to clinicians

Wednesday, May 31, 2017 | ASCP

FULL SCHEDULE

Wednesday, May 31, 2017

6:30 a.m 8:00 a.m.	18th Annual ASCP Fun Run/Walk - Open to ALL Attendees! All participants receive a FREE ASCP T-shirt! St. Moritz Pool
7:00 a.m 8:15 a.m.	ASCP Steering Committee Meeting (Invitation Only) Crown Conch
7:30 a.m 8:15 a.m.	ASCP Curriculum Committee Meeting (Invitation Only) Venus
7:30 a.m 7:00 p.m.	Registration Rotunda East
7:30 a.m 6:30 p.m.	Speaker Ready Room Sundial
7:30 a.m 8:30 a.m.	NIA Breakfast Roundtable (Invitation Only) Neptune
7:30 a.m 9:00 a.m.	Morning Break Americana Foyer

ASCP | Wednesday, May 31, 2017

8:30 a.m. - 10:00 a.m. Regulatory Plenary with FDA & EMA Salon 3

Chair: Mark Rapaport, Emory University School of Medicine

Presenters: Tiffany Farchione, US Food and Drug Administration

Islam Younis, US Food and Drug Administration Luca Pani, European Medicines Agency (EMA) Valentina Mantua, Italian Medicines Agency (AIFA)

This year's plenary session will provide updates on major ongoing projects at FDA and EMA.

FDA will present two initiatives. First is a Critical Path Initiative project entitled, "Optimizing Design Elements of Schizophrenia Clinical Trials." The goals of this project were to assess the feasibility of reducing the number of PANSS items, using time to dropout as a trial endpoint, and shortening trial duration. Topline data from the project will be shared during the plenary. The FDA will also discuss our progress toward revising the Agency guidance on assessment of suicidal ideation and behavior in clinical trials.

EMA will provide a general overview of current activities, including the PRIME (PRIority MEdicines) scheme and planned updates to guidelines.

10:00 a.m. - 10:15 a.m. Break
Americana Foyer

Wednesday, May 31, 2017

10:15 a.m. - 11:15 a.m.

ASCP Awards Ceremony and ASCP Lifetime Awardee Talk - David Kupfer: After Fifty Years, **All Roads Converge** Salon 3

Awards Presented to:

Best Paper in the Journal of Clinical Psychiatry Award: Emil F. Coccaro, University of Chicago

Nominated For: Toxoplasma gondii Infection: Relationship With Aggression in Psychiatric Subjects

Presidential Service Award: Ira Glick, Stanford University School of Medicine

2016 Honorific Research Grant Awardee: Virginie-Anne Chouinard, M.D., Harvard Medical School, McLean Hospital. See her award-winning research at Poster 50 on Thursday, June 1, 2017 from 12:30 PM - 2:00 PM.

Lifetime Awardee: David Kupfer, University of Pittsburgh School of Medicine/ Western Psychiatric Institute and Clinic

The last 50 years in clinical psychopharmacology have reflected both the major advances in neuroscience and the major frustrations in the clinical application of psychopharmacologic agents. My own voyage has been highlighted by many of the themes illustrative both of these advances and these frustrations. In this presentation, I shall briefly review the evolution of the concept of major depression as an example of diagnostic issues that have characterized this half-century and the accompanying views of prognosis. The use of clinical trials, primarily RCT's, has led to more precise terminology and methodological advances. The dialectic between dimensional and categorical approaches to diagnosis illustrates other important aspects of this period in psychopharmacology, as does the necessity of identifying biomarkers to track disease, to move in the direction of more precise prognoses and, ultimately, to elucidate underlying etiology.

11:15 a.m. - 1:00 p.m. Poster Session I with Lunch Salon 4

See pages 75-85 for a complete listing of posters.

Wednesday, May 31, 2017

Panel Sessions

1:00 p.m. - 2:30 p.m. **Optimizing Neuromodulatory and Pharmacologic** Approaches to Treatment Refractory Depression* Poinciana 1-2

Chair: Michael Henry, Massachusetts General Hospital Discussant: William Potter, National Institute of Mental Health

1:00 p.m. - 1:10 p.m. Introduction 1:10 p.m. - 1:30 p.m. Pharmacological Strategies in the Treatment of **Resistant Depression** Maurizio Fava, Massachusetts General Hospital 1:30 p.m. - 1:50 p.m. **Optimizing Transcranial Magnetic Stimulation** (TMS) Therapy for TRD Joan Camprodon, Harvard Medical School/ Massachusetts General Hospital 1:50 p.m. - 2:10 p.m. Strategies for Optimizing ECT: Integration of Pharmacology, Anesthesia and Stimulus Parameters. Michael Henry, Massachusetts General Hospital Discussion 2:10 p.m. - 2:30 p.m. 1:00 p.m. - 2:30 p.m. Impact of Abnormal Involuntary Movements Across Diverse Clinical Populations* Poinciana 3-4

Chair: Joseph Goldberg, Icahn School of Medicine at Mount Sinai **Discussant:** Nina Schooler, SUNY Downstate Medical Center

Introduction

1:00 p.m. - 1:10 p.m. 1:10 p.m. - 1:25 p.m. Prevalence of Akathisia, EPS and TD Across **Agents and Patient Populations** Joseph Goldberg, Icahn School of Medicine at Mount Sinai

Wednesday, May 31, 2017 ASCP

1:00 p.m 2:30 p.m. (continued)	Impact of Abnormal Involuntary Movements Across Diverse Clinical Populations* Poinciana 3-4
1:25 p.m 1:40 p.m.	Who's at Risk for Drug-Induced Movement Disorders? A Focus on Diversity of Patient Risk Factors and Clinical Presentations Peter Weiden, Alkermes, Inc.
1:40 p.m 1:55 p.m.	Treatment Adherence and Antipsychotic-Related Adverse Effects Martha Sajatovic, University Hospitals Case Medical Center
1:55 p.m 2:10 p.m.	Current and Emerging Treatments for Drug Induced Movement Disorders Andrew Cutler, Meridien Research
2:10 p.m 2:30 p.m.	Discussion
1:00 p.m 2:30 p.m.	Regulatory and Methodological Considerations in the Evaluation of Drug Dependence in the Clinical Setting Salon 1

Chair: Beatrice Setnik, INC Research
Discussant: Pierre Geoffroy, INC Research

1:00 p.m 1:10 p.m.	Introduction
1:10 p.m 1:30 p.m.	Regulatory Considerations in the Assessment of Drug Dependence and Withdrawal in Humans Jack Henningfield, Pinney Associates
1:30 p.m 1:50 p.m.	Clinical Methods to Evaluate Physical Dependency and Withdrawal Following Abrupt Drug Discontinuation Beatrice Setnik, INC Research

ASCP Wednesday, May 31, 2017

1:00 p.m 2:30 p.m. (continued)	Regulatory and Methodological Considerations in the Evaluation of Drug Dependence in the Clinical Setting Salon 1
1:50 p.m 2:10 p.m.	Practical Considerations Regarding the Administration of Pharmacodynamic Measures to Evaluate Physical Dependency and Withdrawal Following Abrupt Drug Discontinuation Denise Milovan, INC Research
2:10 p.m 2:30 p.m.	Discussion
1:00 p.m 2:30 p.m.	Medication or Psychotherapy as First-Line Treatment for Posttraumatic Stress Disorder? An Update on the Clinical Practice Guidelines for the Prevention and Treatment of PTSD* Salon 2

Chair: Lori Davis, Veterans Affairs Medical Center

1:00 p.m. - 1:10 p.m.

Discussant: Richard Shelton, University of Alabama at Birmingham

Introduction

р	
1:10 p.m 1:25 p.m.	An Evidence Based Review of Early Intervention and Prevention of Posttraumatic Stress Disorder Badari Birur, University of Alabama at Birmingham
1:25 p.m 1:40 p.m.	An Evidence Based Review of Psychotherapy Interventions for Treatment of Posttraumatic Stress Disorder Sheila Rauch, Atlanta VAMC/Emory University School of Medicine
1:40 p.m 1:55 p.m.	Clinical Practice Guidelines for the Pharmacotherapy of Posttraumatic Stress Disorder Lori Davis, Veterans Affairs Medical Center

Wednesday, May 31, 2017 ASCP

1:00 p.m 2:30 p.m. (continued)	Medication or Psychotherapy as First-Line Treatment for Posttraumatic Stress Disorder? An Update on the Clinical Practice Guidelines for the Prevention and Treatment of PTSD* Salon 2
1:55 p.m 2:10 p.m.	Translating the Facilitation or Impairment of Fear Acquisition and Extinction Memories in Trauma-, Stressor-, and Anxiety-Related Disorders: Implications for PTSD Treatment Seth Norrholm, Emory University School of Medicine
2:10 p.m 2:30 p.m.	Discussion
2:30 p.m 3:30 p.m.	FDA 101 Session: Care and Feeding of an Investigational New Drug Salon 3

Chair: Keith Kiedrow, US Food and Drug Administration
Co-chair: Hiren Patel, US Food and Drug Administration
Presenters: Kofi Ansah, William Bender, Kimberly Updegraff, US Food and Drug Administration

The Division of Psychiatry Products (DPP) is part of the Office of New Drugs (OND) in the Center for Drug Development and Research (CDER) at the Food and Drug Administration (FDA). The Division reviews matters related to Investigational New Drug (IND) Applications and New Drug Applications (NDAs) for indications ranging from Schizophrenia and Major Depressive Disorder to Autism and Insomnia. As an investigator, it is important to know and understand the definition of an IND as set forth under 21 CFR 312.3, as well as FDA's interpretation. In addition, investigators must be aware of the responsibilities related to IND submission and maintenance and must understand that these responsibilities differ depending on whether the investigator is participating as part of an industry-funded clinical trial or as an individual investigator. For the individual investigator, there are many things to consider such as whether an IND is necessary, what to include in an application, what happens after the application is submitted, and reporting requirements for on-going studies. The FDA has numerous resources available to help investigators navigate the process.

3:30 p.m. - 3:45 p.m. Break

Americana Foyer

*of special interest to clinicians

ASCP Wednesday, May 31, 2017

Workshops

3:45 p.m. - 4:00 p.m.

3:45 p.m. - 5:45 p.m. Novel Applications of Ketamine*

Poinciana 1-2

Chair: Waguih IsHak, Cedars-Sinai Medical Center and UCLA

Introduction

4:00 p.m. - 4:25 p.m. Intravenous Ketamine for the Treatment of

Comorbid Pain and Depression

Jonathan Dang, Cedars-Sinai Medical Center

4:25 p.m. - 4:50 p.m. Ketamine for Treatment of Depression in

Parkinson's Disease

Brigitte Vanle, Cedars-Sinai Medical Center

4:50 p.m. - 5:15 p.m. The Challenges of Maintenance and Relapse

Prevention After Ketamine IV: The Role of

Sublingual Ketamine

Waguih IsHak, Cedars-Sinai Medical Center and

UCLA

5:15 p.m. - 5:45 p.m. **Discussion**

3:45 p.m. - 5:45 p.m. Hot Button Topics in Negotiation for Mid-Career

Professionals in Psychopharmacology and Allied

Fields*

Poinciana 3-4

Chair: Andrea Schneider, Marquette University Law School

Wednesday, May 31, 2017 | ASCP

3:45 p.m. - 5:45 p.m. Reducing Health Disparities by Promoting Functional and Life-Satisfaction Assessments in Research and Clinical Practice: Consensus Guidelines to Enhance Measurement-Based Care of Depression*

Salon 1

Chair: Madhukar Trivedi, UT Southwestern Medical Center Co-Chair: Manish Jha, UT Southwestern Medical Center

3:45 p.m. - 4:00 p.m. **Introduction**

4:00 p.m. - 4:25 p.m. Work and Non-Work Related Productivity

Improvement With Antidepressant Medications
Predicts Long-Term Clinical Outcomes in
Outpatients With Major Depressive Disorder
Madhukar Trivedi, UT Southwestern Medical Center

4:25 p.m. - 4:50 p.m. Changes in Life-Satisfaction With Antidepressant

Treatment Predict Long-Term Clinical Outcomes
Manish Jha, UT Southwestern Medical Center

4:50 p.m. - 5:15 p.m. Policy Implications for Treatment Outcomes

of Depressed Patients From Low-Income and

Minority Populations

Michele Guzman, Meadows Mental Health Policy

Institute

5:15 p.m. - 5:45 p.m. **Discussion**

3:45 p.m. - 5:45 p.m. Tardive Dyskinesia: The Forgotten Adverse

Event*
Salon 2

Chair: Jean-Pierre Lindenmayer, New York University

3:45 p.m. - 4:00 p.m. **Introduction**

4:00 p.m. - 4:20 p.m. What is the Current Prevalence and Incidence of

Tardive Dyskinesia?

John Kane, The Zucker Hillside Hospital

ASCP Wednesday, May 31, 2017

3:45 p.m 5:45 p.m. (continued)	Tardive Dyskinesia: The Forgotten Adverse Event* Salon 2
4:20 p.m 4:40 p.m.	Do Psychiatric Residents Underrecognize Tardive Dyskinesia? Jean-Pierre Lindenmayer, New York University
4:40 p.m 5:00 p.m.	Treatment Landscape of Tardive Dyskinesia: What Works, What Doesn't, and Why Leslie Citrome, New York Medical College
5:00 p.m 5:20 p.m.	New Pharmacologic Interventions for Tardive Dyskinesia: An Update Ira Glick, Stanford University School of Medicine
5:20 p.m 5:45 p.m.	Discussion
5:45 p.m 6:45 p.m.	ASCP Business Meeting & Reception (ASCP Members Only) Poinciana 3-4
6:45 p.m 7:45 p.m.	ASCP Reception Americana Lawn

Thursday, June 1, 2017 ASCI

AT-A-GLANCE

Thursday, June 1, 2017

7:00 a.m 8:00 a.m.	Federal Agency Liaison Meeting (Invitation Only) Crown Conch
7:15 a.m 8:15 a.m.	NIA Breakfast Roundtable (Invitation Only) Neptune
7:30 a.m 6:00 p.m.	Registration Rotunda East
7:30 a.m 6:30 p.m.	Speaker Ready Room Sundial
7:30 a.m 9:00 a.m.	Morning Break Americana Foyer
8:15 a.m 9:45 a.m.	Keynote Plenary: Serving the Needs of the Diverse Population* Salon 3
9:45 a.m 10:00 a.m.	Break Americana Foyer
10:00 a.m 12:30 p.m.	Federal Agency Directors Plenary Salon 3
12:30 p.m 2:00 p.m.	Poster Session II with Lunch Salon 4
2:00 p.m 3:30 p.m.	Psychopharmacology State-of-the-Art Updates* Salon 3
3:30 p.m 3:45 p.m.	Break Americana Foyer

ASCP Thursday, June 1, 2017

3:45 p.m. - 5:45 p.m. **Workshops**

Rapid-Acting Antidepressants: Perspective on Issues in Nonclinical and Clinical Development from the Division of Psychiatry Products (DPP), Food and Drug Administration	How to Use the Model Psychopharmacology Curriculum in Various Teachings	Psychotropics and Pregnancy: Current Practice to Evidence Based Approaches*
Poinciana 1-2	Salon 1	Salon 2

6:00 p.m. - 9:00 p.m.

ASCP Board of Directors Meeting (Invitation

Only)

Crown Conch

Thursday, June 1, 2017

ASCP

FULL SCHEDULE

Thursday, June 1, 2017

7:00 a.m. - 8:00 a.m. Federal Agency Liaison Meeting (Invitation Only)

Crown Conch

7:15 a.m. - 8:15 a.m. NIA Breakfast Roundtable (Invitation Only)

Neptune

7:30 a.m. - 6:00 p.m. Registration

Rotunda East

7:30 a.m. - 6:30 p.m. Speaker Ready Room

Sundial

7:30 a.m. - 9:00 a.m. Morning Break

Americana Foyer

8:15 a.m. - 9:45 a.m. Keynote Session: Serving the Needs of the

Diverse Population*

Salon 3

Chair: Marlene Freeman, Massachusetts General Hospital

This Keynote Plenary Session will address disparities and opportunities in treatment engagement across diverse populations, dovetailing with the 2017 ASCP annual meeting theme.

Dr. Roberto Lewis-Fernández will address disparities in psychopharmacology among racial and ethnic minorities. He will present data regarding interventions to overcome specific challenges regarding the barriers at the patient, provider, and organizational level. Dr. Michael Compton will address the societal approaches to disparities, and discuss health promotion policy optimization and social variables. Dr. Andrew Nierenberg will discuss opportunities for patient engagement in research in psychopharmacology and clinical trial methodology. He will discuss the federally funded Mood Disorders Patient Powered Research Network and the Institute of Medicine's concept of a learning health system.

8:15 a.m. - 8:25 a.m. **Introduction**

8:25 a.m. - 8: 45 a.m. Overcoming Disparities in Treatment

Engagement across Diverse Populations
Roberto Lewis-Fernández, Columbia University

*of special interest to clinicians

ASCP Thursday, June 1, 2017

8:15 a.m 9:45 a.m. (continued)	Keynote Session: Serving the Needs of the Diverse Population* Salon 3
8:45 a.m 9:05 a.m.	The Social Determinants of Mental Health: What? Who? and How? Michael Compton, Columbia University
9:05 a.m 9:25 a.m.	People/Participants/Patients at the Center: Re-Engineering Psychopharmacology Trials Andrew Nierenberg, Massachusetts General Hospital
9:25 a.m 9:45 a.m.	Discussion
9:45 a.m 10:00 a.m.	Break Americana Foyer
10:00 a.m 12:30 p.m.	Federal Agency Directors Plenary Salon 3
	Curon C
Chair: Mark H. Rapaport	, Emory University School of Medicine
Chair: Mark H. Rapaport 10:00 a.m 10:05 a.m.	
	, Emory University School of Medicine
10:00 a.m 10:05 a.m.	, Emory University School of Medicine Introduction NIAAA Update Raye Litten, National Institute on Alcohol Abuse and
10:00 a.m 10:05 a.m. 10:05 a.m 10:20 a.m.	, Emory University School of Medicine Introduction NIAAA Update Raye Litten, National Institute on Alcohol Abuse and Alcoholism NINDS Update Amir Tamiz, National Institute of Neurological
10:00 a.m 10:05 a.m. 10:05 a.m 10:20 a.m. 10:20 a.m 10:35 a.m.	, Emory University School of Medicine Introduction NIAAA Update Raye Litten, National Institute on Alcohol Abuse and Alcoholism NINDS Update Amir Tamiz, National Institute of Neurological Disorders and Stroke NIMH Update

Thursday, June 1, 2017 AS

10:00 a.m 12:30 p.m. (continued)	Federal Agency Directors Plenary Salon 3
11:20 a.m 11:35 a.m.	Research Funding in Mental Health at PCORI Grayson Norquist, Patient-Centered Outcomes Research Institute
11:35 a.m 11:50 a.m.	DoD Update COL Dennis McGurk, Department of Defense
11:50 a.m 12:30 p.m.	Discussion and Q&A
12:30 p.m 2:00 p.m.	Poster Session II with Lunch Salon 4 See pages 86-96 for a complete listing of posters.
2:00 p.m 3:30 p.m.	Psychopharmacology State-of-the-Art Updates* Salon 3

Chair: Holly Swartz, University of Pittsburgh

The purpose of this symposium is to provide an overview of the recent advances in clinical psychopharmacology leading to the development of novel treatments for mood disorders. The session will focus on schizophrenia, anxiety disorders, and neuromodulation.

3:30 p.m 3:45 p.m.	Break Americana Foyer
3:10 p.m 3:30 p.m.	Discussion
2:50 p.m 3:10 p.m.	Neuromodulation Sarah Lisanby, M.D., National Institute of Mental Health
2:30 p.m 2:50 p.m.	Update on the Anxiety Disorders Mark Pollack, M.D., Rush University Medical Center
2:10 p.m 2:30 p.m.	Schizophrenia: What's New in 2017? Nina Schooler, Ph.D., SUNY Downstate Medical Center
2:00 p.m 2:10 p.m.	Introduction

^{*}of special interest to clinicians

ASCP | Thursday, June 1, 2017

Workshops

3:45 p.m. - 5:45 p.m. Rapid-Acting Antidepressants: Perspective on Issues in Nonclinical and Clinical Development From the Division of Psychiatry Products (DPP), Food and Drug Administration Poinciana 1-2

Chair: Javier Muniz, US Food and Drug Administration

Co-Chair: Juliette Toure, Center for Drug Evaluation and Research, US Food

and Drug Administration

Discussant: Tiffany Farchione, US Food and Drug Administration

3:45 p.m 4:00 p.m.	Introduction
4:00 p.m 4:15 p.m.	Rapid-Acting Antidepressants: Perspective on Issues in Non-Clinical and Clinical Development from the Division of Psychiatry Products, Food and Drug Administration Shiny Mathew, Center for Drug Evaluation and Research, US Food and Drug Administration
4:15 p.m 4:30 p.m.	Rapid-Acting Antidepressants: Clinical Trial Design Considerations Bernard Fischer, FDA/CDER/DPP
4:30 p.m 4:45 p.m.	Rapid-Acting Antidepressants: Selection and Timing of Efficacy Endpoints Michael Davis, US Food and Drug Administration
4:45 p.m 5:00 p.m.	Rapid-Acting Antidepressants: Clinical Trial Assessments, Interventions and Procedures to Enhance Subject Safety Andy Mattai, Center for Drug Evaluation and Research, US Food and Drug Administration
5:00 p.m 5:15 p.m.	Rapid-Acting Antidepressants: Expedited Programs for Serious Conditions Jean Kim, FDA/CDER/DPP
5:15 p.m 5:45 p.m.	Discussion

Thursday, June 1, 2017



3:45 p.m. - 5:45 p.m. How to Use the Model Psychopharmacology

Curriculum in Various Teachings

Salon 1

Chair: Ira Glick, Stanford University School of Medicine

3:45 p.m. - 5:45 p.m. Psychotropics and Pregnancy: Current Practice

to Evidence Based Approaches

Salon 2

Chair: Crystal Clark, Northwestern University

Discussant: Matthew Rudorfer, National Institutes of Health/NIMH

3:45 p.m. - 4:00 p.m. **Introduction**

4:00 p.m. - 4:15 p.m. **Mood Symptoms in Pregnant Women With**

Bipolar Disorder: How Effective is Psychotropic

Treatment?

Katherine Wisner, Northwestern University Feinberg

School of Medicine

4:15 p.m. - 4:30 p.m. Risk-Benefit Analysis of Psychotropic Use in

Pregnancy: Practical Guidelines for Clinicians

From a Forensic Perspective

Cara Angelotta, Northwestern University Feinberg

School of Medicine

4:30 p.m. - 4:45 p.m. New Approaches to the Design and Analysis of

Studies Evaluating the Safety of Psychotropic

Medications During Pregnancy

Krista Huybrechts, Brigham and Women's Hospital,

Harvard Medical School

4:45 p.m. - 5:00 p.m. Obstetrical Physiology and Its Impact on

Pharmacokinetics

Catherine Stika, Northwestern University Feinberg

School of Medicine

5:00 p.m. - 5:15 p.m. Pharmacokinetics of Lamotrigine and Lithium

Across Pregnancy: Evidence to Inform Dose

Optimization

Crystal Clark, Northwestern University

5:15 p.m. - 5:45 p.m. **Discussion**

ASCP | Thursday, June 1, 2017

6:00 p.m. - 9:00 p.m. A

ASCP Board of Directors Meeting (Invitation Only)

Crown Conch

Friday, June 2, 2017 | ASCI

AT-A-GLANCE

Friday, June 2, 2017

7:30 a.m. - 12:00 p.m. **Registration**

Rotunda East

7:30 a.m. - 10:30 a.m. Speaker Ready Room

Sundial

7:30 a.m. - 9:00 a.m. **Morning Break**

Americana Foyer

8:30 a.m. - 10:00 a.m. **Panel Sessions**

Suicidal Behavior in the Clinical Setting: Relationship Between ADHD, Depression, and Decision-Making Capacity*	Validly and Reliably Measuring Functional Performance in Dementia Patients Across Countries and Languages in Clinical Trials	New Technologies for Reducing Placebo Response and Improving Signal Detection in CNS Clinical Trials	Neuromodulation With Transcranial Near-Infrared Light: Controlled Evidence*
Poinciana 1-2	Poinciana 3-4	Salon 1	Salon 2

10:00 a.m. - 10:15 a.m. Break

Americana Foyer

10:15 a.m. - 11:45 a.m. Regulatory Wrap-Up Plenary

Salon 3

12:00 p.m. Meeting Adjourns

ASCP |

Notes

Friday, June 2, 2017

ASCP

FULL SCHEDULE

Friday, June 2, 2017

7:30 a.m. - 12:00 p.m. Registration

Rotunda East

7:30 a.m. - 10:30 a.m. Speaker Ready Room

Sundial

7:30 a.m. - 9:00 a.m. Morning Break

Americana Foyer

Panel Sessions

8:30 a.m. - 10:00 a.m. Suicidal Behavior in the Clinical Setting:

Relationship Between ADHD, Depression, and

Decision-Making Capacity

Poinciana 1-2

Chair: Martin Katzman, START Clinic for Mood and Anxiety Disorders **Co-Chair:** Tia Sternat, START Clinic for Mood and Anxiety Disorders

Discussant: Larry Klassen, Eden Mental Health Centre

8:30 a.m. - 8:40 a.m. **Introduction**

8:40 a.m. - 9:00 a.m. Phenotypes of Suicidality in Depressed Patients

Irvin Epstein, University of Toronto

9:00 a.m. - 9:20 a.m. Chronic Anhedonia: A Risk Factor for Attention

Deficit Hyperactivity Disorder and Suicidal

Behavior in Depressed Adults

Tia Sternat, START Clinic for Mood and Anxiety

Disorders

9:20 a.m. - 9:40 a.m. **Neurobiological Variance in Suicide Attempt and**

Ideation: Clinical and Treatment Implications

Martin Katzman, START Clinic for Mood and Anxiety

Disorders

9:40 a.m. - 10:00 a.m. **Discussion**

ASCP Friday, June 2, 2017

8:30 a.m. - 10:00 a.m. Validly and Reliably Measuring Functional

Performance in Dementia Patients Across Countries and Languages in Clinical Trials

Poinciana 3-4

Chair: Magdalena Perez, inVentiv Health
Co-Chair: Isabelle Gelinas, McGill University
Discussant: Julie Marsh, inVentiv Health

8:30 a.m. - 8:40 a.m. Introduction

8:40 a.m. - 9:00 a.m. **Measuring Functional Performance in Individuals**

on the Dementia Continuum: What to Consider

Patricia Belchior, McGill University

9:00 a.m. - 9:20 a.m. Linguistically Validating the Disability

Assessment in Dementia (DAD) for Use in

International Clinical Trials

Christelle Giroudet, Mapi Language Services

9:20 a.m. - 9:40 a.m. Training and Monitoring Clinicians Administering

Functional Assessments in Dementia Global

Trials

Magdalena Perez, inVentiv Health

9:40 a.m. - 10:00 a.m. **Discussion**

8:30 a.m. - 10:00 a.m. New Technologies for Reducing Placebo

Response and Improving Signal Detection in

CNS Clinical Trials

Salon 1

Chair: Michael Detke, Indiana University School of Medicine

Discussant: Janet Williams, MedAvante

8:30 a.m. - 8:40 a.m. Introduction

8:40 a.m. - 8:55 a.m. **NEWMEDS Data on Duplicate and Sequential**

Enrollment in Clinical Trials and Online Registry to Reduce Duplicate and Sequential Enrollment

Jonathan Rabinowitz, Bar-Ilan University

Friday, June 2, 2017



8:30 a.m 10:00 a.m. (continued)	New Technologies for Reducing Placebo Response and Improving Signal Detection in CNS Clinical Trials Salon 1
8:55 a.m 9:10 a.m.	Learning From a Computer Simulated Rater: Lessons in Signal Detection Gary Sachs, Bracket
9:10 a.m 9:25 a.m.	Clinical Trial Design, Conduct and Analysis Methodology Options to Reduce Risk, Time, Cost, and Enable Signal Detection in the Presence of High Placebo Response and Variability in Neuroscience Marc De Somer, PPD
9:25 a.m 9:40 a.m.	Expectation Bias and Variance: Challenges to CNS Trial Signal Detection and Some New Technologies to Minimize Them Michael Detke, Indiana University School of Medicine
9:40 a.m 10:00 a.m.	Discussion
8:30 a.m 10:00 a.m.	Neuromodulation With Transcranial Near- Infrared Light: Controlled Evidence Salon 2
	_

Chair: Paolo Cassano, Massachusetts General Hospital **Co-Chair, Discussant:** Dan Iosifescu, Nathan S. Kline Institute/New York University School of Medicine

8:30 a.m 8:40 a.m.	introduction
8:40 a.m 9:00 a.m.	Transcranial Photobiomodulation for Brain Disorders Yingying Huang, Harvard Medical School/ Massachusetts General Hospital
9:00 a.m 9:20 a.m.	Transcranial Photobiomodulation in Major Depressive Disorder Paolo Cassano, Massachusetts General Hospital

Friday, June 2, 2017

8:30 a.m 10:00 a.m. (continued)	Neuromodulation With Transcranial Near- Infrared Light: Controlled Evidence Salon 2
9:20 a.m 9:40 a.m.	Significant Improvement in Cognition in Mild to Moderately-Severe Dementia Cases Treated With Transcranial Plus Intranasal Photobiomodulation: Case Series Report Anita Saltmarche, Saltmarche Health & Associates, Inc.
9:40 a.m 10:00 a.m.	Discussion
10:00 a.m 10:15 a.m.	Break Americana Foyer
10:15 a.m 11:45 a.m.	Regulatory Wrap-Up Plenary Salon 3

Chair: Mark H. Rapaport, Emory University School of Medicine **Presenters:** Tiffany Farchione, US Food and Drug Administration Islam Younis, US Food and Drug Administration

Luca Pani, European Medicines Agency Valentina Mantua, Italian Medicines Agency (AIFA)

12:00 p.m. **Meeting Adjourns**

Wednesday, May 31, 2017

Poster Session I with Lunch

Salon 4

11:15 a.m. - 1:00 p.m.

W1. Quillivant XR in Children With Autism Spectrum Disorder and ADHD: Dose Effects on ADHD Symptoms and Functioning

Mark Stein*, University of Washington

Soo-Jeong Kim, William French, Lindsay Miller, Sophia Shonka, Jennifer Strickland

★ W2. Long-Term Efficacy and Safety of Extended-Release Molindone (SPN-810) to Manage Impulsive Aggression in Children With Attention-Deficit/Hyperactivity Disorder

Toyin Adewole*, Supernus Pharmaceuticals, Inc. Scott Brittain, Janet Johnson, Tesfaye Liranso, Robert Findling

W3. Anxiety as a Confounding Symptom in ADHD Trials

Tammy Steans*, Psychiatric & Behavioral Solutions Frederick Reimherr, Bennett Steans, Thomas Gift, Barrie Marchant

W4. Glutamatergic Network Gene Mutations in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

Liza Squires*, Aevi Genomic Medicine Josephine Elia, Celia Kim, Munir Khan, Diego Mazzotti, Hakon Hakonarson, Colleen Anderson, David Fitts


W5. Do Opiate Antagonists Interfere With the Clinical Benefits of Stimulants in ADHD? A Double-Blind, Placebo-Controlled Trial of the Mixed Opioid Receptor Antagonist Naltrexone

Joseph Biederman*, Massachusetts General Hospital Thomas Spencer, Pradeep Bhide, Maura Fitzgerald, Amy Yule, Stephen Faraone

W6. Effect of Sedative Hypnotic Medications on Sleep in Opioid-Dependent Subjects on Buprenorphine

Venkatesh Krishnamurthy*, Penn State Milton S. Hershey Medical Center

Alissa Coffey, Sanjay Yadav, Lan Kong, Alexndros Vgontzas, Edward Bixler, Douglas Leslie, Roger Meyer



Posters

W7. Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a Noribogaine Multiple-Dose Regimen in Opioid-Dependent Subjects Pierre Geoffroy*, INC Research

Vincent Lam, Pierre Geoffroy, Borje Darpo, Megan Shram, John Howes, R. Steve Crockett, William Kramer, Dennis Fisher, Holger Weis, Roland Gerritsen van der Hoop

W8. Adolescent Social Stress Results in Sex-Specific Transcriptional Reprogramming of the Medial Amygdala, a Critical Region for Sex Differences in Reward

Deena Walker*, Icahn School of Medicine at Mount Sinai Immanuel Purushothaman, Michael Cahill, Casey Lardner, Saima Machlovi, Erin Calipari, Hannah Cates, Rosemary Bagot, Catherine Pena, Georgia Hodes, Scott Russo, Eric Nestler

W9. Identifying Sub-Populations of Heavy Drinkers: A Sweet Road to a Better Phenotypic Characterization?

Sofia Bouhlal*, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, National Institutes of Health Mehdi Farokhnia, Mary Lee, Lorenzo Leggio

- W10. A Proof of Concept Trial of a Novel Combination of Methylphenidate and Ondansetron for Treatment of Stimulant Use Disorder
 Ashwin Patkar*, Duke University Medical Center
- Steven Szabo, Shein Chow, Tong Lee
- W11. Optimizing Clinical Outcomes: A Comparison of Estimated BAC and Self-Report Standards for Heavy Drinking

Emily Olfson*, Child Study Center, Yale School of Medicine Krysten Bold, Lisa Fucito, Ralitza Gueorguieva, Peter Jatlow, Allen Zweben, Stephanie O'Malley

W12. The Role of the Black Church in Improving Treatment Access for Blacks With Substance Use Disorders

Ayana Jordan*, Yale University School of Medicine

W13. Efficacy of Vortioxetine in Working Patients With Generalized Anxiety Disorder

Michael Cronquist Christensen*, H. Lundbeck A/S Henrik Loft, Ioana Florea, Roger McIntyre

💮 = New Investigator Awardee 🗼 = Pharmaceutical Pipeline Presentation



W14. Extended-Release Guanfacine for the Treatment of Hyperactivity in Children With Autism Spectrum Disorder: An Analysis of Secondary Outcome Measures

Laura Politte*, University of North Carolina at Chapel Hill Christopher McDougle, Lawrence Scahill, Janet Figueroa, Courtney McCracken

W15. Neuroinflammatory Signature of Treatment Response to Ketamine in Patients With Treatment-Resistant Depression

Simmie Foster*, Massachusetts General Hospital & Harvard Medical School

Chelsea Dale, Abigail Archibald, Joey Cheung, Kerry Ressler, Maurizio Fava, Dawn Ionescu

W16. A Study of Metabolic Disturbance in Adolescent Patients With Bipolar Disorder

Hanjing Emily Wu*, University of Texas Health Science Center at Houston

Teresa Pigott

W17. Course of Two Common Adverse Events in Aripiprazole Once-Monthly Maintenance Treatment of Bipolar I Disorder During a Double-Blind, Placebo-Controlled, Randomized Withdrawal Study Pedro Such*, H. Lundbeck A/S

Joseph Calabrese, Raymond Sanchez, Na Jin, Joan Amatniek, Kevin Cox, Brian Johnson, Peter Hertel, Phyllis Salzman, Robert McQuade, Margaretta Nyilas, William H. Carson

W18. Patient Selection for Long-Acting Injectable (LAI) Antipsychotic Use in Bipolar Disorder: An Expert Consensus Survey

Martha Sajatovic*, University Hospitals Case Medical Center Susan Legacy, Matthew Byerly, Christoph Correll, John Kane, Faith DiBiasi, Heather Fitzgerald, Ruth Ross

W19. Aripiprazole Once-Monthly Maintenance Treatment of Bipolar I Disorder, a Double-Blind, Placebo-Controlled, Randomized Withdrawal Study: Effects on Types of Recurrence and on Recovery Joan Amatniek*, Otsuka Pharmaceutical Development and Commercialization, Inc.

Joseph Calabrese, Raymond Sanchez, Na Jin, Kevin Cox, Brian Johnson, Pamela Perry, Peter Hertel, Pedro Such, Robert McQuade, Margaretta Nyilas, William H. Carson

😭 = New Investigator Awardee 🗼 = Pharmaceutical Pipeline Presentation

Posters

W20. Network Analysis of Depressive and Manic Symptoms in STEP-BD Study

Cynthia Siu, COS & Associates, Ltd.

W21. Use of Recommended Therapies Following a New Anxiety Diagnosis in Children and Adolescents

Greta Bushnell*, University of North Carolina at Chapel Hill Bradley Gaynes, Scott Compton, Stacie Dusetzina, Alan Brookhart, Til Stürmer

W22. Are Self-Report Scales as Effective as Clinician Rating Scales in Measuring Treatment Response in Routine Clinical Practice? Mark Zimmerman*, Brown University

Emily Walsh, Michael Friedman, Daniela Boerescu, Naureen Attiullah

W23. Expanding the Brief Assessment of Cognition (BAC-App) for Use in Screening for MCI Due to AD

Alexandra Atkins*, NeuroCog Trials Anzalee Khan, Tina Tseng, Adam Vaughan, Christopher Randolph, Harrison John, Brian Saxby, Philip Harvey, Meera Narasimhan, Tom Patterson, Richard Keefe

W24. SAGE-217, A Novel Positive Allosteric Modulator of Synaptic and Extrasynaptic GABA-A Receptors: Phase 1 Single- and Multiple-Ascending Dose Results

Stephen Kanes*, Sage Therapeutics George Nomikos, Mike Quirk, Shane Raines, James Doherty, Ethan Hoffmann, Abdul Sankoh, Helen Colquhoun

★ W25. SAGE-547 and SAGE-217: Novel Positive Allosteric Modulators of Synaptic and Extrasynaptic GABA-A Receptors Being Investigated in the Treatment of Mood Disorders

Stephen Kanes*, Sage Therapeutics Helen Colquhoun, James Doherty, Shane Raines, Ethan Hoffmann, David Rubinow, Samantha Meltzer-Brody, A.J. Robichaud

W26. Efficacy and Safety of Initially Intramuscular Injection Scopolamine in the Treatment of Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial

Le Xiao*, Beijing Anding Hospital, Capital Medical University Jing-jing Zhou, Xue-quan Zhu, Jian Yang

= New Investigator Awardee 🛊 = Pharmaceutical Pipeline Presentation



- W27. Lower Confidence Diagnostic Assignment is Associated With Increased Noise in Efficacy Ratings: An International Analysis
 Joan Busner*, Penn State College of Medicine
 Marcela Roy, Margot Oakley, Alan Kott, Pamela Elias, Michael Scafidi
- ★ W28. Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

Maurizio Fava*, Massachusetts General Hospital Marlene Freeman, Martina Flynn, Heidi Judge, Bettina Hoeppner, Cristina Cusin, Dawn Ionescu, Sanjay Mathew, Lee Chang, Dan Iosifescu, James Murrough, Charles Debattista, Alan Schatzberg, Madhukar Trivedi, Manish Jha, Gerard Sanacora, Samuel Wilkinson, George Papakostas

W29. Clozapine Clinics as Models for Reverse Integrated Care Delivery to Reduce Medical Mortality and Improve Safety in Patients With Serious Mental Illness

Oliver Freudenreich*, Massachusetts General Hospital Sarah MacLaurin, Kelly Irwin, Lauren Donahue, Ben Macri, Benjamin Brent, Leah Namey, Hannah Brown, Abigail Donovan, Corinne Cather, Daphne Holt

W30. Association of Bipolar Illness Course With Family History of Alcoholism, Bipolar Disorder, or Both Conditions in First Degree Relatives of Adults With Co-Occurring Bipolar Disorder and Alcohol Dependence

Bryan Tolliver*, Medical University of South Carolina Helena Brenner, Delisa Brown, Prisciandaro James

W31. Quit Rates of Depressed vs Euthymic Smokers: Is There a Difference?

Ahmad Hameed*, Penn State College of Medicine Susan Valdheer, Usman Hameed, Ayesha Ahmad, Jonathan Foulds

W32. ITI-333: A Novel Modulator of Serotonin, Dopamine, and Mu Opiate Receptors for the Treatment of Mood Disorders

Kimberly Vanover*, Intra-Cellular Therapies, Inc. Gretchen Snyder, Peng Li, Wei Yao, Stephanie Cruz, Lawrence Wennogle, Sharon Mates, Robert Davis

Posters

W33. Designing a Randomized Placebo Controlled Cross-Over Trial Investigating Nabilone as a Treatment for Agitation in Patients With Moderate-to-Severe Alzheimer's Disease

Krista Lanctôt*, Sunnybrook Health Science Centre Myuri Ruthirakuhan, Eleenor Abraham, Chelsea Sherman, Paul Verhoeff, Alex Kiss, Ana Andreazza, Sandra Black, Nathan Herrmann

W34. Challenges in the Translation of the Neuropsychiatric Inventory (NPI) Into 74 Languages

Caroline Anfray*, Mapi Research Trust Jeffrey Cummings, Stefania Vasarri, Christelle Giroudet

W35. Relapse Prevention With Levomilnacipran ER in Adults With Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Suresh Durgam*, Allergan

Changzheng Chen, Raffaele Migliore, Prakash Chandran, Michael Thase

W36. Does Early Improvement With Vilazodone Predict Response and Remission in Patients With MDD?

Ken Kramer*, Allergan Suresh Durgam, Cheng-Tao Chang, Carl Gommoll, John Edwards, Arifulla Khan

W37. Assessment in Work Productivity and the Relationship With Cognitive Symptoms (AtWoRC): Primary Analysis From a Canadian Open-Label Study of Vortioxetine in First Treatment and Switch Patients With Major Depressive Disorder

Pratap Chokka*, Chokka Center Joanna Bougie, Emmanouil Rampakakis, Jean Proulx

W38. Exploration of the Insular Role in Psychological and Physical Pain in Acute Suicidality

Ricardo Caceda*, Psychiatric Research Institute, University of Arkansas for Medical Sciences

Andrew James, Zachary Stowe, Pedro Delgado, Clint Kilts

W39. UCSD Performance-Based Skill Assessment (UPSA): Psychometric Evaluation of the Communication and Financial Skill Domains

Vanessa Perez*, Takeda Development Center Americas, Inc. Elizabeth Merikle, Wei Zhong, Christina Kurre Olsen, William Jacobson

💮 = New Investigator Awardee 🗼 = Pharmaceutical Pipeline Presentation



W40. A Novel Use of the Goal Attainment Scale After Change to Vortioxetine in the Treatment of Major Depressive Disorder

Sagar Parikh*, University of Michigan, Ann Arbor Lisa Mucha, Sara Sarkey, Jen Schuster, Anna Eramo, Maggie McCue, Clément François

W41. Vortioxetine and Suicidal Ideation and Behavior in Adults With Major Depressive Disorder

Atul Mahableshwarkar*, Takeda Development Center Americas, Inc. John Affinito, Paula Jacobsen, Judith Xu, George Nomikos

W42. An Open Label Trial of Dextromethorphan for Depression in Psychiatric Inpatients

Eric Brueckner*, Medical University of South Carolina Prisciandaro James, Bryan Tolliver

W43. Cost-Effectiveness Evaluation of Depressive and Cognitive Outcomes of Vortioxetine in Patients in the United States With Major Depressive Disorder Switching From First Antidepressant Therapy

Larry Ereshefsky*, Follow the Molecule: CNS Consulting, LLC Kokuvi Atsou, Benjamin Briquet, Françoise Diamand, Melanie Brignone, Lisa Mucha, Natalya Danchenko, Clément François

W44. Effect of Adjunctive Brexpiprazole on Metabolic Parameters in Elderly Patients With Major Depressive Disorder: Analysis of an Open-Label, Long-Term, Flexible-Dose Study

Jacquelyn Canning*, Otuska Ross Baker, Nanco Hefting, Doris Zhang, Mary Hobart

W45. Intermittent Explosive Disorder: DSM-5 Diagnosis Primed for a Pharmacotherapeutic Breakthrough?

John Umhau*, US Food and Drug Administration Bernard Fischer, Greg Dubitsky, Andy Mattai, Brian Miller, Jean Kim, Michael Davis

W46. Concomitant Use of Atypical Antipsychotics With Leading Psychotropic Medication Classes and the Risk of Type 2 Diabetes Mellitus: A Population-Based Study of Medicaid Insured Youth Mehmet Burcu*, University of Maryland, Baltimore Julie Zito, Daniel Safer

= New Investigator Awardee 🛊 = Pharmaceutical Pipeline Presentation

Posters

W47. Healthcare Professionals' Satisfaction With a Digital Medicine System in an Open-Label Study of Adult Patients Treated With Oral Aripiprazole

Ross Baker*, Otsuka

Timothy Peters-Strickland, Cathy Zhao, Tao Wang, Margaretta Nyilas, Claudette Brewer, Erica Lawson, Raymond Sanchez

W48. Do Suicidality Phenomena Follow a Linear or a Non-Linear Progression Over Time?

David Sheehan*, University of South Florida College of Medicine Jennifer Giddens

W49. Enhancing Subjects' Awareness of Key Placebo Response Factors: The Importance of Implementing a Brief Educational Placebo Response Video

Howard Hassman*, Hassman Research Institute, LLC Elan Cohen, Shawn Hossain, Paula Amerman, Ashok Joseph, Kimberly Myers

W50. A Model Psychopharmacology Curriculum for Teachers of Psychiatric Residents

Ira Glick*, Stanford University School of Medicine

W51. Pimavanserin for the Treatment of Parkinson's Disease Psychosis: Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed

Leslie Citrome*, New York Medical College James Norton, Kathy Chi-Burris, George Demos

W52. Independent Predictors of Hospitalization in First Episode Psychosis: Baseline Results From the NIMH-ETP Study Jose M. Rubio*, The Zucker Hillside Hospital

Nina Schooler, Delbert Robinson, Christoph Correll, John Kane

W53. Plasma Cotinine is Positively Correlated With Scores on the NIH Toolbox Cognitive Measures in Patients With Schizophrenia Benjamin Naovarat*, UT Houston Medical School

Olaoluwa Okusaga

W54. Efficacy of Cariprazine in Patients With Bipolar Mania by Baseline Symptom Severity

Irma Saliu*, Allergan

Lakshmi Yatham, Willie Earley, Cheng-Tao Chang, Ágota Barabássy

😭 = New Investigator Awardee 🛛 🗱 = Pharmaceutical Pipeline Presentation



W55. Efficacy of Cariprazine in Subgroups of Bipolar Patients With Manic Episodes, Mixed Episodes, and With or Without Psychotic Symptoms

Mehul Patel*, Allergan

Eduard Vieta, Suresh Durgam, Kaifeng Lu, István Laszlovszky, Willie Earley

W56. Efficacy of Cariprazine on Negative Symptoms in Acutely III Patients With Schizophrenia: A Pooled, Post Hoc Analysis

Willie Earley*, Allergan

Hua Guo, Balázs Szatmári, György Németh, Henry Nasrallah, David Daniel, Mehul Patel

W57. Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia: A Post-Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Trial

Steven Potkin*, University of California, Irvine, School of Medicine Christoph Correll, Cheng-Tao Chang, Balázs Szatmári, István Laszlovszky, Willie Earley

W58. ALKS 3831 Attenuates Dose-Dependent, Olanzapine-Induced Weight Gain in Adults With Schizophrenia: Analysis From a Phase 2, Randomized, Olanzapine-Controlled Study

Lauren DiPetrillo*, Alkermes

Ying Jiang, Asif Paker, Peter Weiden, Sanjeev Pathak, David McDonnell, Bernard Silverman

W59. Correlates of Decreased Synaptic Vesicle Glycoproteins 2A (SV2A) in Schizophrenia: An in-vivo [11C]UCB-J Pet Imaging Study

Rajiv Radhakrishnan*, Yale School of Medicine Patrick Skosnik, Sjoerd Finnema, Renee Rotolo, Kimberlee Forselius-Bielen, Gina Creatura, Nabeel Nabulsi, Richard Carson, Deepak D'Souza

W60. Variable Free Fatty Acid Composition Associated With SREBF in Schizophrenia Participants Taking Atypical Antipsychotics

Kristen Ward*, University of Michigan Kathleen Stringer, Vicki Ellingrod

W61. Evaluation of the Potential for Concomitant Medications to Affect Valbenazine Pharmacokinetics

Gordon Loewen*, Neurocrine Biosciences, Inc. Rosa Luo, Evan Smith, Grace Liang, Haig Bozigian, Christopher O'Brien

Representation

New Investigator Awardee

Representation

Posters

- W62. Neurocognition and Duration of Untreated Psychosis in First Episode Psychosis: Findings From the RAISE-ETP Study Srinath Gopinath*, SUNY Health Science Center at Brooklyn Jeremy Weedon, Nina Schooler
- * W63. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
 Thomas A. Macek*, Takeda Development Center Americas, Inc.
 Maggie McCue, Xinxin Dong, Elizabeth Hanson, Paul Goldsmith, John Affinito, Atul Mahableshwarkar
 - W64. Measuring the Elements of Desire in the Bremelanotide Reconnect Study

Robert Jordan*, Palatin Technologies, Inc. Dennis Revicki, Stanley Althof, Leonard DeRogatis, Hilary Wilson, Johna Lucas

- W65. The National Pregnancy Registry for Atypical Antipsychotics:
 Effects of Fetal Exposure on Risk for Major Malformations
 Lee Cohen*, Massachusetts General Hospital
 Adele Viguera, Marlene Freeman, Alexandra Sosinsky, Gina Savella,
 Laura Cheng, David Chitayat, Sonia Hernandez-Diaz
- W66. Assessing the Adequacy of the Blind: An Analysis of Data in IV Ketamine for Rapid Treatment of Depression Study Frances Cena*, Baylor College of Medicine Sanjay Mathew
- W67. Body Temperature Rises Following Successful ECT Treatment of Depression: Does Body Temperature Decline During Depression Due to Dysfunctional Thermoregulatory Pathways?

 Alexander Chen*, Saint Louis University School of Medicine Henry Nasrallah
- W68. Using an Artificial Intelligence Platform on Mobile Devices to Monitor and Increase Adherence in Subjects With Schizophrenia Adam Hanina*, AiCure
 Laura Shafner, Markus Abt, Russell Kinch, Paul Tamburri, Daniel Umbricht
 - 💮 = New Investigator Awardee 🗼 = Pharmaceutical Pipeline Presentation



W69. A Pilot Study of Acute Anti-Psychotic-Induced Blood Pressure **Changes Among Psychiatric Inpatients**

Obiora Onwuameze*, Southern Illinois University School of Medicine Jeffrey Bennett, Jonathan Yost

W70. Are There Cultural Differences in Depression Symptom Expression as Measured by the HAMD-17 in Patient Cohorts in North America and Eastern Europe/Russia?

William Yavorsky*, Cronos CCS

Kristy Wolanski, Nina Engelhardt, Cynthia McNamara, Francisco Burger, Guillermo DiClemente

W71. Clin301-203: A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment Ronald Marcus*, Cerecor Arifulla Khan, Michael Liebowitz, Eileen McNulty, Heather Fraser

W72. Marijuana - Is it a Medicine?

Maryam Davari*, Central Michigan University Thersilla Oberbarnscheidt

- W73. Lauflumide (R)-(-)-) (NLS-4): A New Potent Wake-Promoting Agent Mehdi Tafti*, University of Lausanne Gianina Luca
- W74. A Novel Vasopressin 1a Receptor Antagonist in Phase II Development for Multiple Disorders of Stress, Mood, and Behavior Neal Simon*, Azevan Pharmaceuticals, Inc. Michael Brownstein, Shi-fang Lu, Christophe Guillon, Ned Heindel

Posters

Thursday, June 1, 2017

Poster Session II with Lunch

Salon 4

12:30 p.m. - 2:00 p.m.

- T1. Formal Cardiac Screening Prior to Initiating Stimulant Medication in ADHD Child and Adolescent Minority Population: A Dual Assessment in an Inner-City Teaching Outpatient Clinic Shaheen Alam*, Brookdale University Hospital & Medical Center Marian Moca
- T2. Efficacy and Safety of HLD200, a Novel Delayed-Release and Extended-Release Methylphenidate Formulation, in Children With Attention-Deficit/Hyperactivity Disorder: Results From a Pivotal Phase 3 Trial

Floyd Sallee*, Ralph H. Johnson VAMC Steven Pliszka, Valerie Arnold, Andrea Marraffino, Norberto DeSousa, Bev Incledon, Timothy Wilens, Jeffrey Newcorn

T3. Stimulant Medication Versus Behavioral Parent Training Effects on Mothers With ADHD

Mark Stein*, University of Washington

William French, Jennifer Strickland, Erin Schoenfelder, Samuel Zinner, Lindsay Miller, Tyler Sasser, Andrea Chronis-Tuscano

T4. Effect of Baseline Inflammatory Biomarker (hs-CRP) on Response to Lurasidone Treatment in Patients With Bipolar Depression: An Exploratory Analysis

Andrei Pikalov*, Sunovion Pharmaceuticals, Inc. Charles Raison, Cynthia Siu, Ken Koblan, Antony Loebel

T5. Abnormal Fear Circuitry in ADHD: A Controlled Magnetic Resonance Imaging Study

Joseph Biederman*, Massachusetts General Hospital Andrea Spencer, Marie-France Marin, Mohammed Milad, Thomas Spencer

★ T6. Double-Blind, Placebo-Controlled Study of the Novel Therapeutic AEVI-001 in Adolescents With ADHD and Glutamatergic Network Gene Mutations

> Garry Neil*, Aevi Genomic Medicine Robert Findling, Colleen Anderson, David Fitts, Liza Squires

😭 = New Investigator Awardee 🔭 = Pharmaceutical Pipeline Presentation



T7. Dysregulation of the Histone Demethylase KDM6B in Alcohol Dependence is Associated With Epigenetic Regulation of Inflammatory Signaling Pathways

Zane Zeier*, Miller School of Medicine, University of Miami Andrea Johnstone, Nadja Andrade, Estelle Barbier, Markus Heilig, Claes Wahlestedt

- T8. Epigenetic Mechanisms in Alcohol Use Disorder Quantified by Non-Invasive PET Imaging
 Changning Wang*, Harvard University/Massachusetts General Hospital
- ★ T9. Low-Dose Bedtime Sublingual Cyclobenzaprine (TNX-102 SL*) for the Treatment of Military-Related PTSD: Retrospective Analyses of the Mediators and Moderators of Treatment Response Gregory Sullivan*, Tonix Pharmaceuticals, Inc. Judith Gendreau, Michael Gendreau, Jean Engels, Ashild Peters, Perry Peters, Seth Lederman
- ★ T10. A Phase Ib Dose Ranging Study of Direct Nose to Brain Delivery of Neuropeptide Y in Patients With Posttraumatic Stress Disorder James Murrough*, Icahn School of Medicine at Mount Sinai Sehrish Sayed, Nicholas Van Dam, Sarah Horn, Marin Mautz, Michael Parides, Sara Costi, Katherine Collins, Dan Iosifescu, Aleksander Mathé, Steven Southwick, Adriana Feder, Dennis Charney
 - **T11.** Role of Soterogram Measuring Arterial Compliance in Psychiatry Maju Koola*, George Washington University, School of Medicine and Health Sciences
- T12. Suicide Risk Prediction Using Machine Learning Techniques in Self-Report vs. Clinician-Derived Data

 Laura M. Hack*, Emory University School of Medicine
 Tanja Jovanovic, Sierra Carter, Kerry Ressler, Alicia Smith
 - T13. Aripiprazole Once-Monthly Maintenance Treatment of Bipolar I Disorder: A Blinded, Placebo-Controlled, Randomized Study: Clinical Evaluation of Bipolar Symptoms
 Pedro Such*, H. Lundbeck A/S
 Joseph Calabrese, Raymond Sanchez, Na Jin, Joan Amatniek, Kevin Cox, Brian Johnson, Peter Hertel, Phyllis Salzman, Robert McQuade,

Margaretta Nyilas, William H. Carson

Representation

New Investigator Awardee

Representation

Posters

T14. Aripiprazole Once-Monthly Maintenance Treatment of Bipolar I Disorder: A Blinded, Placebo-Controlled, Randomized Study; Effects on Symptoms and Functioning

Na Jin*, Otsuka Pharmaceutical Development & Commercialization, Inc. Joseph Calabrese, Raymond Sanchez, Na Jin, Joan Amatniek, Kevin Cox, Brian Johnson, Pamela Perry, Peter Hertel, Pedro Such, Phyllis Salzman, Robert McQuade, Margaretta Nyilas, William H. Carson

T15. Safety of Lurasidone in Adolescents With Schizophrenia: Interim Analysis of a 24-Month, Open-Label Extension Study

Michael Tocco*, Sunovion

Christoph Correll, Celso Arango, Robert Goldman, Josephine Cucchiaro, Ling Deng, Antony Loebel

T16. Effectiveness of Lurasidone in Adolescents With Schizophrenia: Interim Analysis of a 24-Month, Open-Label Extension Study Michael Tocco*, Sunovion

Celso Arango, Christoph Correll, Robert Goldman, Josephine Cucchiaro, Ling Deng, Antony Loebel

★ T17. Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Cardiac Safety of Extended-Release Viloxazine (SPN-812 ER) in Healthy Adult Subjects

Erika Roers*, Supernus Pharmaceuticals, Inc. Toyin Adewole, Janet Johnson, Scott Brittain

T18. The Prominent Role of Clinical Pharmacology and Dosing in PMAs of Approved NMEs in the Last Ten Years

William Bender*, US Food and Drug Administration

T19. A Clinically Useful Screen for Attention-Deficit/Hyperactivity Disorder in Adult Psychiatric Outpatients

Mark Zimmerman*, Brown University Eugenia Gorlin, Kristy Dalrymple, Iwona Chelminski

T20. Serving the Needs of Our Diverse Population: It All Begins With Recruitment!

Charles Wilcox*, Pharmacology Research Institute [PRI] Daniel Grosz, My-Linh Tong, David Rosenberg, Judy Morrissey, Don DeFrancisco, Clifford Feldman, Mellissa Henry, Lynn Badgett, Nader Oskooilar

💮 = New Investigator Awardee 🗼 = Pharmaceutical Pipeline Presentation



T21. H2 Antagonists as Potential Biomarkers of Adherence in Clinical Research: Detection Windows in Urine

Ashwin Patkar*, Duke University Medical Center Robert Millet, Philip Radford

T22. A Pilot Study of SD-809 (Deutetrabenazine) in Tics Associated With Tourette Syndrome

Barbara Coffey*, Icahn School of Medicine at Mount Sinai Joseph Jankovic, Joohi Jimenez-Shahed, Cathy Budman, Tanya Murphy, David Shprecher, David Stamler

T23. The Nocebo Phenomenon in a Series of First-Time-In-Human, Double-Blind, Placebo-Controlled, Single Ascending-Dose Trials of CNS Active Agents

Christina Charriez*, Dart NeuroScience David Carpenter, Jeffery Anderson, Rebecca Crean, Joseph Djan, Jessica Berrett, Jodi Parsons, Jon Ruckle, Philip Perera

T24. Tolerability and Efficiency of Desvenlafaxine in Methadone Maintained Patients Suffering From Major Depressive Disorder

Cynthia El Hage*, Centre of Research of University of Montréal Hospital Center; University of Montréal

Maykel Ghabrash, Simon Dubreucq, Clairélaine Ouellet-Plamondon, Suzanne Brissette, Paul Lespérance, Julie Bruneau, François Lespérance, Didier Jutras-Aswad

T25. Data Surveillance to Improve Endpoint Assessment in Global Alzheimer's Disease

Theresa Shackleford*, ePharmasolutions

T26. Translation of the Zarit Burden Interview 22 Items (ZBI-22) Into 95 Languages: Challenges and Importance of the Conceptual Definition of the Original Version

Caroline Anfray*, Mapi Research Trust Steven Zarit, Stefania Vasarri, Christelle Giroudet

T27. The Residual Symptoms and Functioning of Major Depressive Patients After Partial Response to Acute Antidepressant Treatment in Clinical Setting

Le Xiao*, Beijing Anding Hospital, Capital Medical University Lei Feng, Xue-quan Zhu, Jing-jing Zhou

😭 = New Investigator Awardee 🗼 = Pharmaceutical Pipeline Presentation

Posters

T28. Antidepressant Augmentation and Co-Initiation Treatment in Acute Major Depressive Disorder: A Systematic Review, Meta-Analysis and Metaregression Analysis

Britta Galling*, The Zucker Hillside Hospital Christoph Correll

T29. Prevalence of Subtherapeutic Prescribing of Antidepressants in the United States

Mary March*, inVentiv Health Kristina Bertzos, Chris Brady, Jason Fox

T30. Mechanisms of Pain and Opioid Induced Hyperalgesia

Maryam Davari*, Central Michigan University Thersilla Oberbarnscheidt

T31. Prevalence, Cost of Care, and Treatment Patterns for Major Depressive Disorder Related Hospitalizations

Ken Kramer*, Allergan Sanjida Ali, Pamela Landsman-Blumberg, Marla Kugel

T32. Ex Vivo Inflammatory Response Patterns Among Non-Medicated Depressed Patients

Marzieh Majd*, Pennsylvania State University Jody Greaney, Erika Saunders, Christopher Engeland

T33. Adjunctive Brexpiprazole Effects on Weight According to Antidepressant Treatment (ADT) in Short-Term Major Depressive Disorder Studies

Jehan Marino*, Otsuka America Peter Zhang, Catherine Weiss, Emmanuelle Weiller, Mary Hobart

T34. Long-Term Efficacy of Adjunctive Brexpiprazole in Major Depressive Disorder (MDD) – Pooled Analysis of Two Short-Term Placebo-Controlled Studies and of an Open-Label, Long-Term Extension Study

Catherine Weiss*, Otsuka Pharmaceutical Development & Commercialization, Inc.

Emmanuelle Weiller, Peter Zhang, Na Jin, Ross Baker, Mary Hobart



T35. What is the Overlap Between Subjective and Objective Cognitive Impairment in Major Depressive Disorder (MDD)?

Maurizio Fava*, Massachusetts General Hospital William Jacobson, Wei Zhong, Richard S.E. Keefe, Christina Kurre Olsen, Judith Jaeger

T36. Metabolic and Cellular Distress Gene Expression Patterns are Associated With Treatment Resistance and Reversed by Deep Brain Stimulation in Rodent Model

Kriti Gandhi*, Mayo Clinic Sutor Shari, Mark Frye, Susannah Tye

T37. Adjunctive Brexpiprazole in Patients With MDD and Anxiety Symptoms: Results From Post-Hoc Analyses of Three Placebo-Controlled Studies

Emmanuelle Weiller*, H. Lundbeck A/S Anna-Greta Nylander, Catherine Weiss, Peter Zhang, Mary Hobart

T38. Acute Ketamine Administration Corrects Abnormal Inflammatory Bone Markers in Major Depressive Disorder

Bashkim Kadriu*, National Institute of Mental Health Philip Gold, David Luckenbaugh, Rodrigo Machado-Vieira, Carlos Zarate, Jr.

T39. A Breathing-Based Meditation Intervention for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Randomized Pilot Study

Anup Sharma*, University of Pennsylvania Marna Barrett, Andrew Cucchiara, Nalaka Gooneratne, Michael Thase

- T40. A Novel Approach to Relapse Prevention Studies in the Treatment of Major Depressive Disorder: A Phase 4 Study With Vortioxetine Paula Jacobsen*, Takeda Development Center Americas, Inc. Wei Zhong, George Nomikos
- T41. Relationship Between Sexual Abuse and Suicidality: What is the Evidence?

Ahmad Hameed*, Penn State College of Medicine Michael Mitchell, Eric Youngstrom, Roger Meyer, Alan Gelenberg

💮 = New Investigator Awardee 🗼 = Pharmaceutical Pipeline Presentation

Posters

T42. Neurochemical Alterations Following Supplementation With a Putative Caloric Restriction Mimetic Blend of Nutrients and Phytochemicals

Chandni Sheth*, University of Utah Medical School, Brain Institute Angela Mastouldis, Shelly Hester, Steven Wood, Erin McGlade, Perry Renshaw, Deborah Yurgelun-Todd

T43. A Multicenter, 8-Week, Open-Label Study to Assess Usability of a Digital Medicine System in Adult Patients With Schizophrenia Treated With Oral Aripiprazole

Timothy Peters-Strickland*, Otsuka Pharmaceutical Alex Kopelowicz, Ross Baker, Cathy Zhao, Raymond Sanchez, Margaretta Nyilas, Claudette Brewer, Erica Lawson

T44. A Classification of Suicidality Disorder Phenotypes

David Sheehan*, University of South Florida College of Medicine Jennifer M. Giddens

T45. Medication Non-Adherence in Older Patients Prescribed Antipsychotic Medications

Mancia Ko*, Ingenuity Health Thomas Smith

T46. NIMH IRP Translational Neuropsychopharmacology InitiativeJanet Clark*, NIMH/NIH Susan Amara

★ T47. Rationale for the Clinical Development of ITI-214, a PDE1 Inhibitor Kimberly Vanover*, Intra-Cellular Therapies, Inc. Robert Davis, Lawrence Wennogle, Peng Li, Gretchen Snyder, Joseph Hendrick, Allen Fienberg, Cedric O'Gorman, Sharon Mates

T48. Personal Experiences With the Digital Medicine System – A Case Series

Sonal Batra*, Rutgers Robert Wood Johnson Medical School Ross Baker, Lada Markovtsova, Akshay Vashist, Praveen Raja, Timothy Peters-Strickland

T49. Subgroup Analyses of Baseline Characteristics and Treatment Response to Lisdexamfetamine vs. Placebo in Adults With Binge Eating Disorder

Susan Kornstein*, Virginia Commonwealth University Caleb Bliss, Judith Kando, Manisha Madhoo



T50. Glucose Metabolism and Brain Bioenergetics Measured by 31P Magnetic Resonance Spectroscopy in Unaffected Siblings of Patients With Psychotic Disorders

Virginie-Anne Chouinard*, Harvard Medical School, McLean Hospital Fei Du, Sang-Young Kim, Chiara Dalla Man, Claudio Cobelli, Aaron Cypess, Linda Valeri, Kyle Ryan, Guy Chouinard, David Henderson, Bruce Cohen, Dost Ongur

T51. Anti-Toxoplasma gondii IgM is Positively Correlated With Scores on the NIH Toolbox Flanker Inhibitory Control and Attention Test in Patients With Schizophrenia

Shiva Sharma*, University of Texas Harris County Psychiatric Center Samy Abdullah, Robert Yolken, Olaoluwa Okusaga

T52. Audio vs. Audio-Video Recording as a Quality Measure in Schizophrenia Clinical Trials

David Daniel*, Bracket Global, LLC Alan Kott

T53. Patient Selection for Long-Acting Injectable (LAI) Antipsychotic Use in Schizophrenia/Schizoaffective Disorder: An Expert Consensus Survey

Faith DiBiasi*, Otsuka Pharmaceutical Development & Commercialization

Martha Sajatovic, Susan Legacy, Matthew Byerly, Christoph Correll, John Kane, Heather Fitzgerald, Ruth Ross

T54. Off-Hours Use of a Smartphone Application in Patients With Schizophrenia Spectrum Disorders Following Hospital Discharge Eric Achtyes*, Michigan State University College of Human Medicine Dror Ben-Zeev, Zhehui Luo, Heather Mayle, Roshanah Dayton, Brandi Burke, Armando Rotondi, Jennifer Gottlieb, Mary Brunette, Kim Mueser, Susan Gingerich, Piper Meyer-Kalos, Patricia Marcy, Nina Schooler, Delbert Robinson, John Kane

T55. Should Antipsychotic Medications for Schizophrenia be Given for a Lifetime? A Naturalistic Follow-Up Study

Ira Glick*, Stanford University School of Medicine

Posters

T56. Prognosis of Patients With Schizophrenia Treated With Antipsychotic Combinations: A Secondary Analysis of PROACTIVE Data

Adriana Foster*, Florida International University
Peter F. Buckley, John Lauriello, Stephen Looney, Nina Schooler

T57. Effects of Once-Daily Valbenazine on Tardive Dyskinesia by Body Region: Shift Analyses of KINECT 3 Study Data

Cherian Verghese*, Keystone Clincial Studies, LLC Roger S. McIntyre, Joshua Burke, Hadley Le, Clinton Wright, Grace S. Liang

★ T58. Results of a Double-Blind, Placebo-Controlled, Tolerability Study of KarXT: A Novel Combination Targeting Muscarinic Acetylcholine Receptors Using Xanomeline With Trospium Chloride to Mitigate Cholinergic Side Effects

Stephen Brannan*, Karuna Richard Kavoussi, Andrew Miller, Alan Breier

T59. Mean Square Successive Difference as a Marker of Data Quality in Schizophrenia Trials - Exploratory Analysis

Alan Kott*, Bracket Xingmei Wang, Gary Sachs, David Daniel

T60. PANSS and CGI-S: 10-Years Later a Further Examination of Their Relationship

Janet Williams*, MedAvante Selam Negash, Barbara Echevarria, Lisa Stein, Elisabeth Prochnik, Michael Ropacki

T61. Population Pharmacokinetic Analysis and Simulations of a 2-Month Regimen for Aripiprazole Lauroxil

Marjie Hard*, Alkermes, Inc. Richard Mills, Brian Sadler, Lisa von Moltke

T62. Safety and Tolerability of 4, 6 and 8 Week Dose Intervals of Long-Acting Aripiprazole Lauroxil

Peter Weiden*, Alkermes, Inc.

Marjie Hard, Robert Risinger, Yangchun Du, David Walling, Chih-Chin Liu, Morteza Marandi

💮 = New Investigator Awardee 🗼 = Pharmaceutical Pipeline Presentation



T63. Long-Term Safety of Aripiprazole Lauroxil for Maintenance Treatment of Schizophrenia

Ralph Aquila*, Fountain House Henry Nasrallah, Robert Risinger, Arielle Stanford, Yangchun Du, Chih-Chin Liu, Peter Weiden

T64. Evaluation of the Potential for Valbenazine to Elicit Drug Interactions

Gordon Loewen*, Neurocrine Biosciences, Inc. Rosa Luo, Evan Smith, Grace S. Liang, Haig Bozigian, Christopher O'Brien

★ T65. Bremelanotide (BMT) for Hypoactive Sexual Desire Disorder (HSDD): Efficacy Analyses From the Reconnect Study

Anita Clayton*, University of Virginia Sheryl Kingsberg, James Simon, Robert Jordan, Johna Lucas

T66. A Phase 2, Double-Blind, Placebo-Controlled Study of SAGE-547 Injection in the Treatment of Severe Postpartum Depression Stephen Kanes*, Sage Therapeutics

Helen Colquhoun, Handan Gunduz-Bruce, Shane Raines, Ryan Arnold, Amy Schacterle, James Doherty, C. Neill Epperson, Kristina Deligiannidis, Robert Riesenberg, Ethan Hoffmann, Jeffrey Jonas, Samantha Meltzer-Brody

T67. Double-Blind, Randomized, Placebo-Controlled Study of Immediate-Release Viloxazine (SPN-812 IR) as a Novel Non-Stimulant Therapy in Adults With Attention-Deficit/Hyperactivity Disorder

Janet Johnson*, Supernus Pharmaceuticals, Inc. Keith Saylor, Gabriela Tulloch, Tesfaye Liranso, Scott Brittain

T68. An Updated Genetic Model for Clozapine Response

Eric Huang*, Neurogenetics Section, Campbell Family Research Institute, Centre for Addiction and Mental Health Clement Zai, Vanessa Goncalves, Arun Tiwari, James Kennedy

T69. Using Artificial Intelligence Platforms to Monitor and Identify Early Nonadherence Activity Based on Visual Confirmation of Medication Ingestion

Adam Hanina*, AiCure Laura Shafner, Maggie McCue, Anne Rubin, Xinxin Dong, Elizabeth Hanson, Atul Mahableshwarkar, Thomas Macek

💮 = New Investigator Awardee 🗼 = Pharmaceutical Pipeline Presentation

Posters

T70. Dasotraline in Children With Attention-Deficit/Hyperactivity Disorder: Results of a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study

Robert Goldman*, Sunovion

Lenard Adler, Thomas Spencer, Robert Findling, Seth Hopkins, Kenneth Koblan, Kaushik Sarma, Xiaohai Wan, Antony Loebel

T71. Efficacy and Safety of Lurasidone in Children and Adolescent **Patients With Bipolar I Depression**

Robert Goldman*, Sunovion

Melissa DelBello, Debra Phillips, Ling Deng, Josephine Cucchiaro, Antony Loebel

T72. Short and Long-Term Effects of LPS on Behavior and Oxidative Stress in Male and Female C57bl/6 Mice

Caitlin Millett*, Penn State Milton S. Hershey Medical Center Shannon Kelleher, Erika Saunders

T73. Is Parity a Protective Factor Against Suicide Attempts in Women Who Have Experienced Sexual Violence?

Victoria Valdez*, Kennedy University Hospital- Catholic University Pablo Dueñas, Joyce Jimenez

T74. Adult Glucocorticoid Receptor mRNA in Response to an Acute Stressor: Role of CSF Corticotropin-Releasing Factor in HPA Axis Regulation Following Early Life Stress

Shariful Syed*, University of Miami Jeremy Coplan

SCP

Author Index

Aaronson, Scott	19	Biederman, Joseph	75, 86
Abdullah, Samy	93	Birur, Badari	56
Abraham, Eleenor	80	Bishnoi, Ram	19
Abt, Markus	84	Bixler, Edward	75
Achtyes, Eric	93	Black, Sandra	80
Adewole, Toyin	43, 75, 88	Bliss, Caleb	92
Adler, Lenard	96	Boerescu, Daniela	78
Affinito, John	81, 84	Bold, Krysten	76
Ahmad, Ayesha	79	Bougie, Joanna	80
Ahmed, Mohammed	19	Bouhlal, Sofia	7, 76
Alam, Shaheen	86	Bozigian, Haig	83, 95
Ali, Sanjida	90	Brady, Chris	90
Alpert, Jonathan	35	Brannan, Stephen	42, 94
Althof, Stanley	84	Breier, Alan	94
Amara, Susan	92	Brenner, Helena	79
Amatniek, Joan	77, 87, 88	Brent, Benjamin	79
Amerman, Paula	82	Brewer, Claudette	82, 92
Anderson, Colleen	75, 86	Brignone, Melanie	81
Anderson, Jeffery	89	Briquet, Benjamin	81
Andrade, Nadja	87	Brissette, Suzanne	89
Andreazza, Ana	80	Brittain, Scott	75, 88, 95
Anfray, Caroline	80, 89	Brookhart, Alan	78
Angelotta, Cara	67	Brown, Delisa	79
Ansah, Kofi	57	Brown, Hannah	79
Aquila, Ralph	95	Brownstein, Michael	85
Arango, Celso	88	Brueckner, Eric	81
Archibald, Abigail	77	Bruneau, Julie	89
Arnold, Ryan	95	Brunette, Mary	93
Arnold, Valerie	86	Buckley, Peter F.	94
Atkins, Alexandra	45, 78	Budman, Cathy	89
Atsou, Kokuvi	81	Burcu, Mehmet	7, 81
Attiullah, Naureen	78	Burger, Francisco	85
Badgett, Lynn	88	Burke, Brandi	93
Bagot, Rosemary	76	Burke, Joshua	94
Baker, Ross	18, 81, 82, 90,	Burke, Shanna L.	7, 46
,	92	Bushnell, Greta	78
Barabássy, Ágota	82	Busner, Joan	79
Barbier, Estelle	87	Byerly, Matthew	77, 93
Barrett, Marna	91	Caceda, Ricardo	80
Batra, Sonal	92	Cahill, Michael	76
Bauer, Isabelle	19	Calabrese, Joseph	22, 77, 87, 88
Belchior, Patricia	72	Caldieraro, Marco Antonio	7, 44
Bender, William	57, 88	Calipari, Erin	76
Bennett, Jeffrey	85	Camprodon, Joan	54
Ben-Zeev, Dror	93	Canning, Jacquelyn	81
Berrett, Jessica	89	Carpenter, David	89
Bertzos, Kristina	90	Carson, Richard	83
Bhide, Pradeep	75	Carson, William H.	77, 87, 88

ASCP |

Author Index

Carter, Sierra 87 Crockett, R. Steve 76 Cassano, Paolo 73 Cruz, Stephanie 79 Cates, Hannah 76 Cucchiara, Andrew 91 Cather, Corinne 79 Cucchiaro, Josephine 88, 96 Cena, Frances 84 Cummings, Jeffrey 80 Chandran, Prakash 80 Cusin, Cristina 79 Chang, Cheng-Tao 80, 82, 83 Cutler, Andrew 55 Chang, Lee 79 Cypess, Aaron 93 Charney, Dennis 87 Dale, Chelsea 77 Charriez, Christina 89 Dalrymple, Kristy 88 Chelminski, Iwona 88 Danchenko, Natalya 81 Chen, Changzheng 80 Daniel, David 83, 93, 94 Chen, Changzheng 80 Daniel, David 83, 93, 94 Cheung, Joey 77 Davari, Maryam 55, 90 Chi-Burris, Kathy 82 Davis, Michael 29, 66, 81 Choka, Pratap 80 Davis, Robert 79, 92	Conton Cionno	07	Crackett D. Ctave	70
Cates, Hannah 76 Cucchiara, Andrew 91 Cather, Corinne 79 Cucchiara, Josephine 88, 96 Cena, Frances 84 Cummings, Jeffrey 80 Chang, Cheng-Tao 80, 82, 83 Cutler, Andrew 55 Chang, Lee 79 Cypess, Aaron 93 Charriez, Christina 89 Dalrymple, Kristy 88 Chelminski, Iwona 88 Danchenko, Natalya 81 Chen, Changzheng 80 Daniel, David 83, 93, 94 Chen, Changzheng 80 Daniel, David 83, 93, 94 Chen, Changzheng 80 Daniel, David 83, 93, 94 Cheung, Joey 77 Davari, Maryam 85, 90 Chi-Burris, Kathy 82 Davis, Lori 18, 21, 56 Chitayat, David 84 Davis, Michael 29, 66, 81 Choka, Pratap 80 Davis, Michael 29, 66, 81 Chotinard, Suy 93 Dayton, Roshanah 93 Chouinard, Virginie-Anne 7, 53, 93 Debattista, Charles				
Cather, Corinne 79 Cucchiarro, Josephine 88, 96 Cena, Frances 84 Cummings, Jeffrey 80 Chandran, Prakash 80 Cusin, Cristina 79 Chang, Cheng-Tao 80, 82, 83 Cutter, Andrew 55 Chang, Lee 79 Cypess, Aaron 93 Charney, Dennis 87 Dale, Chelsea 77 Charriez, Christina 89 Dalrymple, Kristy 88 Chelminski, Iwona 88 Danchenko, Natalya 81 Chen, Alexander 84 Dang, Jonathan 58 Chen, Changzheng 80 Daniel, David 83, 93, 94 Cheng, Laura 84 Darpo, Borje 76 Cheung, Joey 77 Davari, Maryam 85, 90 Chi-Burris, Kathy 82 Davis, Lori 18, 21, 56 Chitayat, David 84 Davis, Robert 79, 92 Chouinard, Guy 93 Davis, Robert 79, 92 Chouinard, Wirginie-Anne 7, 53, 93 Debattista, Charles 79				
Cena, Frances 84 Cummings, Jeffrey 80 Chandran, Prakash 80 Cusin, Cristina 79 Chang, Cheng-Tao 80, 82, 83 Cutler, Andrew 55 Chang, Lee 79 Cypess, Aaron 93 Charney, Dennis 87 Dale, Chelsea 77 Charriez, Christina 89 Dalrymple, Kristy 88 Chelminski, Iwona 88 Danchenko, Natalya 81 Chen, Alexander 84 Dang, Jonathan 58 Chen, Changzheng 80 Daniel, David 83, 93, 94 Cheng, Laura 84 Darpo, Borje 76 Cheung, Joey 77 Davari, Maryam 85, 90 Chi-Burris, Kathy 82 Davis, Hori 18, 21, 56 Chokka, Pratap 80 Davis, Robert 79, 92 Chouinard, Guy 93 Dayton, Roshanah 93 Chouinard, Virginie-Anne 7, 53, 93 Debattista, Charles 79 Chow, Shein 76 Delfalo, Melissa 96	•		*	
Chandran, Prakash 80 Cusin, Cristina 79 Chang, Cheng-Tao 80, 82, 83 Cutler, Andrew 55 Chang, Lee 79 Cypess, Aaron 93 Charney, Dennis 87 Dale, Chelsea 77 Charriez, Christina 89 Dalrymple, Kristy 88 Chelminski, Iwona 88 Danchenko, Natalya 81 Chen, Changzheng 80 Daniel, David 83, 93, 94 Chen, Changzheng 80 Daniel, David 83, 93, 94 Cheng, Laura 84 Darpo, Borje 76 Cheung, Joey 77 Davari, Maryam 85, 90 Chi-Burris, Kathy 82 Davis, Cori 18, 21, 56 Chitayat, David 84 Davis, Robert 79, 92 Chitayat, David 84 Davis, Robert 79, 92 Chouinard, Guy 93 Dayton, Roshanah 93 Chouinard, Virginie-Anne 7, 53, 93 Debattista, Charles 79 Chow, Shein 76 DeFrancisco, Don 88 <td></td> <td></td> <td></td> <td></td>				
Chang, Cheng-Tao 80, 82, 83 Cutler, Andrew 55 Chang, Lee 79 Cypess, Aaron 93 Charney, Dennis 87 Dale, Chelsea 77 Charriez, Christina 89 Dalrymple, Kristy 88 Chelm, Changaren 84 Dang, Jonathan 58 Chen, Changzheng 80 Daniel, David 83, 93, 94 Cheng, Laura 84 Darpo, Borje 76 Cheung, Joey 77 Davari, Maryam 85, 90 Chi-Burris, Kathy 82 Davis, Lori 18, 21, 56 Chitayat, David 84 Davis, Lori 18, 21, 56 Chitayat, David 84 Davis, Michael 29, 66, 81 Chitayat, David 84 Davis, Robert 79, 92 Choulnard, Virginie-Anne 7, 53, 93 Debattista, Charles 79 Chow, Shein 76 Defrancisco, Don 88 Chronis-Tuscano, Andrea 86 Deliganinidis, Kristina 22, 95 Clark, Crystal 19, 44, 67 Demos, George				
Chang, Lee 79 Cypess, Aaron 93 Charney, Dennis 87 Dale, Chelsea 77 Charriez, Christina 89 Dalrymple, Kristy 88 Chelminski, Iwona 88 Danchenko, Natalya 81 Chen, Changzheng 80 Daniel, David 83, 93, 94 Chen, Changzheng 80 Daniel, David 83, 93, 94 Cheng, Laura 84 Darpo, Borje 76 Cheung, Joey 77 Davari, Maryam 85, 90 Chitayat, David 84 Daris, Michael 29, 66, 81 Chitayat, David 84 Davis, Michael 29, 66, 81 Chokka, Pratap 80 Davis, Robert 79, 92 Chouinard, Guy 93 Dayton, Roshanah 93 Chouinard, Virginie-Anne 7, 53, 93 Debattista, Charles 79 Chow, Shein 76 DelTarcisco, Don 88 Christensen, Michael Cronquist 6 DelBello, Melissa 96 Chronis-Tuscano, Andrea 86 Delgado, Pedro <				
Charney, Dennis 87 Dale, Chelsea 77 Charriez, Christina 89 Dalrymple, Kristy 88 Chelminski, Iwona 88 Danchenko, Natalya 81 Chen, Alexander 84 Dang, Jonathan 58 Chen, Changzheng 80 Daniel, David 83, 93, 94 Cheng, Laura 84 Darpo, Borje 76 Cheung, Joey 77 Davari, Maryam 85, 90 Chi-Burris, Kathy 82 Davis, Lori 18, 21, 56 Chitayat, David 84 Davis, Michael 29, 66, 81 Chokak, Pratap 80 Davis, Robert 79, 92 Chouinard, Virginie-Anne 7, 53, 93 Debattista, Charles 79 Chouinard, Virginie-Anne 7, 53, 93 Debattista, Charles 79 Chow, Shein 76 DelFrancisco, Don 88 Christensen, Michael Cronquist 76 DelBello, Melissa 96 Christensen, Michael Cronquist 76 Delagdo, Pedro 80 Clark, Crystal 19, 42, 95				
Charriez, Christina 89 Dalrymple, Kristy 88 Chelminski, Iwona 88 Danchenko, Natalya 81 Chen, Alexander 84 Dang, Jonathan 58 Chen, Changzheng 80 Daniel, David 83, 93, 94 Cheng, Laura 84 Darpo, Borje 76 Cheung, Joey 77 Davari, Maryam 85, 90 Chi-Burris, Kathy 82 Davis, Lori 18, 21, 56 Chitayat, David 84 Davis, Michael 29, 66, 81 Chokka, Pratap 80 Davis, Robert 79, 92 Chouinard, Guy 93 Dayton, Roshanah 93 Chouinard, Virginie-Anne 7, 53, 93 Debattista, Charles 79 Chow, Shein 76 DelBello, Melissa 96 Christensen, Michael Cronquist 76 DelBello, Melissa 96 Citark, Crystal 19, 24, 67 Demos, George 82 Clark, Crystal 19, 44, 67 Demos, Ling 83, 96 Clark, Crystal 19, 42, 95 DeRogatis, Leon				
Chelminski, Iwona 88 Danchenko, Natalya 81 Chen, Alexander 84 Dang, Jonathan 58 Chen, Changzheng 80 Daniel, David 83, 93, 94 Cheng, Laura 84 Darpo, Borje 76 Cheung, Joey 77 Davari, Maryam 85, 90 Chi-Burris, Kathy 82 Davis, Lori 18, 21, 56 Chitayat, David 84 Davis, Michael 29, 66, 81 Chokka, Pratap 80 Davis, Robert 79, 92 Chouinard, Guy 93 Dayton, Roshanah 93 Chouinard, Virginie-Anne 7, 53, 93 Debattista, Charles 79 Chow, Shein 76 DeFrancisco, Don 88 Christensen, Michael Cronquist 76 DelBello, Melissa 96 Christensen, Andrea 86 Delgado, Pedro 80 Citrome, Leslie 19, 22, 60, 82 Deligiannidis, Kristina 22, 95 Clark, Crystal 19, 44, 67 Demos, George 82 Clark, Janet 92 Deng, Ling <td></td> <td></td> <td></td> <td></td>				
Chen, Alexander 84 Dang, Jonathan 58 Chen, Changzheng 80 Daniel, David 83, 93, 94 Cheng, Laura 84 Darpo, Borje 76 Cheung, Joey 77 Davari, Maryam 85, 90 Chi-Burris, Kathy 82 Davis, Lori 18, 21, 56 Chitayat, David 84 Davis, Michael 29, 66, 81 Choka, Pratap 80 Davis, Robert 79, 92 Chouinard, Guy 93 Dayton, Roshanah 93 Chouinard, Virginie-Anne 7, 53, 93 Debattista, Charles 79 Chow, Shein 76 DeFrancisco, Don 88 Christensen, Michael Cronquist 76 DelBello, Melissa 96 Chronis-Tuscano, Andrea 6 Delgado, Pedro 80 Citrome, Leslie 19, 22, 60, 82 Deligiannidis, Kristina 22, 95 Clark, Crystal 19, 44, 67 Demos, George 82 Clark, Crystal 19, 44, 67 Demos, George 82 Clark, Lawret 92 Deng, Ling				
Chen, Changzheng 80 Daniel, David 83, 93, 94 Cheng, Laura 84 Darpo, Borje 76 Cheung, Joey 77 Davari, Maryam 85, 90 Chi-Burris, Kathy 82 Davis, Lori 18, 21, 56 Chitayat, David 84 Davis, Michael 29, 66, 81 Chokka, Pratap 80 Davis, Robert 79, 92 Chouinard, Guy 93 Dayton, Roshanah 93 Chouinard, Virginie-Anne 7, 53, 93 Debattista, Charles 79 Chow, Shein 76 DelFrancisco, Don 88 Christensen, Michael Cronquist 76 DelBello, Melissa 96 Chronis-Tuscano, Andrea 86 Delgado, Pedro 80 Citrome, Leslie 19, 22, 60, 82 Deligiannidis, Kristina 22, 95 Clark, Janet 92 Deng, Ling 88 Clark, Janet 92 Deng, Ling 84 Cobelli, Claudio 93 De Somer, Marc 73 Cobelli, Claudio 93 De Somer, Marc <				
Cheng, Laura 84 Darpo, Borje 76 Cheung, Joey 77 Davari, Maryam 85, 90 Chi-Burris, Kathy 82 Davis, Lori 18, 21, 56 Chitayat, David 84 Davis, Michael 29, 66, 81 Chokka, Pratap 80 Davis, Robert 79, 92 Chouinard, Guy 93 Dayton, Roshanah 93 Chow, Shein 76 DeFrancisco, Don 88 Christensen, Michael Cronquist 76 DelBello, Melissa 96 Chronis-Tuscano, Andrea 86 Delgado, Pedro 80 Citrome, Leslie 19, 22, 60, 82 Deligiannidis, Kristina 22, 95 Clark, Crystal 19, 44, 67 Demos, George 82 Clark, Janet 92 Deng, Ling 88, 96 Clark, Janet 92 Deng, Ling 88, 96 Clark, Janet 93 De Somer, Marc 73 Cobelli, Claudio 93 De Somer, Marc 73 Cobelli, Claudio 93 De Somer, Marc 73 <td></td> <td>84</td> <td>Dang, Jonathan</td> <td>58</td>		84	Dang, Jonathan	58
Cheung, Joey 77 Davari, Maryam 85, 90 Chi-Burris, Kathy 82 Davis, Lori 18, 21, 56 Chitayat, David 84 Davis, Michael 29, 66, 81 Chokka, Pratap 80 Davis, Robert 79, 92 Chouinard, Guy 93 Dayton, Roshanah 93 Chouinard, Virginie-Anne 7, 53, 93 Debattista, Charles 79 Chow, Shein 76 DeFrancisco, Don 88 Christensen, Michael Cronquist 76 Delgado, Pedro 80 Christensen, Michael Cronquist 76 Delgado, Pedro 80 Christensen, Michael 19, 22, 60, 82 Deligiannidis, Kristina 22, 95 Chronis-Tuscano, Andrea 86 Delgado, Pedro 80 Citrome, Leslie 19, 22, 60, 82 Deligiannidis, Kristina 22, 95 Clark, Crystal 19, 42, 67 Demos, George 82 Clark, Janet 92 Deng, Ling 88, 96 Clark, Janet 93 De Somer, Marc 73 Coctark, Crystal <t< td=""><td>Chen, Changzheng</td><td>80</td><td>Daniel, David</td><td>83, 93, 94</td></t<>	Chen, Changzheng	80	Daniel, David	83, 93, 94
Chi-Burris, Kathy 82 Davis, Lori 18, 21, 56 Chitayat, David 84 Davis, Michael 29, 66, 81 Chokka, Pratap 80 Davis, Robert 79, 92 Chouinard, Guy 93 Dayton, Roshanah 93 Chounard, Virginie-Anne 7, 53, 93 Debattista, Charles 79 Chow, Shein 76 DelFrancisco, Don 88 Christensen, Michael Cronquist 76 DelBello, Melissa 96 Chronis-Tuscano, Andrea 86 Delgado, Pedro 80 Citrome, Leslie 19, 22, 60, 82 Deligiannidis, Kristina 22, 95 Clark, Crystal 19, 44, 67 Demos, George 82 Clark, Janet 92 Denos, George 82 Clayton, Anita 19, 42, 95 DeRogatis, Leonard 84 Cobelli, Claudio 93 De Somer, Marc 73 Coccaro, Emil F. 6, 53 DeSousa, Norberto 86 Coffey, Alissa 75 Detke, Michael 72, 73 Coffey, Barbara 89 <t< td=""><td>Cheng, Laura</td><td>84</td><td>Darpo, Borje</td><td></td></t<>	Cheng, Laura	84	Darpo, Borje	
Chitayat, David 84 Davis, Michael 29, 66, 81 Chokka, Pratap 80 Davis, Robert 79, 92 Chouinard, Guy 93 Dayton, Roshanah 93 Chounard, Virginie-Anne 7, 53, 93 Debattista, Charles 79 Chow, Shein 76 DeFrancisco, Don 88 Christensen, Michael Cronquist 76 DelBello, Melissa 96 Chronis-Tuscano, Andrea 86 Delgado, Pedro 80 Citrome, Leslie 19, 22, 60, 82 Deligiannidis, Kristina 22, 95 Clark, Crystal 19, 44, 67 Demos, George 82 Clark, Janet 92 Deng, Ling 88 Clark, Janet 92 Deng, Ling 84 Cobelli, Claudio 93 De Somer, Marc 73 Coccaro, Emil F. 6, 53 De Sousa, Norberto 86 Coffey, Alissa 75 Detke, Michael 72, 73 Coffey, Barbara 89 Diamand, Françoise 81 Cohen, Bruce 93 DiiBerili, Calument	Cheung, Joey	77	Davari, Maryam	85, 90
Chokka, Pratap 80 Davis, Robert 79, 92 Chouinard, Guy 93 Dayton, Roshanah 93 Chouinard, Virginie-Anne 7, 53, 93 Debattista, Charles 79 Chow, Shein 76 DeFrancisco, Don 88 Christensen, Michael Cronquist 76 DelBello, Melissa 96 Chronis-Tuscano, Andrea 86 Delgado, Pedro 80 Citrome, Leslie 19, 22, 60, 82 Deligiannidis, Kristina 22, 95 Clark, Crystal 19, 44, 67 Demos, George 82 Clark, Janet 92 Deng, Ling 88, 96 Clayton, Anita 19, 42, 95 DeRogatis, Leonard 84 Cobelli, Claudio 93 De Sousa, Norberto 86 Coffey, Barbara 75 Detke, Michael 72, 73 Coffey, Barbara 89 Diamand, Françoise 81 Cohen, Bruce 93 DiBlasi, Faith 77, 93 Cohen, Lawrence 19 DiPetrillo, Lauren 83 Cohen, Lee 39, 84 Djan,	Chi-Burris, Kathy	82	Davis, Lori	18, 21, 56
Chouinard, Guy 93 Dayton, Roshanah 93 Chouinard, Virginie-Anne 7, 53, 93 Debattista, Charles 79 Chow, Shein 76 DeFrancisco, Don 88 Christensen, Michael Cronquist 76 DelBello, Melissa 96 Chronis-Tuscano, Andrea 86 Delgado, Pedro 80 Citrome, Leslie 19, 22, 60, 82 Deligiannidis, Kristina 22, 95 Clark, Crystal 19, 44, 67 Demos, George 82 Clark, Janet 92 Deng, Ling 88, 96 Clayton, Anita 19, 42, 95 DeRogatis, Leonard 84 Cobelli, Claudio 93 De Somer, Marc 73 Coccaro, Emil F. 6, 53 DeSousa, Norberto 86 Coffey, Alissa 75 Detke, Michael 72, 73 Coffey, Barbara 89 Diamand, Françoise 81 Cohen, Bruce 93 DiBiasi, Faith 77, 93 Cohen, Elan 82 DiClemente, Guillermo 85 Cohen, Lee 39, 84 Djan, J	Chitayat, David	84	Davis, Michael	29, 66, 81
Chouinard, Guy 93 Dayton, Roshanah 93 Chouinard, Virginie-Anne 7, 53, 93 Debattista, Charles 79 Chow, Shein 76 DeFrancisco, Don 88 Christensen, Michael Cronquist 76 DelBello, Melissa 96 Chronis-Tuscano, Andrea 86 Delgado, Pedro 80 Citrome, Leslie 19, 22, 60, 82 Deligiannidis, Kristina 22, 95 Clark, Crystal 19, 44, 67 Demos, George 82 Clark, Janet 92 Deng, Ling 88, 96 Clayton, Anita 19, 42, 95 DeRogatis, Leonard 84 Cobelli, Claudio 93 De Somer, Marc 73 Coccaro, Emil F. 6, 53 DeSousa, Norberto 86 Coffey, Alissa 75 Detke, Michael 72, 73 Coffey, Barbara 89 Diamand, Françoise 81 Cohen, Bruce 93 DiBiasi, Faith 77, 93 Cohen, Elan 82 DiClemente, Guillermo 85 Cohen, Lee 39, 84 Djan, J	Chokka, Pratap	80	Davis, Robert	79, 92
Chouinard, Virginie-Anne 7, 53, 93 Debattista, Charles 79 Chow, Shein 76 DeFrancisco, Don 88 Christensen, Michael Cronquist 76 DelBello, Melissa 96 Chronis-Tuscano, Andrea 86 Delgado, Pedro 80 Citrome, Leslie 19, 22, 60, 82 Deligiannidis, Kristina 22, 95 Clark, Crystal 19, 44, 67 Demos, George 82 Clark, Janet 92 Deng, Ling 88, 96 Clayton, Anita 19, 42, 95 DeRogatis, Leonard 84 Cobelli, Claudio 93 De Somer, Marc 73 Coccaro, Emil F. 6, 53 DeSousa, Norberto 86 Coffey, Alissa 75 Detke, Michael 72, 73 Coffey, Barbara 89 Diamand, Françoise 81 Cohen, Bruce 93 DiBiasi, Faith 77, 93 Cohen, Elan 82 DiClemente, Guillermo 85 Cohen, Lee 39, 84 Djan, Joseph 89 Collins, Katherine 87 Doherty	Chouinard, Guy	93	Dayton, Roshanah	
Chow, Shein 76 DeFrancisco, Don 88 Christensen, Michael Cronquist 76 DelBello, Melissa 96 Chronis-Tuscano, Andrea 86 Delgado, Pedro 80 Citrome, Leslie 19, 22, 60, 82 Deligiannidis, Kristina 22, 95 Clark, Crystal 19, 44, 67 Demos, George 82 Clark, Janet 92 Deng, Ling 88, 96 Clayton, Anita 19, 42, 95 DeRogatis, Leonard 84 Cobelli, Claudio 93 De Somer, Marc 73 Coccaro, Emil F. 6, 53 DeSousa, Norberto 86 Coffey, Alissa 75 Detke, Michael 72, 73 Coffey, Alissa 75 Detke, Michael 72, 73 Coffey, Barbara 89 Diamand, Françoise 81 Cohen, Bruce 93 DiBiasi, Faith 77, 93 Cohen, Elan 82 DiClemente, Guillermo 85 Cohen, Lee 39, 84 Djan, Joseph 89 Collins, Katherine 87 Donahue, Lauren	Chouinard, Virginie-Anne	7, 53, 93		79
Christensen, Michael Cronquist 76 DelBello, Melissa 96 Chronis-Tuscano, Andrea 86 Delgado, Pedro 80 Citrome, Leslie 19, 22, 60, 82 Deligiannidis, Kristina 22, 95 Clark, Crystal 19, 44, 67 Demos, George 82 Clark, Janet 92 Deng, Ling 88, 96 Clayton, Anita 19, 42, 95 DeRogatis, Leonard 84 Cobelli, Claudio 93 De Somer, Marc 73 Coccaro, Emil F. 6, 53 DeSousa, Norberto 86 Coffey, Alissa 75 Detke, Michael 72, 73 Coffey, Barbara 89 Diamand, Françoise 81 Cohen, Bruce 93 DiBlasi, Faith 77, 93 Cohen, Elan 82 DiClemente, Guillermo 85 Cohen, Lee 39, 84 Djan, Joseph 89 Collins, Katherine 87 Doherty, James 78, 95 Colquhoun, Helen 78, 95 Donahue, Lauren 79 Compton, Scott 78 Donovan, Abigail<	=			88
Chronis-Tuscano, Andrea 86 Delgado, Pedro 80 Citrome, Leslie 19, 22, 60, 82 Deligiannidis, Kristina 22, 95 Clark, Crystal 19, 44, 67 Demos, George 82 Clark, Janet 92 Deng, Ling 88, 96 Clayton, Anita 19, 42, 95 DeRogatis, Leonard 84 Cobelli, Claudio 93 De Somer, Marc 73 Coccaro, Emil F. 6, 53 DeSousa, Norberto 86 Coffey, Alissa 75 Detke, Michael 72, 73 Coffey, Barbara 89 Diamand, Françoise 81 Cohen, Bruce 93 DiBlasi, Faith 77, 93 Cohen, Elan 82 DiClemente, Guillermo 85 Cohen, Lawrence 19 DiPetrillo, Lauren 83 Cohen, Lee 39, 84 Djan, Joseph 89 Collins, Katherine 87 Doherty, James 78, 95 Colquhoun, Helen 78, 95 Donahue, Lauren 79 Compton, Michael T. 10, 64 Dong, Xinxin		76	DelBello, Melissa	96
Citrome, Leslie 19, 22, 60, 82 Deligiannidis, Kristina 22, 95 Clark, Crystal 19, 44, 67 Demos, George 82 Clark, Janet 92 Deng, Ling 88, 96 Clayton, Anita 19, 42, 95 DeRogatis, Leonard 84 Cobelli, Claudio 93 De Somer, Marc 73 Coccaro, Emil F. 6, 53 DeSousa, Norberto 86 Coffey, Alissa 75 Detke, Michael 72, 73 Coffey, Barbara 89 Diamand, Françoise 81 Cohen, Bruce 93 DiBlasi, Faith 77, 93 Cohen, Lawrence 19 DiPetrillo, Lauren 85 Cohen, Lawrence 19 DiPetrillo, Lauren 83 Collins, Katherine 87 Doherty, James 78, 95 Colquhoun, Helen 78, 95 Donahue, Lauren 79 Compton, Michael T. 10, 64 Dong, Xinxin 84, 95 Compton, Scott 78 Donovan, Abigail 79 Coplan, Jeremy 96 D'Souza, Deepak	•			80
Clark, Crystal 19, 44, 67 Demos, George 82 Clark, Janet 92 Deng, Ling 88, 96 Clayton, Anita 19, 42, 95 DeRogatis, Leonard 84 Cobelli, Claudio 93 De Somer, Marc 73 Coccaro, Emil F. 6, 53 DeSousa, Norberto 86 Coffey, Alissa 75 Detke, Michael 72, 73 Coffey, Barbara 89 Diamand, Françoise 81 Cohen, Bruce 93 DiBiasi, Faith 77, 93 Cohen, Elan 82 DiClemente, Guillermo 85 Cohen, Lawrence 19 DiPetrillo, Lauren 83 Cohen, Lee 39, 84 Djan, Joseph 89 Collins, Katherine 87 Doherty, James 78, 95 Colquhoun, Helen 78, 95 Donahue, Lauren 79 Compton, Michael T. 10, 64 Dong, Xinxin 84, 95 Compton, Scott 78 Donovan, Abigail 79 Coplan, Jeremy 96 D'Souza, Deepak 83		19, 22, 60, 82		
Clark, Janet 92 Deng, Ling 88, 96 Clayton, Anita 19, 42, 95 DeRogatis, Leonard 84 Cobelli, Claudio 93 De Somer, Marc 73 Coccaro, Emil F. 6, 53 DeSousa, Norberto 86 Coffey, Alissa 75 Detke, Michael 72, 73 Coffey, Barbara 89 Diamand, Françoise 81 Cohen, Bruce 93 DiBiasi, Faith 77, 93 Cohen, Elan 82 DiClemente, Guillermo 85 Cohen, Lawrence 19 DiPetrillo, Lauren 83 Cohen, Lee 39, 84 Djan, Joseph 89 Collins, Katherine 87 Doherty, James 78, 95 Colquhoun, Helen 78, 95 Donahue, Lauren 79 Compton, Michael T. 10, 64 Dong, Xinxin 84, 95 Compton, Scott 78 Donovan, Abigail 79 Coplan, Jeremy 96 D'Souza, Deepak 83 Correll, Christoph U. 19, 21, 22, 77, Du, Fei 93			_	
Clayton, Anita 19, 42, 95 DeRogatis, Leonard 84 Cobelli, Claudio 93 De Somer, Marc 73 Coccaro, Emil F. 6, 53 DeSousa, Norberto 86 Coffey, Alissa 75 Detke, Michael 72, 73 Coffey, Barbara 89 Diamand, Françoise 81 Cohen, Bruce 93 DiBiasi, Faith 77, 93 Cohen, Bruce 93 DiClemente, Guillermo 85 Cohen, Elan 82 DiClemente, Guillermo 85 Cohen, Lawrence 19 DiPetrillo, Lauren 83 Cohen, Lee 39, 84 Djan, Joseph 89 Collins, Katherine 87 Doherty, James 78, 95 Colquhoun, Helen 78, 95 Donahue, Lauren 79 Compton, Scott 78 Donoyan, Abigail 79 Compton, Scott 78 Donovan, Abigail 79 Coplan, Jeremy 96 D'Souza, Deepak 83 Correll, Christoph U. 19, 21, 22, 77, Du, Fei 93 93 <				
Cobelli, Claudio 93 De Somer, Marc 73 Coccaro, Emil F. 6, 53 DeSousa, Norberto 86 Coffey, Alissa 75 Detke, Michael 72, 73 Coffey, Barbara 89 Diamand, Françoise 81 Cohen, Bruce 93 DiBiasi, Faith 77, 93 Cohen, Elan 82 DiClemente, Guillermo 85 Cohen, Lawrence 19 DiPetrillo, Lauren 83 Cohen, Lee 39, 84 Djan, Joseph 89 Collins, Katherine 87 Doherty, James 78, 95 Colquhoun, Helen 78, 95 Donahue, Lauren 79 Compton, Michael T. 10, 64 Dong, Xinxin 84, 95 Compton, Scott 78 Donovan, Abigail 79 Coplan, Jeremy 96 D'Souza, Deepak 83 Correll, Christoph U. 19, 21, 22, 77, Du, Fei 93 82, 83, 88, 90, Du, Yangchun 94, 95 93 Dubreucq, Simon 89 Costi, Sara 87 Duefaas, Pablo <td></td> <td></td> <td></td> <td></td>				
Coccaro, Emil F. 6, 53 DeSousa, Norberto 86 Coffey, Alissa 75 Detke, Michael 72, 73 Coffey, Barbara 89 Diamand, Françoise 81 Cohen, Bruce 93 DiBiasi, Faith 77, 93 Cohen, Elan 82 DiClemente, Guillermo 85 Cohen, Lawrence 19 DiPetrillo, Lauren 83 Cohen, Lee 39, 84 Djan, Joseph 89 Collins, Katherine 87 Doherty, James 78, 95 Colquhoun, Helen 78, 95 Donahue, Lauren 79 Compton, Michael T. 10, 64 Dong, Xinxin 84, 95 Compton, Scott 78 Donovan, Abigail 79 Coplan, Jeremy 96 D'Souza, Deepak 83 Correll, Christoph U. 19, 21, 22, 77, Du, Fei 93 82, 83, 88, 90, Du, Yangchun 94, 95 93 Dubitsky, Greg 81 Costi, Sara 87 Dubreucq, Simon 89 Cox, Kevin 77, 87, 88 Dueñas, Pablo <td>-</td> <td></td> <td>-</td> <td></td>	-		-	
Coffey, Alissa 75 Detke, Michael 72, 73 Coffey, Barbara 89 Diamand, Françoise 81 Cohen, Bruce 93 DiBiasi, Faith 77, 93 Cohen, Elan 82 DiClemente, Guillermo 85 Cohen, Lawrence 19 DiPetrillo, Lauren 83 Cohen, Lee 39, 84 Djan, Joseph 89 Collins, Katherine 87 Doherty, James 78, 95 Colquhoun, Helen 78, 95 Donahue, Lauren 79 Compton, Michael T. 10, 64 Dong, Xinxin 84, 95 Compton, Scott 78 Donovan, Abigail 79 Coplan, Jeremy 96 D'Souza, Deepak 83 Correll, Christoph U. 19, 21, 22, 77, Du, Fei 93 82, 83, 88, 90, Du, Yangchun 94, 95 93 Dubitsky, Greg 81 Costi, Sara 87 Dubreucq, Simon 89 Cox, Kevin 77, 87, 88 Dueñas, Pablo 96 Creatura, Gina 83 Dusetzina, Stacie				
Coffey, Barbara 89 Diamand, Françoise 81 Cohen, Bruce 93 DiBiasi, Faith 77, 93 Cohen, Elan 82 DiClemente, Guillermo 85 Cohen, Lawrence 19 DiPetrillo, Lauren 83 Cohen, Lee 39, 84 Djan, Joseph 89 Collins, Katherine 87 Doherty, James 78, 95 Colquhoun, Helen 78, 95 Donahue, Lauren 79 Compton, Michael T. 10, 64 Dong, Xinxin 84, 95 Compton, Scott 78 Donovan, Abigail 79 Coplan, Jeremy 96 D'Souza, Deepak 83 Correll, Christoph U. 19, 21, 22, 77, Du, Fei 93 82, 83, 88, 90, Du, Yangchun 94, 95 93 Dubitsky, Greg 81 Costi, Sara 87 Dubreucq, Simon 89 Cox, Kevin 77, 87, 88 Dueñas, Pablo 96 Crean, Rebecca 89 Durgam, Suresh 80, 83 Creatura, Gina 83 Dusetzina, Stacie			*	
Cohen, Bruce 93 DiBiasi, Faith 77, 93 Cohen, Elan 82 DiClemente, Guillermo 85 Cohen, Lawrence 19 DiPetrillo, Lauren 83 Cohen, Lee 39, 84 Djan, Joseph 89 Collins, Katherine 87 Doherty, James 78, 95 Colquhoun, Helen 78, 95 Donahue, Lauren 79 Compton, Michael T. 10, 64 Dong, Xinxin 84, 95 Compton, Scott 78 Donovan, Abigail 79 Coplan, Jeremy 96 D'Souza, Deepak 83 Correll, Christoph U. 19, 21, 22, 77, Du, Fei 93 82, 83, 88, 90, Du, Yangchun 94, 95 93 Dubitsky, Greg 81 Costi, Sara 87 Dubreucq, Simon 89 Cox, Kevin 77, 87, 88 Dueñas, Pablo 96 Crean, Rebecca 89 Durgam, Suresh 80, 83 Creatura, Gina 83 Dusetzina, Stacie 78				
Cohen, Elan 82 DiClemente, Guillermo 85 Cohen, Lawrence 19 DiPetrillo, Lauren 83 Cohen, Lee 39, 84 Djan, Joseph 89 Collins, Katherine 87 Doherty, James 78, 95 Colquhoun, Helen 78, 95 Donahue, Lauren 79 Compton, Michael T. 10, 64 Dong, Xinxin 84, 95 Compton, Scott 78 Donovan, Abigail 79 Coplan, Jeremy 96 D'Souza, Deepak 83 Correll, Christoph U. 19, 21, 22, 77, Du, Fei 93 82, 83, 88, 90, Du, Yangchun 94, 95 93 Dubitsky, Greg 81 Costi, Sara 87 Dubreucq, Simon 89 Cox, Kevin 77, 87, 88 Dueñas, Pablo 96 Crean, Rebecca 89 Durgam, Suresh 80, 83 Creatura, Gina 83 Dusetzina, Stacie 78				
Cohen, Lawrence 19 DiPetrillo, Lauren 83 Cohen, Lee 39, 84 Djan, Joseph 89 Collins, Katherine 87 Doherty, James 78, 95 Colquhoun, Helen 78, 95 Donahue, Lauren 79 Compton, Michael T. 10, 64 Dong, Xinxin 84, 95 Compton, Scott 78 Donovan, Abigail 79 Coplan, Jeremy 96 D'Souza, Deepak 83 Correll, Christoph U. 19, 21, 22, 77, Du, Fei 93 82, 83, 88, 90, Du, Yangchun 94, 95 93 Dubitsky, Greg 81 Costi, Sara 87 Dubreucq, Simon 89 Cox, Kevin 77, 87, 88 Dueñas, Pablo 96 Crean, Rebecca 89 Durgam, Suresh 80, 83 Creatura, Gina 83 Dusetzina, Stacie 78				
Cohen, Lee 39, 84 Djan, Joseph 89 Collins, Katherine 87 Doherty, James 78, 95 Colquhoun, Helen 78, 95 Donahue, Lauren 79 Compton, Michael T. 10, 64 Dong, Xinxin 84, 95 Compton, Scott 78 Donovan, Abigail 79 Coplan, Jeremy 96 D'Souza, Deepak 83 Correll, Christoph U. 19, 21, 22, 77, Du, Fei 93 82, 83, 88, 90, Du, Yangchun 94, 95 93 Dubitsky, Greg 81 Costi, Sara 87 Dubreucq, Simon 89 Cox, Kevin 77, 87, 88 Dueñas, Pablo 96 Crean, Rebecca 89 Durgam, Suresh 80, 83 Creatura, Gina 83 Dusetzina, Stacie 78				
Collins, Katherine 87 Doherty, James 78, 95 Colquhoun, Helen 78, 95 Donahue, Lauren 79 Compton, Michael T. 10, 64 Dong, Xinxin 84, 95 Compton, Scott 78 Donovan, Abigail 79 Coplan, Jeremy 96 D'Souza, Deepak 83 Correll, Christoph U. 19, 21, 22, 77, Du, Fei 93 82, 83, 88, 90, Du, Yangchun 94, 95 93 Dubitsky, Greg 81 Costi, Sara 87 Dubreucq, Simon 89 Cox, Kevin 77, 87, 88 Dueñas, Pablo 96 Crean, Rebecca 89 Durgam, Suresh 80, 83 Creatura, Gina 83 Dusetzina, Stacie 78				
Colquhoun, Helen 78, 95 Donahue, Lauren 79 Compton, Michael T. 10, 64 Dong, Xinxin 84, 95 Compton, Scott 78 Donovan, Abigail 79 Coplan, Jeremy 96 D'Souza, Deepak 83 Correll, Christoph U. 19, 21, 22, 77, Du, Fei 93 82, 83, 88, 90, Du, Yangchun 94, 95 93 Dubitsky, Greg 81 Costi, Sara 87 Dubreucq, Simon 89 Cox, Kevin 77, 87, 88 Dueñas, Pablo 96 Crean, Rebecca 89 Durgam, Suresh 80, 83 Creatura, Gina 83 Dusetzina, Stacie 78				
Compton, Michael T. 10, 64 Dong, Xinxin 84, 95 Compton, Scott 78 Donovan, Abigail 79 Coplan, Jeremy 96 D'Souza, Deepak 83 Correll, Christoph U. 19, 21, 22, 77, Du, Fei 93 82, 83, 88, 90, Du, Yangchun 94, 95 93 Dubitsky, Greg 81 Costi, Sara 87 Dubreucq, Simon 89 Cox, Kevin 77, 87, 88 Dueñas, Pablo 96 Crean, Rebecca 89 Durgam, Suresh 80, 83 Creatura, Gina 83 Dusetzina, Stacie 78				
Compton, Scott 78 Donovan, Abigail 79 Coplan, Jeremy 96 D'Souza, Deepak 83 Correll, Christoph U. 19, 21, 22, 77, Du, Fei 93 82, 83, 88, 90, Du, Yangchun 94, 95 93 Dubitsky, Greg 81 Costi, Sara 87 Dubreucq, Simon 89 Cox, Kevin 77, 87, 88 Dueñas, Pablo 96 Crean, Rebecca 89 Durgam, Suresh 80, 83 Creatura, Gina 83 Dusetzina, Stacie 78	•			
Coplan, Jeremy 96 D'Souza, Deepak 83 Correll, Christoph U. 19, 21, 22, 77, Du, Fei 93 82, 83, 88, 90, Du, Yangchun 94, 95 93 Dubitsky, Greg 81 Costi, Sara 87 Dubreucq, Simon 89 Cox, Kevin 77, 87, 88 Dueñas, Pablo 96 Crean, Rebecca 89 Durgam, Suresh 80, 83 Creatura, Gina 83 Dusetzina, Stacie 78				
Correll, Christoph U. 19, 21, 22, 77, 82, 83, 88, 90, 93 Du, Yangchun 94, 95 82, 83, 88, 90, 93 Dubitsky, Greg 81 Costi, Sara 87 Dubreucq, Simon 89 Cox, Kevin 77, 87, 88 Dueñas, Pablo 96 Crean, Rebecca 89 Durgam, Suresh 80, 83 Creatura, Gina 83 Dusetzina, Stacie 78				
82, 83, 88, 90, Du, Yangchun 94, 95 93 Dubitsky, Greg 81 Costi, Sara 87 Dubreucq, Simon 89 Cox, Kevin 77, 87, 88 Dueñas, Pablo 96 Crean, Rebecca 89 Durgam, Suresh 80, 83 Creatura, Gina 83 Dusetzina, Stacie 78				
93 Dubitsky, Greg 81 Costi, Sara 87 Dubreucq, Simon 89 Cox, Kevin 77, 87, 88 Dueñas, Pablo 96 Crean, Rebecca 89 Durgam, Suresh 80, 83 Creatura, Gina 83 Dusetzina, Stacie 78	Correii, Criristopii U.			
Costi, Sara87Dubreucq, Simon89Cox, Kevin77, 87, 88Dueñas, Pablo96Crean, Rebecca89Durgam, Suresh80, 83Creatura, Gina83Dusetzina, Stacie78				
Cox, Kevin77, 87, 88Dueñas, Pablo96Crean, Rebecca89Durgam, Suresh80, 83Creatura, Gina83Dusetzina, Stacie78	Oneti Como			
Crean, Rebecca89Durgam, Suresh80, 83Creatura, Gina83Dusetzina, Stacie78			• *	
Creatura, Gina 83 Dusetzina, Stacie 78				
·	•			
Crismon, Lynn 19 Eack, Shaun 37			*	
	Crismon, Lynn	19	eack, Shaun	3/

Author Index

ASCP

E 1 14000	00.00	E 1 14500	75.00
Earley, Willie	82, 83	French, William	75, 86
Echevarria, Barbara	94	Freudenreich, Oliver	79
Edelen, Maria	39	Friedman, Michael	78
Edwards, John	80	Frye, Mark	91
Ehrich, Elliot	18, 35	Fucito, Lisa	76
El Hage, Cynthia	89	Galling, Britta	90
Elia, Josephine	75	Gandhi, Kriti	91
Elias, Pamela	79	Gaynes, Bradley	19, 46, 78
Ellingrod, Vicki	83	Gelenberg, Alan	17, 18, 22, 36,
Engeland, Christopher	90		91
Engelhardt, Nina	85	Gelinas, Isabelle	72
Engels, Jean	87	Gendreau, Judith	87
Epperson, C. Neill	95	Gendreau, Michael	87
Epstein, Irvin	71	Geoffroy, Pierre	55, 76
Eramo, Anna	81	Ghabrash, Maykel	89
Ereshefsky, Larry	81	Giddens, Jennifer M.	82, 92
Falk, Daniel	38, 39	Gift, Thomas	75
Faraone, Stephen	75	Gingerich, Susan	93
Farchione, Tiffany	8, 16, 18, 19, 21,	Giroudet, Christelle	72, 80, 89
	29, 52, 66, 74	Glick, Ira	60, 67, 82, 93
Farokhnia, Mehdi	76	Goldberg, Joseph	22, 54
Fava, Maurizio	19, 22, 35, 41,	Goldman, Robert	88, 96
	43, 54, 77, 79,	Gold, Philip	91
	91	Goldsmith, Paul	84
Feder, Adriana	87	Gommoll, Carl	80
Feldman, Clifford	88	Goncalves, Vanessa	95
Felger, Jennifer	37	Gooneratne, Nalaka	91
Feng, Lei	89	Gopinath, Srinath	7, 84
Fienberg, Allen	92	Gordon, Josh	14, 64
Figueroa, Janet	77	Gorlin, Eugenia	88
Findling, Robert	75, 86, 96	Gottlieb, Jennifer	93
Finnema, Sjoerd	83	Greaney, Jody	90
Fischer, Bernard	66, 81	Grosz, Daniel	88
Fisher, Dennis	76	Gueorguieva, Ralitza	76
Fitts, David	75, 86	Guillon, Christophe	85
Fitzgerald, Heather	77, 93	Gunduz-Bruce, Handan	95
Fitzgerald, Maura	75	Guo, Hua	83
Florea, Ioana	76	Guzman, Michele	59
Flynn, Martina	79	Hack, Laura M.	7, 87
Forselius-Bielen, Kimberlee	83	Hakonarson, Hakon	75
Foster, Adriana	94	Hameed, Ahmad	19, 79, 91
Foster, Simmie	7, 35, 77	Hameed, Usman	19, 45, 79
Foulds, Jonathan	79	Hanina, Adam	84, 95
Fox, Jason	90	Hanson, Elizabeth	84, 95
François, Clément	81	Hard, Marjie	94
Fraser, Heather	85	Haroon, Ebrahim	19
Freeman, Marlene	17, 22, 39, 40,	Harvey, Philip	78
	63, 79, 84	Hassman, Howard	82
	55, 15, 5 1	nacoman, nowara	OL.

ASCP |

Author Index

Hefting, Nanco	81	Jordan, Ayana	7, 76
Heilig, Markus	87	Jordan, Robert	84, 95
Heindel, Ned	85	Joseph, Ashok	82
Henderson, David	93	Jovanovic, Tanja	87
Hendrick, Joseph	92	Judge, Heidi	79
Henningfield, Jack	55	Jutras-Aswad, Didier	89
Henry, Mellissa	88	Kadriu, Bashkim	7, 91
Henry, Michael	20, 54	Kando, Judith	92
Hernandez-Diaz, Sonia	84	Kane, John	22, 37, 59, 77,
Herrmann, Nathan	80		82, 93
Hertel, Peter	77, 87, 88	Kanes, Stephen	41, 42, 78, 95
Hester, Shelly	92	Katzelnick, David	36
Hobart, Mary	81, 90, 91	Katzman, Martin	71
Hodes, Georgia	76	Kavoussi, Richard	94
Hoeppner, Bettina	79	Keck, Paul	36
Hoffmann, Ethan	78, 95	Keefe, Richard	20, 45, 78, 91
Holt, Daphne	79	Kelleher, Shannon	96
Hopkins, Seth	96	Kennedy, James	95
Horn, Sarah	87	Khan, Anzalee	78
Hossain, Shawn	82	Khan, Arifulla	22, 80, 85
Howes, John	76	Khan, Munir	75
Huang, Eric	95	Kiedrow, Keith	57
Huang, Yingying	73	Kilts, Clint	80
Huybrechts, Krista	67	Kim, Celia	75
Incledon, Bev	86	Kim, Jean	66, 81
lonescu, Dawn	77, 79	Kim, Sang-Young	93
losifescu, Dan	73, 79, 87	Kim, Soo-Jeong	75
Irwin, Kelly	79	Kinch, Russell	84
IsHak, Waguih	58	Kingsberg, Sheryl	95
Jacobsen, Paula	81, 91	Kinon, Bruce	21, 29
Jacobson, William	80, 91	Kiss, Alex	80
Jaeger, Judith	91	Klassen, Larry	71
James, Andrew	80	Ko, Mancia	92
James, Prisciandaro	79, 81	Koblan, Kenneth	86, 96
Jankovic, Joseph	89	Kolla, Bhanu Prakash	7, 44
Jatlow, Peter	76	Kong, Lan	75
Jha, Manish	59, 79	Koola, Maju	87
Jiang, Ying	83	Kopelowicz, Alex	92
Jimenez, Daniel	30	Kornstein, Susan	20, 92
Jimenez, Joyce	96	Kott, Alan	79, 93, 94
Jimenez-Shahed, Joohi	89	Kramer, Ken	80, 90
Jin, Na	77, 87, 88, 90	Kramer, William	76
Johe, Karl	41	Krishnamurthy, Venkatesh	75
John, Harrison	78	Kugel, Marla	90
Johnson, Brian	77, 87, 88	Kupfer, David J.	5, 18, 53
Johnson, Janet	75, 88, 95	Lam, Vincent	76
Johnstone, Andrea	87	Lanctôt, Krista	80
Jonas, Jeffrey	95	Landsman-Blumberg, Pamela	90
oonas, oomoy	00	Earasman-Diamberg, Famela	50

Author Index

ASCP

Lardner, Casey	76	Marcy, Patricia	93
Laszlovszky, István	83	Marder, Stephen	18, 20, 22
Lauriello, John	94	Mariano, Tim	20
Lawson, Erica	82, 92	Marin, Marie-France	86
Le, Hadley	94	Marino, Jehan	90
Lederman, Seth	87	Markovtsova, Lada	92
Lee, Mary	76	Marraffino, Andrea	86
	76 76	Marsh, Julie	72
Lee, Tong	76 77, 93	Mastouldis, Angela	92
Legacy, Susan Leggio, Lorenzo	77, 93 76		
	76 75	Mates, Sharon Mathé, Aleksander	79, 92
Leslie, Douglas		•	87
Lespérance, François	89	Mathew, Sanjay	79, 84
Lespérance, Paul	89	Mathew, Shiny	66
Lewis-Fernández, Roberto	10, 63	Mathis, Mitchell	40
Li, Peng	79, 92	Mattai, Andy	66, 81
Liang, Grace S.	83, 94, 95	Mautz, Marin	87
Liebowitz, Michael	85	Mayle, Heather	93
Lindenmayer, Jean-Pierre	59, 60	Mazzotti, Diego	75 77
Liranso, Tesfaye	75, 95	McCracken, Courtney	77
Lisanby, Sarah	65	McCue, Maggie	81, 84, 95
Lisotto, Maria	20	McDonnell, David	83
Litten, Raye	12, 18, 64	McDougle, Christopher	77
Liu, Chih-Chin	94, 95	McGlade, Erin	92
Loebel, Antony	18, 86, 88, 96	McGurk, Dennis	16, 65
Loewen, Gordon	83, 95	McIntyre, Roger S.	76, 94
Loft, Henrik	76	McNamara, Cynthia	85
Looney, Stephen	94	McNulty, Eileen	85
Lu, Kaifeng	83	McQuade, Robert	77, 87, 88
Lu, Shi-fang	85	Meltzer-Brody, Samantha	39, 78, 95
Luca, Gianina	85	Merikle, Elizabeth	80
Lucas, Johna	84, 95	Meyer-Kalos, Piper	93
Luckenbaugh, David	91	Meyer, Roger	75, 91
Luo, Rosa	83, 95	Migliore, Raffaele	80
Luo, Zhehui	93	Milad, Mohammed	86
Macek, Thomas A.	43, 84, 95	Miller, Andrew	94
Machado-Vieira, Rodrigo	31, 91	Miller, Brian	81
Machlovi, Saima	76	Miller, Lindsay	75, 86
MacLaurin, Sarah	79	Millet, Robert	89
Macri, Ben	79	Millett, Caitlin	96
Madhoo, Manisha	92	Mills, Richard	94
Mahableshwarkar, Atul	81, 84, 95	Milovan, Denise	56
Majd, Marzieh	90	Milrod, Barbara	20
Man, Chiara Dalla	93	Mitchell, Michael	91
Mantua, Valentina	9, 16, 52, 74	Moca, Marian	86
Marandi, Morteza	94	Montoya, Ivan	21
Marchant, Barrie	75	Moreno, Francisco	20, 30, 31
March, Mary	90	Morin, Lynn	21, 29, 41
Marcus, Ronald	35, 85	Morrissey, Judy	88

Author Index

M. de Ita	04	D L. P	00
Mucha, Lisa	81	Parsons, Jodi	89
Mueser, Kim	93	Patel, Hiren	57
Muniz, Javier	66	Patel, Mehul	83
Murphy, Tanya	89	Pathak, Sanjeev	83
Murrough, James	43, 79, 87	Patkar, Ashwin	76, 89
Myers, Kimberly	82	Patterson, Tom	78
Nabulsi, Nabeel	83	Pena, Catherine	76
Nakamura, Richard K.	15, 64	Perera, Philip	89
Namey, Leah	79	Perez, Magdalena	72
Naovarat, Benjamin	82	Perez, Vanessa	80
Narasimhan, Meera	78	Perry, Pamela	77, 88
Nasrallah, Henry	83, 84, 95	Peters, Ashild	87
Navia, Bradford	44	Peters, Perry	87
Negash, Selam	94	Peters-Strickland, Timothy	82, 92
Neil, Garry	43, 86	Phillips, Debra	96
Nelson, Craig	20	Phillips, Katharine	20, 21, 22
Németh, György	83	Pigott, Teresa	77
Nestler, Eric	76	Pikalov, Andrei	86
Newcomer, John	17, 22	Pliszka, Steven	86
Newcorn, Jeffrey	86	Polimanti, Renato	45
Nierenberg, Andrew	11, 64	Politte, Laura	7, 77
Nomikos, George	78, 81, 91	Pollack, Mark	65
Norquist, Grayson	15, 65	Potkin, Steven	83
Norrholm, Seth	57	Potter, William	54
Norton, James	82	Prochnik, Elisabeth	94
Nuechterlein, Keith	38	Proulx, Jean	80
Nyilas, Margaretta	77, 82, 87, 88,	Puentes, Ruby Castilla	30
rryas, margarotta	92	Purushothaman, Immanuel	76
Nylander, Anna-Greta	91	Quirk, Mike	78
Oakley, Margot	79	Rabinowitz, Jonathan	72
Oberbarnscheidt, Thersilla	85, 90	Radford, Philip	89
O'Brien, Christopher	83, 95	Radhakrishnan, Rajiv	7, 83
O'Gorman, Cedric	45, 92	Raines, Shane	78, 95
Okusaga, Olaoluwa	82, 93	Raison, Charles	86
Olfson, Emily	7, 76	Raja, Praveen	92
Olsen, Christina Kurre	80, 91	Rampakakis, Emmanouil	80
O'Malley, Stephanie		Randolph, Christopher	78
Ongur, Dost	18, 38, 76 93	Rapaport, Mark H.	
=	85	napaport, iviai k 11.	17, 18, 22, 29,
Onwuameze, Obiora	88	Rauch, Sheila	37, 52, 64, 74
Oskooilar, Nader		•	56 75
Ouellet-Plamondon, Clairélaine	89	Reimherr, Frederick	75 02
Paker, Asif	83	Renshaw, Perry	92
Palumbo, Joseph	18	Ressler, Kerry	77, 87
Pani, Luca	9, 16, 18, 52, 74	Revicki, Dennis	84
Papadopoulos, Elektra	38	Riesenberg, Robert	95
Papakostas, George	41, 79	Risinger, Robert	94, 95
Parides, Michael	87	Robichaud, A.J.	78
Parikh, Sagar	81	Robinson, Delbert	38, 82, 93

Author Index

ASCP

Rodriquez, Carolyn	30	Schooler, Nina R.	21, 29, 37, 54,
Roers, Erika	42, 88		65, 82, 84, 93,
Ropacki, Michael	94		94
Rosenberg, David	88	Schuster, Jen	81
Ross, Ruth	77, 93	Seo, Dongju	7, 46
Rotolo, Renee	83	Setnik, Beatrice	55
Rotondi, Armando	93	Shackleford, Theresa	89
Roy, Marcela	79	Shafner, Laura	84, 95
Rubin, Anne	95	Shari, Sutor	91
Rubinow, David	78	Sharma, Anup	7, 91
Rubio, Jose M.	7, 82	Sharma, Shiva	93
Ruckle, Jon	89	Sheehan, David	82, 92
Rudorfer, Matthew	67	Shelton, Richard	20, 37, 56
Rush, A. John	21, 29, 36	Sherman, Chelsea	80
Russo, Scott	76	Sheth, Chandni	92
Ruthirakuhan, Myuri	80	Shonka, Sophia	75
	93		
Ryan, Kyle		Shprecher, David	89 76
Sachs, Gary	73, 94	Shram, Megan	76
Sadler, Brian	94	Silverman, Bernard	38, 83
Safer, Daniel	81	Silverstein, Alison	47
Sajatovic, Martha	55, 77, 93	Simon, James	95
Saliu, Irma	82	Simon, Neal	85
Sallee, Floyd	86	Siu, Cynthia	78, 86
Saltmarche, Anita	74	Skosnik, Patrick	83
Saltz, Bruce	20	Smith, Alicia	87
Salvadore, Giacomo	41	Smith, Evan	83, 95
Salzman, Phyllis	77, 87, 88	Smith, Thomas	92
Sanacora, Gerard	79	Snyder, Gretchen	79, 92
Sanchez, Raymond	77, 82, 87, 88,	Soares, Jair	20
	92	Sosinsky, Alexandra	84
Sankoh, Abdul	78	Southwick, Steven	87
Sarampote, Christopher	17	Spencer, Andrea	86
Sarkey, Sara	81	Spencer, Thomas	75, 86, 96
Sarma, Kaushik	96	Squires, Liza	75, 86
Sasser, Tyler	86	Stamler, David	89
Saunders, Erika	20, 36, 90, 96	Stanford, Arielle	95
Savella, Gina	84	Steans, Bennett	75
Saxby, Brian	78	Steans, Tammy	75
Sayed, Sehrish	87	Stein, Lisa	94
Saylor, Keith	95	Stein, Mark	20, 75, 86
Scafidi, Michael	79	Sternat, Tia	71
Scahill, Lawrence	77	Stika, Catherine	67
Schacterle, Amy	95	Stowe, Zachary	80
Schatzberg, Alan	79	Strickland, Jennifer	75, 86
Schneider, Andrea	58	Stringer, Kathleen	83
Schoenfelder, Erin	86	Stürmer, Til	78
•		Such, Pedro	77, 87, 88
		Sullivan, Gregory	42, 87
		,37	,

Author Index

Suppes, Trisha	22	Walton, Kevin	14, 29, 64
Swardfager, Walter	46	Wan, Xiaohai	96
Swartz, Holly A.	17, 18, 21, 29,	Wang, Changning	87
	39, 65	Wang, Tao	82
Syed, Shariful	96	Wang, Xingmei	94
Szabo, Steven	76	Wang, Yaning	40
Szatmári, Balázs	83	Ward, Kristen	7, 83
Tafti, Mehdi	85	Waschbusch, Daniel	36
Tamburri, Paul	84	Weedon, Jeremy	84
Tamiz, Amir	13, 64	Weiden, Peter	55, 83, 94, 95
Teixeira, Antonio	20	Weiller, Emmanuelle	90, 91
Thase, Michael	22, 80, 91	Weis, Holger	76
Tiwari, Arun	95	Weiss, Catherine	90, 91
Tocco, Michael	88	Wennogle, Lawrence	79, 92
Tolliver, Bryan	79, 81	Wilcox, Charles	88
Tong, My-Linh	88	Wilens, Timothy	86
Toure, Juliette	66	Wilkinson, Samuel	7, 46, 79
Trivedi, Madhukar	18, 22, 37, 59,	Williams, Janet	72, 94
oui, maananai	79	Wilson, Hilary	84
Tseng, Tina	78	Wisner, Katherine	44, 67
Tulloch, Gabriela	95	Wojtalik, Jessica	7, 46
Tye, Susannah	91	Wolanski, Kristy	85
Umbricht, Daniel	84	Wood, Steven	92
Umhau, John	81	Wright, Clinton	94
Updegraff, Kimberly	57	Wu, Hanjing Emily	77
Valdez, Victoria	31, 96	Xiao, Le	78, 89
Valdheer, Susan	79	Xu, Judith	81
Valeri, Linda	93	Yadav, Sanjay	75
Van Dam, Nicholas	87	Yang, Fang	45
van der Hoop, Roland Gerritsen		Yang, Jian	78
Vanle, Brigitte	58	Yao, Wei	79
Vanover, Kimberly	42, 79, 92	Yatham, Lakshmi	82
Vasarri, Stefania		Yavorsky, William	85
Vashist, Akshay	80, 89 92	Yolken, Robert	93
Vaughan, Adam	78	Yost, Jonathan	85
Velligan, Dawn	37		91
0 ,		Youngstrom, Eric	
Verghese, Cherian	94	Younis, Islam	8, 16, 40, 52, 74
Verhoeff, Paul	80	Yule, Amy	75
Vgontzas, Alexndros	75	Yurgelun-Todd, Deborah	92
Vieta, Eduard	83	Zai, Clement	95
Viguera, Adele	84	Zarate, Carlos A.	21, 41, 42, 91
Villarreal, Gerardo	31	Zarit, Steven	89
Vitiello, Benedetto	18, 21	Zeier, Zane	87
von Moltke, Lisa	94	Zhang, Doris	81
Wahlestedt, Claes	87	Zhang, Jianping	21, 45
Walker, Deena	7, 76	Zhang, Peter	90, 91
Walling, David	94	Zhao, Cathy	82, 92
Walsh, Emily	78	Zhong, Wei	80, 91

Author Index

ASCP

Zhou, Jing-jing	78, 89	Zinner, Samuel	86
Zhu, Hao	40	Zisook, Sidney	22
Zhu, Xue-quan	78, 89	Zito, Julie	81
Zimmerman, Mark	47, 78, 88	Zweben, Allen	76

Notes

FUTURE ASCP MEETINGS



Fall 2017 Psychopharmacology Update: State-of-the Art Meeting October 21-22, 2017

The Roosevelt New York, New York



2018 ASCP Annual Meeting May 28 – June 1, 2018 Loews Miami Beach, Miami Beach, Florida



www.ascpp.org

ASCP Executive Office 5034A Thoroughbred Lane Brentwood, Tennessee 37027 phone: 615-649-3085 fax: 888-417-3311

email: info@ascpp.org

